https://flcube.com/zhenge-biotech-secures-rmb-100-million-in-series-c-funding-for-cdmo-expansion/2025-02-12T23:49:12+08:00https://flcube.com/zhejiang-eryings-acetaminophen-set-for-cde-priority-review-in-pediatric-fever-and-pain/2025-02-12T23:43:38+08:00https://flcube.com/henlius-pharmas-2022-interim-revenue-jumps-103-5-on-biosimilar-sales-and-licensing/2025-02-12T23:38:43+08:00https://flcube.com/longbio-pharma-raises-series-a-funding-to-advance-autoimmune-disease-drug-development/2025-02-12T23:35:01+08:00https://flcube.com/fosun-kites-yescarta-car-t-therapy-secures-new-clinical-trial-approval-in-china/2025-02-12T23:32:41+08:00https://flcube.com/sanyou-biopharmaceuticals-and-kangabio-ink-licensing-deal-for-antibody-drug-candidate/2025-02-12T23:28:58+08:00https://flcube.com/innocare-pharmas-2022-interim-report-shows-strong-revenue-growth-driven-by-orelabrutinib-sales/2025-02-12T23:23:22+08:00https://flcube.com/porton-biologics-completes-rmb-520m-series-b-to-expand-gene-and-cell-therapy-cdmo-platform/2025-02-12T23:20:17+08:00https://flcube.com/nuance-pharma-gets-nmpa-green-light-for-ensifentrine-copd-trials-in-china/2025-02-12T23:17:28+08:00https://flcube.com/lundbecks-vyepti-fails-to-accelerate-china-launch-via-sunlight-trial/2025-02-12T23:08:42+08:00https://flcube.com/mindray-bio-medicals-h1-2022-revenues-jump-20-17-to-rmb-15-3b/2025-02-12T23:05:58+08:00https://flcube.com/jjet-raises-rmb-700m-in-series-a-and-b-rounds-for-cardiac-electrophysiology-products/2025-02-12T23:02:58+08:00https://flcube.com/iaso-biotherapeutics-bcma-car-t-therapy-approved-for-nmosd-in-china/2025-02-12T23:00:27+08:00https://flcube.com/hengrui-medicines-h1-2022-revenues-drop-23-amid-generic-price-cuts-and-covid-19-disruptions/2025-02-12T22:56:42+08:00https://flcube.com/allist-pharmaceuticals-receives-nmpa-approval-for-furmonertinib-in-exon-20-insertion-nsclc/2025-02-12T22:52:47+08:00https://flcube.com/ascletis-pharmas-h1-2022-revenue-rises-4-8-on-rd-and-product-sales-growth/2025-02-12T22:13:10+08:00https://flcube.com/viatris-pharmaceuticals-hiv-aids-drug-prioritized-for-cde-review/2025-02-12T22:10:39+08:00https://flcube.com/hansoh-pharma-licenses-ghddis-gdi-4405-for-global-development-in-covid-19/2025-02-12T22:06:54+08:00https://flcube.com/anhui-ankes-hk010-bispecific-antibody-receives-nmpa-review-for-cancer-trials/2025-02-12T22:01:48+08:00https://flcube.com/china-based-firms-form-partnership-to-advance-cell-and-gene-therapy-ecosystem/2025-02-12T21:58:55+08:00https://flcube.com/biopsee-series-a-financing-confocal-microendoscope/2025-02-12T21:44:42+08:00https://flcube.com/cspc-pharmaceuticals-dbpr108-hits-endpoints-in-type-2-diabetes-trials/2025-02-12T21:38:00+08:00https://flcube.com/shanghai-pharmaceuticals-gets-nmpa-approval-for-b013-in-triple-negative-breast-cancer/2025-02-12T21:19:39+08:00https://flcube.com/scitop-bio-techs-kex02-live-bacteria-therapy-gets-fda-ind-approval-for-nsclc/2025-02-12T21:09:33+08:00https://flcube.com/cspc-pharmaceuticals-sys6006-mrna-vaccine-shows-strong-safety-and-efficacy-in-trials/2025-02-12T18:46:14+08:00https://flcube.com/chinas-health-commission-promotes-medical-elderly-care-integration/2025-02-12T18:42:23+08:00https://flcube.com/china-passes-who-nra-evaluation-for-vaccine-regulatory-system/2025-02-12T18:39:00+08:00https://flcube.com/sinomab-biosciences-sn1011-gets-nmpa-nod-for-nmosd-trial/2025-02-12T18:36:38+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-approval-for-6mw3511-clinical-trial-in-solid-tumors/2025-02-12T18:34:16+08:00https://flcube.com/bio-thera-solutions-receives-nmpa-approval-for-bat8008-clinical-trial-in-solid-tumors/2025-02-12T18:31:25+08:00https://flcube.com/beigenes-tislelizumab-receives-11th-nmpa-filing-for-first-line-esophageal-cancer/2025-02-12T18:28:46+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-australia-trial-for-pd-1-il-2-bispecific-antibody-ibi363/2025-02-12T18:25:14+08:00https://flcube.com/lees-pharma-expands-global-rights-to-windtrees-kl4-surfactant-products/2025-02-12T18:22:44+08:00https://flcube.com/genetron-holdings-receives-buyout-offer-from-ceo-wang-sizhen-at-usd-1-36-per-ads/2025-02-12T18:18:50+08:00https://flcube.com/supreme-peoples-court-rules-against-chugai-in-chinas-first-patent-linkage-case/2025-02-12T18:14:07+08:00https://flcube.com/akeso-biopharmas-h1-2022-revenue-rises-26-8-on-penpulimab-sales/2025-02-12T18:11:31+08:00https://flcube.com/alpha-biopharma-completes-everest-trial-for-zorifertinib-in-egfr-nsclc-with-cns-metastases/2025-02-12T18:04:10+08:00https://flcube.com/etherna-raises-eur-39m-in-series-b2-to-expand-mrna-services-and-leadership/2025-02-12T18:00:42+08:00https://flcube.com/sorrento-therapeutics-abivertinib-shows-positive-long-term-data-in-nsclc-trial/2025-02-12T17:53:30+08:00https://flcube.com/porton-biologics-and-royaltech-med-partner-on-bacterial-and-mrna-drug-platforms/2025-02-12T17:19:58+08:00https://flcube.com/nmpa-suspends-ucbs-keppra-over-labeling-issues-prompting-recall/2025-02-12T17:05:14+08:00https://flcube.com/biocytogen-and-merck-kgaa-ink-global-deal-for-renmice-platform-licensing/2025-02-12T17:01:40+08:00https://flcube.com/3sbio-inc-reports-h1-2020-revenue-of-rmb-3-091b-net-profit-up-6-19/2025-02-12T16:59:04+08:00https://flcube.com/betta-pharmaceuticals-h1-2022-revenues-rise-8-5-on-drug-sales-growth/2025-02-12T16:56:00+08:00https://flcube.com/ranok-therapeutics-doses-first-patient-in-rnk05047-study-for-brd4-targeted-cancers/2025-02-12T16:52:40+08:00https://flcube.com/eli-lilly-expands-collaboration-with-advancell-on-targeted-alpha-therapies-for-cancer/2025-02-12T16:30:35+08:00https://flcube.com/eli-lilly-licenses-olix-pharmas-olx75016-for-mash-and-cardiometabolic-diseases/2025-02-12T15:52:45+08:00https://flcube.com/gilead-sciences-q4-2024-financials-show-6-revenue-growth-driven-by-hiv-and-oncology/2025-02-12T15:30:15+08:00https://flcube.com/lion-tcrs-liocyx-m00-therapy-receives-fda-clearance-for-hbv-related-hcc-study/2025-02-12T15:15:57+08:00https://flcube.com/hainan-poly-pharms-generic-prohance-wins-fda-approval-in-us/2025-02-12T14:59:39+08:00https://flcube.com/kexing-biopharm-and-bio-thera-solutions-form-alliance-for-global-expansion/2025-02-12T14:45:15+08:00https://flcube.com/kexing-pharma-receives-ethical-approval-for-phase-ii-study-of-shen26-covid-19-drug/2025-02-12T14:41:51+08:00https://flcube.com/double-crane-pharma-gains-nmpa-approval-for-covid-19-drug-cx2101a-clinical-trials/2025-02-12T14:41:50+08:00https://flcube.com/tonghua-dongbao-licenses-biosimilar-victoza-to-kexing-for-emerging-markets/2025-02-12T14:41:49+08:00https://flcube.com/kexing-pharmaceutical-initiates-phase-i-trial-for-ifn-alpha-1b-inhalation-solution/2025-02-12T14:41:48+08:00https://flcube.com/kexing-pharmaceutical-secures-commercial-rights-for-convalifes-neratinib-generic-outside-china/2025-02-12T14:41:47+08:00https://flcube.com/convalife-pharmaceuticals-gets-nmpa-approval-for-generic-neratinib-clinical-study/2025-02-12T14:41:47+08:00https://flcube.com/kexing-pharmaceutical-enters-global-licensing-agreement-with-xiling-lab-for-eribulin-generic/2025-02-12T14:41:46+08:00https://flcube.com/kexing-pharmaceutical-partners-with-yabao-to-distribute-generic-nexavar-in-ten-countries/2025-02-12T14:41:45+08:00https://flcube.com/kexing-pharmaceutical-secures-rights-for-chia-tai-tianqings-generic-ibrance-in-11-countries/2025-02-12T14:41:44+08:00https://flcube.com/kexing-pharmaceutical-secures-global-rights-for-qingfengs-generic-olaparib/2025-02-12T14:41:44+08:00https://flcube.com/kexing-pharmaceutical-secures-nmpa-approval-for-childhood-growth-hormone-deficiency-study/2025-02-12T14:41:43+08:00https://flcube.com/zhejiang-haichang-biotech-secures-eu-approval-for-apexelsin-a-new-hope-in-cancer-treatment/2025-02-12T14:41:42+08:00https://flcube.com/mabpharms-cmab807-biosimilar-receives-market-approval-in-indonesia-and-peru/2025-02-12T14:41:41+08:00https://flcube.com/mabpharms-cmab807-biosimilar-infliximab-approved-in-pakistan/2025-02-12T14:41:40+08:00https://flcube.com/kexing-pharmaceutical-partners-with-shandong-boan-for-biosimilar-commercialization-in-hong-kong-and-macau/2025-02-12T14:41:40+08:00https://flcube.com/kexing-and-kelun-partner-to-expand-overseas-business-for-generic-drugs-and-therapies/2025-02-12T14:41:39+08:00https://flcube.com/microport-medbots-toumai-surgical-robot-wins-nmpa-approval-for-single-hole-laparoscopy/2025-02-12T14:22:01+08:00https://flcube.com/jd-healthcares-h1-2022-financial-report-shows-strong-growth-in-revenue-and-profits/2025-02-11T23:38:50+08:00https://flcube.com/everest-medicines-ceo-resigns-as-trodelvy-sale-completed/2025-02-11T23:34:49+08:00https://flcube.com/shanghai-bao-pharma-raises-usd-100m-in-series-b-to-advance-drug-delivery-tech/2025-02-11T23:32:07+08:00https://flcube.com/lab-direct-raises-usd-10m-in-series-a-to-expand-digital-supply-chain-platform/2025-02-11T23:29:47+08:00https://flcube.com/health-plus-receives-strategic-investment-from-meinian-onehealth-to-drive-healthcare-innovation/2025-02-11T23:26:28+08:00https://flcube.com/prismlab-china-raises-usd-29-1m-in-series-c-for-3d-printing-expansion/2025-02-11T23:17:51+08:00https://flcube.com/junshi-biosciences-tab009-js009-and-js110-advance-in-cancer-trials/2025-02-11T23:12:31+08:00https://flcube.com/illumina-opens-first-china-manufacturing-base-for-gene-sequencers-2/2025-02-11T23:09:13+08:00https://flcube.com/junshi-biosciences-gets-nmpa-go-ahead-for-tab009-js009-cancer-study/2025-02-11T23:06:02+08:00https://flcube.com/illumina-opens-first-china-manufacturing-base-for-gene-sequencers/2025-02-11T23:02:32+08:00https://flcube.com/novartis-to-spin-off-sandoz-focus-on-innovative-drugs/2025-02-11T23:00:03+08:00https://flcube.com/clover-biopharmaceuticals-scb-2019-vaccine-proves-effective-in-teenagers/2025-02-11T22:58:04+08:00https://flcube.com/cstone-pharmaceuticals-h1-2022-revenue-jumps-229-on-drug-sales-growth/2025-02-11T22:55:20+08:00https://flcube.com/innovent-biologics-h1-2022-revenue-rises-15-3-on-drug-sales-growth/2025-02-11T22:51:42+08:00https://flcube.com/ascentage-pharmas-h1-2022-revenue-surges-636-9-on-olverembatinib-sales/2025-02-11T22:48:35+08:00https://flcube.com/china-u-s-listing-agreement-clears-path-for-chinese-firms-to-stay-listed-in-the-u-s/2025-02-11T22:45:00+08:00https://flcube.com/shandong-releases-off-label-drug-use-consensus-expanding-clinical-guidance/2025-02-11T22:31:20+08:00https://flcube.com/immuneoncos-imm40h-receives-nmpa-clinical-trial-approval-for-cd70-antibody/2025-02-11T22:28:30+08:00https://flcube.com/innocare-pharma-files-for-star-market-ipo-to-raise-rmb-4b-for-drug-rd/2025-02-11T22:26:10+08:00https://flcube.com/nmpa-releases-57th-batch-of-reference-drugs-for-generic-consistency-evaluation/2025-02-11T22:23:56+08:00https://flcube.com/jj-medtech-joins-chinas-surgical-training-program-to-skill-up-surgeons/2025-02-11T22:21:49+08:00https://flcube.com/sirnaomics-stp705-achieves-100-complete-remission-in-basal-cell-carcinoma-study/2025-02-11T22:18:45+08:00https://flcube.com/nmpa-reclassifies-omeprazole-tablets-from-prescription-to-otc-status/2025-02-11T22:16:07+08:00https://flcube.com/henlius-biotechs-pd-1-inhibitor-serplulimab-secures-nmpa-review-for-esophageal-cancer/2025-02-11T22:13:30+08:00https://flcube.com/acchrom-tech-raises-usd-14-45m-in-angel-round-led-by-biotrack-capital-to-expand-chromatography-solutions/2025-02-11T22:09:07+08:00https://flcube.com/fosun-pharmas-h1-2022-revenue-rises-25-9-on-new-drug-launches-global-expansion/2025-02-11T18:11:21+08:00https://flcube.com/clover-biopharmas-scb-2019-vaccine-shows-strong-immune-response-to-omicron-ba-5/2025-02-11T18:08:02+08:00https://flcube.com/staidson-and-jjs-teclistamab-gain-breakthrough-designation-for-hemophilia-and-myeloma/2025-02-11T18:05:26+08:00https://flcube.com/fosun-pharma-to-invest-rmb-1b-in-chengdu-vaccine-base/2025-02-11T18:02:38+08:00https://flcube.com/innocare-pharma-and-cstone-pharmaceuticals-drugs-receive-prioritized-cde-review/2025-02-11T18:00:21+08:00https://flcube.com/luca-healthcare-raises-pre-series-a-funding-for-digital-biomarker-rd/2025-02-11T17:56:29+08:00https://flcube.com/biocytogen-and-tracon-pharmaceuticals-gain-fda-ind-approval-for-sarcoma-trial/2025-02-11T17:54:11+08:00https://flcube.com/hengrui-medicines-dalpiciclib-hits-superiority-criteria-in-phase-iii-study/2025-02-11T17:51:12+08:00https://flcube.com/beijing-adjusts-uebmi-account-management-boosting-outpatient-coverage/2025-02-11T17:37:38+08:00https://flcube.com/junshi-biosciences-h1-2022-financials-show-tuoyi-sales-growth-despite-revenue-drop/2025-02-11T17:35:31+08:00https://flcube.com/connect-biopharma-completes-phase-i-trial-of-cbp-174-for-itch-in-skin-diseases/2025-02-11T17:32:12+08:00https://flcube.com/roosterbio-taps-mbl-beijing-biotech-as-exclusive-distributor-in-china/2025-02-11T17:24:56+08:00https://flcube.com/boehringer-eli-lillys-jardiance-wins-nmpa-approval-for-heart-failure-with-preserved-ejection-fraction/2025-02-11T17:11:59+08:00https://flcube.com/e-nitiate-biopharma-raises-rmb-100m-in-series-a-to-advance-autoimmune-disease-drugs/2025-02-11T17:07:01+08:00https://flcube.com/kangtai-bio-partners-with-philippine-firm-on-pneumonia-vaccines/2025-02-11T17:00:54+08:00https://flcube.com/microport-scientific-posts-10-revenue-growth-despite-covid-19-in-2022-interim-results/2025-02-11T16:58:41+08:00https://flcube.com/mercks-gardasil-9-valent-hpv-vaccine-approved-for-expanded-age-range-in-china/2025-02-11T16:53:44+08:00https://flcube.com/onekdrug-raises-series-b-funding-to-boost-pharmaceutical-b2b-services/2025-02-11T16:48:53+08:00https://flcube.com/sinocelltechs-ripertamab-wins-nmpa-approval-for-dlbcl-treatment/2025-02-11T16:38:54+08:00https://flcube.com/novartis-to-acquire-anthos-therapeutics-for-3-1b-boosting-factor-xi-inhibitor-portfolio/2025-02-11T16:30:25+08:00https://flcube.com/kelun-biotech-to-present-skb264-mk-2870-data-for-urothelial-carcinoma-at-asco-gu-2025/2025-02-11T16:00:44+08:00https://flcube.com/jjs-rybrevant-and-talvey-win-separate-nmpa-approvals-in-china/2025-02-11T15:58:15+08:00https://flcube.com/degron-therapeutics-deg6498-receives-fda-clearance-for-clinical-trials/2025-02-11T15:46:42+08:00https://flcube.com/roche-transfers-intermune-and-esbriet-to-legacy-pharma-in-ip-deal/2025-02-11T15:36:43+08:00https://flcube.com/bio-thera-solutions-bat1006-wins-nmpa-approval-for-her2-breast-cancer-trial/2025-02-11T14:16:22+08:00https://flcube.com/china-resources-double-crane-pharmaceutical-co-ltd-receives-nmpa-approval-for-generic-purinethol/2025-02-11T14:07:45+08:00https://flcube.com/henlius-biotechs-hlx99-receives-fda-approval-for-als-clinical-study/2025-02-11T13:56:00+08:00https://flcube.com/henlius-biotech-doses-first-patient-in-hlx43-phase-ii-study-for-esophageal-cancer/2025-02-11T13:45:54+08:00https://flcube.com/bayer-files-for-eylea-8-mg-ema-approval-to-extend-amd-dme-treatment-intervals/2025-02-11T13:37:40+08:00https://flcube.com/bristol-myers-squibbs-breyanzi-hits-primary-endpoint-in-lymphoma-study/2025-02-11T13:29:41+08:00https://flcube.com/cspc-pharmaceuticals-syh2039-wins-fda-clinical-approval-for-advanced-tumors/2025-02-11T13:19:52+08:00https://flcube.com/boehringer-ingelheims-nerandomilast-hits-primary-endpoint-in-ppf-phase-iii-study/2025-02-11T13:11:01+08:00https://flcube.com/cspc-pharmaceuticals-omalizumab-biosimilar-wins-nmpa-approval-for-allergic-asthma/2025-02-11T12:01:11+08:00https://flcube.com/sinopep-allsino-wins-nmpa-approval-for-generic-liptruzet-in-china/2025-02-11T11:20:17+08:00https://flcube.com/r-nanoablation-raises-usd-13-7m-in-series-b-to-advance-nanosecond-ablation-tech/2025-02-11T11:05:41+08:00https://flcube.com/henlius-biotech-plans-us-bridging-study-for-serplulimab-in-es-sclc/2025-02-11T01:17:04+08:00https://flcube.com/redcloud-bio-doses-first-patient-in-h002-egfr-tki-phase-i-iia-trial-for-nsclc/2025-02-11T01:13:42+08:00https://flcube.com/lepu-biopharmas-mrg002-earns-fda-orphan-drug-status-for-gastric-cancer/2025-02-11T01:08:05+08:00https://flcube.com/keymed-and-lepus-cmg901-receives-breakthrough-therapy-designation-for-gastric-cancer/2025-02-11T01:07:30+08:00https://flcube.com/lepu-biotechnologys-mrg003-receives-orphan-drug-designation-from-fda/2025-02-11T01:07:29+08:00https://flcube.com/lepu-biotechnologys-pd-1-inhibitor-hx008-gains-new-indication-approval/2025-02-11T01:07:28+08:00https://flcube.com/lepu-biotechnologys-mrg003-receives-breakthrough-therapy-designation-for-nasopharyngeal-carcinoma/2025-02-11T01:07:28+08:00https://flcube.com/lepu-and-keymed-license-cldn18-2-adc-cmg901-to-astrazeneca/2025-02-11T01:07:27+08:00https://flcube.com/lepu-biotechnologys-mrg003-gains-fast-track-status-from-u-s-fda-for-nasopharyngeal-carcinoma/2025-02-11T01:07:27+08:00https://flcube.com/biocytogen-and-lepu-biotechnology-develop-wt1-targeted-trispecific-antibody-for-cancer-treatment/2025-02-11T01:07:26+08:00https://flcube.com/lepu-biotechnologys-pancreatic-cancer-drug-earns-orphan-drug-status-from-fda/2025-02-11T01:07:26+08:00https://flcube.com/lepu-biotechnology-completes-enrollment-for-phase-iib-trial-of-mrg003-in-nasopharyngeal-carcinoma/2025-02-11T01:07:25+08:00https://flcube.com/lepu-biotechnology-reports-1347-yoy-revenue-increase-in-2023-financial-results/2025-02-11T01:07:24+08:00https://flcube.com/lepu-biotechnologys-mrg004a-adc-gains-fast-track-designation-for-pancreatic-cancer/2025-02-11T01:07:24+08:00https://flcube.com/lepu-biotechnologys-mrg003-earns-fda-breakthrough-therapy-designation-for-nasopharyngeal-carcinoma/2025-02-11T01:07:23+08:00https://flcube.com/chinese-pharma-companies-set-to-showcase-cancer-treatments-at-asco-2024/2025-02-11T01:07:23+08:00https://flcube.com/lepu-biopharma-licenses-potential-best-in-class-adc-mrg007-to-arrivent/2025-02-11T01:07:22+08:00https://flcube.com/cde-lists-five-drugs-and-one-companion-diagnostic-for-priority-review-status/2025-02-11T01:07:22+08:00https://flcube.com/akeso-biopharma-receives-development-payment-for-pd-l1-monoclonal-antibody/2025-02-11T01:07:21+08:00https://flcube.com/cde-releases-62nd-batch-of-chemical-generic-references-updates-39-specifications/2025-02-11T01:00:38+08:00https://flcube.com/jacobio-pharmaceuticals-doses-first-patient-in-jab-21822-phase-iia-trial-for-kras-g12c-nsclc/2025-02-11T00:52:12+08:00https://flcube.com/novartis-partners-with-beijings-changping-district-to-expand-drug-development/2025-02-11T00:49:12+08:00https://flcube.com/genscript-biotechs-h1-2022-revenue-rises-32-7-on-carvykti-car-t-sales/2025-02-11T00:46:04+08:00https://flcube.com/mayo-clinic-launches-mayflower-bioventures-to-accelerate-cell-and-gene-therapies/2025-02-11T00:42:40+08:00https://flcube.com/biointron-raises-usd-72m-in-series-b-to-expand-cro-services-and-antibody-platform/2025-02-11T00:38:34+08:00https://flcube.com/simcere-pharmas-h1-2022-revenue-rises-27-on-new-drug-sales-rd-push/2025-02-11T00:31:24+08:00https://flcube.com/alphamab-oncology-reports-h1-2022-revenue-growth-driven-by-envafolimab-commercialization/2025-02-11T00:26:26+08:00https://flcube.com/akeso-bios-ak112-wins-breakthrough-designation-for-first-line-nsclc/2025-02-11T00:22:45+08:00https://flcube.com/remegens-h1-2022-revenue-soars-1094-on-aidixi-taiai-sales/2025-02-11T00:19:11+08:00https://flcube.com/samr-issues-new-rules-for-online-drug-sales-in-china/2025-02-11T00:16:11+08:00https://flcube.com/nmpa-designates-shijiazhuang-airport-as-drug-import-port-for-narcotics-psychotropics/2025-02-11T00:13:51+08:00https://flcube.com/walvax-biotech-wins-nmpa-approval-for-mrna-and-recombinant-covid-19-vaccines/2025-02-11T00:11:41+08:00https://flcube.com/medim-science-raises-funds-for-macrophage-targeting-biologics-in-cancer-therapy/2025-02-10T23:56:38+08:00https://flcube.com/chinas-pharmaceutical-industry-sees-revenue-decline-amid-export-shifts/2025-02-10T23:51:26+08:00https://flcube.com/tibet-duo-rui-and-nanjing-heron-forge-pharmaceutical-collaboration-in-china/2025-02-10T23:48:32+08:00https://flcube.com/carsgen-therapeutics-launches-gmp-manufacturing-for-car-t-cell-therapies-in-north-carolina/2025-02-10T23:41:02+08:00https://flcube.com/megarobo-and-danaher-life-sciences-partner-on-lab-automation-in-china/2025-02-10T23:38:02+08:00https://flcube.com/hengrui-medicines-hrg2101-inhaler-wins-nmpa-approval-for-ipf-clinical-trial/2025-02-10T23:15:28+08:00https://flcube.com/u-protech-secures-angel-financing-for-protac-and-molecular-glue-drug-pipeline/2025-02-10T23:02:03+08:00https://flcube.com/jj-china-tencent-launch-digital-rhinitis-platform-love-nose-e-station/2025-02-10T22:51:51+08:00https://flcube.com/neukio-biotherapeutics-completes-usd-50m-series-a-1-financing-for-ipsc-car-nk-therapy/2025-02-10T22:44:11+08:00https://flcube.com/acorda-therapeutics-licenses-preclinical-drug-nepicastat-to-chinas-asieris/2025-02-10T22:39:50+08:00https://flcube.com/bgis-stereo-seq-tech-maps-axolotl-brain-regeneration-in-world-first-study/2025-02-10T22:36:38+08:00https://flcube.com/yingli-pharma-doses-first-patient-in-linperlisib-phase-ii-trial-for-ptcl/2025-02-10T22:34:25+08:00https://flcube.com/junshi-biosciences-plans-usd-572m-private-placement-to-fund-drug-rd-and-expansion/2025-02-10T22:31:47+08:00https://flcube.com/cansino-livzon-win-china-euas-for-covid-19-booster-vaccines/2025-02-10T22:28:19+08:00https://flcube.com/aws-partners-with-zhongshan-to-launch-smart-manufacturing-and-biomedical-digital-center/2025-02-10T22:25:13+08:00https://flcube.com/boomray-pharmaceuticals-raises-usd-43m-in-series-a-for-rdc-pipeline-expansion/2025-02-10T22:22:14+08:00https://flcube.com/zelgen-biopharmaceuticals-jacktinib-wins-fda-approval-for-severe-alopecia-areata/2025-02-10T22:17:07+08:00https://flcube.com/jacobio-pharmaceuticals-doses-first-patient-in-jab-bx102-phase-i-iia-trial-for-cd73-targeted-cancer-therapy/2025-02-10T22:14:46+08:00https://flcube.com/northeast-pharma-licenses-medabomes-mab11-22-1-for-adc-and-car-t-development/2025-02-10T22:10:29+08:00https://flcube.com/alphamab-oncology-highlights-kn046-kn026-advances-at-esmo-2022/2025-02-10T22:04:14+08:00https://flcube.com/astrazenecas-farxiga-wins-china-approval-for-chronic-kidney-disease/2025-02-10T21:57:24+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-higher-dose-mazdutide-obesity-trial/2025-02-10T21:54:55+08:00https://flcube.com/shanghai-pharmas-cd20-antibody-advances-to-primary-nephropathy-trial-after-nmpa-approval/2025-02-10T21:52:05+08:00https://flcube.com/jacobios-kras-g12c-inhibitor-jab-21822-advances-to-pivotal-phase-ii-in-nsclc/2025-02-10T18:45:50+08:00https://flcube.com/lianren-digital-health-partners-with-ningbo-government-on-health-data-ecosystem/2025-02-10T18:43:04+08:00https://flcube.com/bio-heart-invests-rmb-50m-in-cardiotek-to-advance-balloon-expandable-tavr-device/2025-02-10T18:38:20+08:00https://flcube.com/hitgens-vernalis-subsidiary-collaborates-with-unison-medicines-on-undruggable-bacterial-target/2025-02-10T18:34:11+08:00https://flcube.com/clover-biopharmaceuticals-covid-19-vaccine-scb-2019-shows-superior-booster-efficacy-in-phase-iii-trial/2025-02-10T18:28:23+08:00https://flcube.com/astellas-fezolinetant-hits-menopause-trial-goals-in-china-eyes-global-launch/2025-02-10T18:25:51+08:00https://flcube.com/cellorigin-and-qilu-partner-on-global-car-imac-cancer-therapy-development/2025-02-10T18:23:19+08:00https://flcube.com/bio-heart-plans-star-board-ipo-after-hong-kong-debut-to-advance-cardiovascular-therapies/2025-02-10T18:18:24+08:00https://flcube.com/fosun-pharmas-controlling-shareholder-to-sell-3-stake-for-usd-461-million/2025-02-10T18:11:23+08:00https://flcube.com/sciclone-pharmaceuticals-doses-first-patient-in-rrx-001-phase-iii-study-for-sclc/2025-02-10T17:59:39+08:00https://flcube.com/hotgen-biotech-receives-uk-approvals-for-monkeypox-and-covid-19-antigen-detection-kits/2025-02-10T17:56:56+08:00https://flcube.com/zelgen-biopharms-donafenib-shows-promise-in-phase-iii-study-for-rair-dtc/2025-02-10T17:52:13+08:00https://flcube.com/bio-thera-solutions-licenses-bat2506-to-intas-pharmaceuticals-for-us-market/2025-02-10T17:42:52+08:00https://flcube.com/changchun-genesciences-gensci120-receives-nmpa-approval-for-rheumatoid-arthritis-trials/2025-02-10T17:23:12+08:00https://flcube.com/carsgens-allogeneic-bcma-car-t-therapy-achieves-scr-in-first-patient/2025-02-10T16:56:26+08:00https://flcube.com/haisco-pharmaceutical-group-registers-delaware-subsidiary-to-expand-global-operations/2025-02-10T16:48:11+08:00https://flcube.com/beijing-luzhu-submits-bla-for-lz901-herpes-zoster-vaccine-to-nmpa/2025-02-10T16:28:28+08:00https://flcube.com/hainan-boao-lecheng-pilot-zone-implements-baclofen-intrathecal-therapy/2025-02-10T16:15:09+08:00https://flcube.com/xtalpi-invests-in-alternative-bio-for-cancer-and-inflammation-drugs/2025-02-10T16:02:48+08:00https://flcube.com/nmpas-new-guidelines-for-drug-registration-review/2025-02-10T15:53:37+08:00https://flcube.com/shanghais-three-year-plan-to-boost-elderly-care-quality/2025-02-10T15:39:05+08:00https://flcube.com/nmpa-approves-sinocelltechs-finotonlimab-for-head-and-neck-cancer/2025-02-10T15:28:46+08:00https://flcube.com/tianjin-municipality-boosts-biopharmaceutical-industry-with-new-measures/2025-02-10T15:20:30+08:00https://flcube.com/hansoh-pharmas-uplizna-receives-priority-review-for-igg4-rd-treatment/2025-02-10T15:05:31+08:00https://flcube.com/nmpa-seeks-public-feedback-on-export-drug-manufacturing-rules/2025-02-10T14:40:32+08:00https://flcube.com/vectorbuilder-and-eureka-bio-form-alliance-to-advance-cgt-solutions-globally/2025-02-10T14:22:33+08:00https://flcube.com/suzhou-innobm-pharmaceuticals-raises-series-a-funding-for-tumor-immunotherapy/2025-02-10T14:06:16+08:00https://flcube.com/laekna-therapeutics-doses-first-patient-in-lae001-lae002-study-for-prostate-cancer/2025-02-10T13:53:47+08:00https://flcube.com/laekna-therapeutics-files-for-ipo-on-hong-kong-stock-exchange-aims-to-expand-cancer-and-hepatic-fibrosis-therapies/2025-02-10T13:50:45+08:00https://flcube.com/laekna-raises-791-million-in-hong-kong-ipo-for-pipeline-expansion/2025-02-10T13:50:44+08:00https://flcube.com/sino-us-laekna-receives-fda-clearance-for-lae102-clinical-trial-in-nsclc/2025-02-10T13:50:44+08:00https://flcube.com/laekna-therapeutics-reports-phase-ii-data-for-afuresertib-in-platinum-resistant-ovarian-cancer/2025-02-10T13:50:43+08:00https://flcube.com/sino-us-laeknas-lae102-clinical-trial-filing-accepted-for-review-in-obesity-and-metabolic-disorders/2025-02-10T13:50:42+08:00https://flcube.com/laeknas-actriia-monoclonal-antibody-lae102-gets-green-light-from-chinas-cde-for-obesity-treatment/2025-02-10T13:50:41+08:00https://flcube.com/laeknas-anti-actriia-antibody-lae102-clears-fda-hurdle-for-obesity-treatment-trial/2025-02-10T13:50:41+08:00https://flcube.com/laekna-therapeutics-mcrpc-drug-combo-advances-to-phase-iii-with-fda-approval/2025-02-10T13:50:40+08:00https://flcube.com/laekna-therapeutics-initiates-phase-iii-trial-for-breast-cancer-candidate-lae002-in-combination-with-fulvestrant/2025-02-10T13:50:39+08:00https://flcube.com/laekna-advances-obesity-treatment-candidate-lae102-with-subcutaneous-dosing-in-phase-i-study/2025-02-10T13:50:39+08:00https://flcube.com/laekna-and-eli-lilly-co-enter-clinical-cooperation-to-advance-obesity-treatment-lae102/2025-02-10T13:50:38+08:00https://flcube.com/laekna-inc-initiates-ind-enabling-study-for-monoclonal-antibody-lae123-in-severe-diseases/2025-02-10T13:50:37+08:00https://flcube.com/nhsa-reveals-drugs-passing-initial-review-for-nrdl-inclusion/2025-02-10T13:47:08+08:00https://flcube.com/innovents-tyvyt-combo-shows-pfs-benefit-in-egfr-mutant-nsclc/2025-02-10T13:44:42+08:00https://flcube.com/huadong-medicine-pays-eur-105m-for-35-stake-in-heidelberg-pharma/2025-02-10T13:42:07+08:00https://flcube.com/cstone-pharmaceuticals-partners-with-rigen-biotech-on-thyroid-cancer-ret-gene-testing/2025-02-10T13:39:12+08:00https://flcube.com/biocytogen-and-fineimmune-partner-on-innovative-cell-therapy-drug-development/2025-02-10T13:29:59+08:00https://flcube.com/cmss-rxilient-medical-licenses-insulin-products-from-hefei-tianmai-biotech/2025-02-10T13:27:54+08:00https://flcube.com/kelun-pharmaceutical-receives-usd-35-million-from-merck-sharp-dohme-corp/2025-02-10T13:19:35+08:00https://flcube.com/hainan-yuekangs-yk-029a-biosimilar-set-for-btd-in-egfr-ex20ins-nsclc/2025-02-10T13:16:42+08:00https://flcube.com/walvax-biotech-enrolls-first-subject-in-phase-iii-hpv-vaccine-study/2025-02-10T13:10:17+08:00https://flcube.com/sinocelltechs-ripertamab-officially-launched-in-china-for-dlbcl-treatment/2025-02-10T13:07:41+08:00https://flcube.com/innovents-tyvyt-shows-pfs-benefit-in-egfr-mutant-nsclc-at-esmo/2025-02-10T13:05:13+08:00https://flcube.com/luye-pharmas-cd25-monoclonal-antibody-ba1106-gains-nmpa-approval-for-clinical-trials/2025-02-10T13:02:39+08:00https://flcube.com/fosun-pharma-inks-licensing-deal-with-neovii-for-gvhd-therapy-grafalon/2025-02-10T12:59:54+08:00https://flcube.com/fudan-zhangjiangs-jak1-inhibitor-fzj-003-gel-enters-phase-i-trial-for-atopic-dermatitis/2025-02-10T12:53:31+08:00https://flcube.com/hutchmeds-elunate-shows-survival-benefit-in-global-crc-study-at-esmo/2025-02-10T12:48:07+08:00https://flcube.com/chinas-drug-procurement-under-scrutiny-addressing-quality-concerns-and-policy-reforms/2025-02-10T11:57:13+08:00https://flcube.com/chinas-retail-pharmacy-o2o-sales-surge-to-usd-2-9b-in-2021/2025-02-10T00:54:00+08:00https://flcube.com/national-high-value-medical-consumables-vbp-round-targets-orthopedic-spine-products/2025-02-10T00:51:58+08:00https://flcube.com/chinas-cecolin-hpv-vaccine-shows-100-efficacy-in-66-month-study/2025-02-10T00:45:47+08:00https://flcube.com/dizal-pharmas-sunvozertinib-gains-nmpa-approval-for-egfr-mutation-nsclc-trial/2025-02-10T00:43:50+08:00https://flcube.com/mofcoms-2021-pharma-distribution-report-shows-market-recovery/2025-02-10T00:41:37+08:00https://flcube.com/nhsa-issues-notice-on-special-treatment-of-oral-implant-medical-service-charges/2025-02-10T00:39:36+08:00https://flcube.com/realcan-pharma-and-aws-expand-partnership-for-digital-transformation/2025-02-10T00:35:14+08:00https://flcube.com/salipro-biotech-secures-patent-protection-for-membrane-protein-stabilization-tech/2025-02-10T00:29:26+08:00https://flcube.com/in-depth-analysis-of-nhsas-drg-dip-payment-reforms-a-path-to-streamlined-healthcare-management/2025-02-10T00:24:36+08:00https://flcube.com/bidens-executive-order-boosts-us-bio-economy-targets-chinas-biotech-rise/2025-02-09T00:53:32+08:00https://flcube.com/quantumdx-and-sansure-biotech-partner-to-commercialize-q-poc-in-china/2025-02-09T00:49:21+08:00https://flcube.com/innocare-pharmas-bcl2-inhibitor-icp-248-gains-nmpa-approval-for-clinical-study/2025-02-09T00:42:15+08:00https://flcube.com/beigenes-tislelizumab-meets-primary-endpoint-in-hcc-study-at-esmo/2025-02-09T00:39:51+08:00https://flcube.com/luye-pharmas-ba-covmab-receives-nmpa-approval-for-covid-19-clinical-trials/2025-02-09T00:36:52+08:00https://flcube.com/jiangsu-healthcare-to-cover-all-psychological-treatments-under-bmi/2025-02-09T00:33:32+08:00https://flcube.com/leadinno-medical-valley-raises-rmb-100m-in-series-a-financing-for-neuromodulation-devices/2025-02-09T00:31:10+08:00https://flcube.com/transcentas-tst001-shows-promise-in-gastric-cancer-trial-with-73-3-response-rate/2025-02-09T00:26:50+08:00https://flcube.com/cspc-pharmaceuticals-tg103-gains-nmpa-approval-for-nash-and-alzheimers-trials/2025-02-09T00:23:46+08:00https://flcube.com/jingxin-pharmaceutical-receives-nmpa-approval-for-jbpos0101-and-jx7002-trials/2025-02-09T00:21:18+08:00https://flcube.com/frontier-biotechs-fb2001-inhalant-accepted-for-nmpa-review/2025-02-09T00:18:45+08:00https://flcube.com/luye-pharmas-ly03015-receives-fda-approval-for-phase-i-clinical-study/2025-02-09T00:13:04+08:00https://flcube.com/hengrui-medicine-to-incentivize-employees-with-share-distribution/2025-02-09T00:09:41+08:00https://flcube.com/i-mabs-lemzoparlimab-gains-cde-approval-for-hr-mds-phase-iii-trial/2025-02-08T23:36:52+08:00https://flcube.com/takedas-modakafusp-alfa-and-tak-981-gain-nmpa-clinical-trial-approvals/2025-02-08T23:33:03+08:00https://flcube.com/huahai-pharmaceutical-gains-fda-approval-for-generic-fingolimod/2025-02-08T23:29:54+08:00https://flcube.com/vathin-medical-instrument-raises-pre-series-b-funding-led-by-idg-capital/2025-02-08T23:21:58+08:00https://flcube.com/nmpa-issues-guidelines-on-medical-device-grading-administration/2025-02-08T23:17:08+08:00https://flcube.com/great-bay-bio-completes-usd-15m-pre-series-b-financing-to-advance-ai-bioprocessing-platforms/2025-02-08T23:15:00+08:00https://flcube.com/cspc-pharmaceuticals-mrna-vaccine-sys6017-gains-nmpa-approval-for-herpes-zoster-study/2025-02-08T17:14:33+08:00https://flcube.com/nuance-pharmas-ohtuvayre-receives-regulatory-approval-in-macau-for-copd-treatment/2025-02-08T17:05:04+08:00https://flcube.com/regend-therapeutics-pulmovinci-receives-fda-orphan-drug-designation-for-ipf/2025-02-08T16:28:10+08:00https://flcube.com/sichuan-kelun-biotechs-datailai-gains-nmpa-approval-for-colorectal-cancer-treatment/2025-02-08T15:55:02+08:00https://flcube.com/cansino-biologics-dtcp-vaccine-for-infants-gains-priority-review-in-china/2025-02-08T15:39:08+08:00https://flcube.com/keymed-biosciences-kangyueda-gains-nmpa-approval-for-seasonal-allergic-rhinitis/2025-02-08T15:17:31+08:00https://flcube.com/novo-nordisks-mim8-shows-promise-in-hemophilia-a-trial-with-98-caregiver-preference/2025-02-08T15:09:43+08:00https://flcube.com/remegens-executive-director-he-ruyi-resigns-for-career-development/2025-02-08T14:51:59+08:00https://flcube.com/biokin-pharmaceuticals-bl-m07d1-gains-nmpa-approval-for-phase-iii-study/2025-02-08T14:43:23+08:00https://flcube.com/abbvies-emblaveo-wins-fda-approval-for-complicated-intra-abdominal-infections/2025-02-08T14:30:30+08:00https://flcube.com/zhongsheng-pharma-gains-fda-approval-for-phase-ii-study-of-ray1225/2025-02-08T14:01:17+08:00https://flcube.com/siemens-healthineers-posts-strong-q1-results-with-5-7-revenue-growth/2025-02-08T13:55:05+08:00https://flcube.com/bio-theras-biosimilars-bat2306-and-bat2506-accepted-for-review-by-nmpa-and-ema/2025-02-08T13:49:46+08:00https://flcube.com/bain-capital-backed-tenacia-strikes-deal-with-praxis-precision-medicines-for-essential-tremor-treatment/2025-02-08T13:05:12+08:00https://flcube.com/tianjin-lisheng-pharmaceutical-co-ltd-to-sell-stake-in-mitsubishi-tanabes-china-subsidiary/2025-02-08T12:55:04+08:00https://flcube.com/henlius-biotech-licenses-hlx15-to-dr-reddys-for-us-and-european-markets/2025-02-07T23:10:05+08:00https://flcube.com/innovent-biologics-posts-strong-q4-sales-eyes-2025-product-launches/2025-02-07T23:01:27+08:00https://flcube.com/bristol-myers-squibb-posts-8-q4-revenue-growth-driven-by-opdivo-and-new-products/2025-02-07T22:53:48+08:00https://flcube.com/cansinos-tetanus-vaccine-nda-accepted-for-review-by-nmpa/2025-02-07T22:46:06+08:00https://flcube.com/huahai-pharma-set-to-launch-il-17-antibody-hb0017-clinical-study-for-hs/2025-02-07T22:38:05+08:00https://flcube.com/hotgen-biotech-gains-nmpa-approval-for-aa001-clinical-trials-in-alzheimers-disease/2025-02-07T22:27:10+08:00https://flcube.com/merck-initiates-phase-iii-waveline-010-study-for-zilovertamab-vedotin-in-dlbcl/2025-02-07T22:16:56+08:00https://flcube.com/chipscreen-biosciences-gains-nmpa-approval-for-epidaza-phase-iii-study/2025-02-07T22:02:59+08:00https://flcube.com/alphamab-and-cspc-gain-nmpa-approval-for-jskn003-phase-iii-trial-in-her2-positive-breast-cancer/2025-02-07T21:50:28+08:00https://flcube.com/gene-cradles-gc310-receives-tacit-approval-from-nmpa-for-wilsons-disease/2025-02-07T21:41:12+08:00https://flcube.com/hanx-biopharmaceuticals-gains-nmpa-approval-for-hx044-clinical-trials/2025-02-07T21:30:38+08:00https://flcube.com/likang-life-sciences-gains-fda-approval-for-lk101-clinical-trials/2025-02-07T21:18:07+08:00https://flcube.com/cr-sanjiu-gains-sasac-approval-for-tasly-pharma-acquisition/2025-02-07T21:03:35+08:00https://flcube.com/ema-committee-backs-subcutaneous-rybrevant-for-lung-cancer-treatment/2025-02-07T20:54:13+08:00https://flcube.com/akeso-completes-enrollment-for-global-phase-iii-trial-of-ivonescimab-in-lung-cancer/2025-02-07T19:47:16+08:00https://flcube.com/bayer-files-for-ema-approval-of-kerendia-for-heart-failure/2025-02-07T19:40:50+08:00https://flcube.com/boston-scientific-posts-strong-q4-and-full-year-2024-results/2025-02-07T19:32:28+08:00https://flcube.com/vigonvita-life-sciences-files-for-ipo-on-hong-kong-stock-exchange/2025-02-07T19:25:16+08:00https://flcube.com/nhsa-regulates-drg-dip-payment-methods-under-13n-system/2025-02-07T19:11:59+08:00https://flcube.com/chinas-nhsa-and-mof-push-for-drg-dip-payment-reforms-by-2025/2025-02-07T19:08:07+08:00https://flcube.com/sino-biopharmaceuticals-tulobuterol-patch-gains-nmpa-approval/2025-02-07T19:00:14+08:00https://flcube.com/regenerons-q4-financials-show-10-revenue-growth-driven-by-eylea-and-libtayo/2025-02-07T17:33:39+08:00https://flcube.com/eli-lillys-q4-sales-soar-45-to-13-53b-on-strength-of-glp-1-drugs/2025-02-07T11:48:45+08:00https://flcube.com/zhonghong-pulin-partners-with-shanghai-pharma-for-logistics-and-distribution/2025-02-06T22:30:05+08:00https://flcube.com/suzhou-jade-biomedical-secures-usd-10-million-series-b-financing/2025-02-06T22:19:58+08:00https://flcube.com/worg-pharmaceuticals-raises-rmb-400-million-in-series-b-funding/2025-02-06T22:11:03+08:00https://flcube.com/luye-life-sciences-partners-with-uzbekistan-to-establish-vaccine-center/2025-02-06T22:08:48+08:00https://flcube.com/celregen-licenses-regenerative-therapy-cls001-from-japans-cellusion/2025-02-06T22:05:41+08:00https://flcube.com/transcentas-first-in-class-gremlin1-antibody-tst003-receives-fda-ind-clearance/2025-02-06T21:53:20+08:00https://flcube.com/bide-pharmatech-set-for-ipo-on-shanghais-star-market/2025-02-06T21:49:04+08:00https://flcube.com/nmpa-releases-58th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2025-02-06T21:41:50+08:00https://flcube.com/alphamab-3dmeds-envafolimab-gains-fda-fast-track-status-for-sarcoma-treatment/2025-02-06T21:38:24+08:00https://flcube.com/guangdong-launches-free-hpv-vaccination-program-for-school-aged-girls/2025-02-06T21:21:43+08:00https://flcube.com/suzhou-zelgen-completes-phase-ii-study-of-jakinib-for-ankylosing-spondylitis/2025-02-06T21:19:37+08:00https://flcube.com/hubei-province-proposes-national-tcm-patent-medicine-procurement-alliance/2025-02-06T21:16:07+08:00https://flcube.com/buchang-pharmaceuticals-gains-nmpa-approval-for-bc008-1a-clinical-study/2025-02-06T21:11:01+08:00https://flcube.com/cde-prioritizes-review-of-pearl-bios-breatinib-for-nsclc-treatment/2025-02-06T21:08:12+08:00https://flcube.com/jiangsu-hengrui-medicine-gains-nmpa-approval-for-hrs-6209-clinical-study/2025-02-06T21:00:16+08:00https://flcube.com/hainans-lecheng-zone-updates-special-drug-insurance-list-with-expanded-coverage/2025-02-06T20:57:43+08:00https://flcube.com/shenzhen-vivolight-raises-rmb-100-million-in-series-d1-financing-for-laser-therapy-development/2025-02-06T20:49:50+08:00https://flcube.com/best-covered-raises-rmb-100-million-in-series-a-funding-for-cognitive-impairment-solution/2025-02-06T20:19:47+08:00https://flcube.com/us-blocks-asymchems-acquisition-of-snapdragon-chemistry/2025-02-06T20:15:02+08:00https://flcube.com/ascletis-completes-enrollment-for-hiv-functional-cure-study-with-pd-l1-antibody-asc22/2025-02-06T20:12:08+08:00https://flcube.com/cde-issues-guidelines-for-anti-tumor-adc-clinical-development/2025-02-06T20:07:34+08:00https://flcube.com/eli-lilly-announces-global-c-suite-changes-new-leadership-in-china/2025-02-06T20:05:43+08:00https://flcube.com/chinas-policy-shifts-medical-device-procurement-toward-domestic-products/2025-02-06T20:03:19+08:00https://flcube.com/antengene-expands-to-australia-with-new-melbourne-office/2025-02-06T20:00:59+08:00https://flcube.com/gsk-reports-7-full-year-sales-growth-in-2024-driven-by-specialty-medicines/2025-02-06T18:54:17+08:00https://flcube.com/msd-reports-strong-global-sales-growth-in-2024-despite-china-challenges/2025-02-06T18:49:45+08:00https://flcube.com/amgen-reports-strong-q4-and-full-year-2024-sales-growth/2025-02-06T18:43:12+08:00https://flcube.com/novo-nordisk-reports-soaring-global-sales-in-2024-driven-by-diabetes-and-obesity-care/2025-02-06T18:06:39+08:00https://flcube.com/astellas-pharma-submits-nda-for-avacincaptad-pegol-in-japan-for-geographic-atrophy/2025-02-06T17:57:20+08:00https://flcube.com/roches-susvimo-approved-by-fda-for-diabetic-macular-edema/2025-02-06T17:45:32+08:00https://flcube.com/fda-approves-enhertu-for-her2-low-and-her2-ultralow-breast-cancer/2025-02-06T16:39:03+08:00https://flcube.com/immunophage-partners-with-gobroad-cancer-hospital-for-ipg1094-phase-ii-study/2025-02-06T16:10:51+08:00https://flcube.com/betta-pharmaceuticals-gains-nmpa-approval-for-bpi-452080-clinical-study/2025-02-06T15:14:07+08:00https://flcube.com/haiscos-hsk39004-gains-nmpa-approval-for-copd-clinical-trials/2025-02-06T15:03:58+08:00https://flcube.com/sino-medical-sciences-nc-rockstar-catheter-gains-mda-approval-in-malaysia/2025-02-06T14:56:24+08:00https://flcube.com/henan-lingrui-to-acquire-yingu-pharma-for-rmb-704-million/2025-02-06T14:03:10+08:00https://flcube.com/junshi-biosciences-receives-nmpa-approval-for-js213-clinical-trials/2025-02-06T13:37:16+08:00https://flcube.com/cloudr-group-deepseeker-r1-chronic-disease-management/2025-02-06T13:11:03+08:00https://flcube.com/henlius-serplulimab-receives-eu-approval-for-extensive-stage-small-cell-lung-cancer/2025-02-06T12:58:03+08:00https://flcube.com/harbour-biomed-receives-nmpa-clearance-for-copd-treatment-hbm9378-skb378/2025-02-06T12:45:32+08:00https://flcube.com/lepu-medtech-receives-approval-for-innovative-peripheral-cutting-balloon/2025-02-06T02:18:06+08:00https://flcube.com/lepu-medtech-prices-gdr-offering-for-international-expansion/2025-02-06T02:15:35+08:00https://flcube.com/zhongao-biopharmaceutical-secures-series-a-funding-for-cancer-and-hpv-related-disease-rd/2025-02-06T02:13:21+08:00https://flcube.com/nhsa-launches-expert-review-for-2025-nrdl-update-in-china/2025-02-06T02:05:57+08:00https://flcube.com/daehwa-pharmaceutical-files-nda-for-liporaxel-in-china-for-gastric-cancer-treatment/2025-02-06T02:03:23+08:00https://flcube.com/antengenes-atg-101-receives-orphan-drug-designation-for-pancreatic-cancer/2025-02-06T01:58:02+08:00https://flcube.com/ascletis-pharma-and-roche-terminate-promotion-agreement-for-pegasys/2025-02-06T01:55:23+08:00https://flcube.com/apollomics-set-to-merge-with-maxpro-capital-for-nasdaq-listing/2025-02-06T01:52:41+08:00https://flcube.com/everest-medicines-appoints-rogers-yongqing-luo-as-new-ceo/2025-02-06T01:46:25+08:00https://flcube.com/lees-pharmaceutical-reports-h1-revenue-growth-amid-product-portfolio-shift/2025-02-06T01:43:35+08:00https://flcube.com/junshi-biosciences-tuoyi-approved-for-first-line-nsclc-treatment-in-china/2025-02-06T01:40:04+08:00https://flcube.com/sun-novos-stc007-gains-nmpa-approval-for-postoperative-pain-study/2025-02-06T01:36:41+08:00https://flcube.com/wuxi-biologics-partners-with-elpiscience-for-macromolecule-development/2025-02-06T01:34:18+08:00https://flcube.com/tasly-pharmaceuticals-gains-nmpa-approval-for-b1344-diabetes-study/2025-02-06T01:30:56+08:00https://flcube.com/clover-biopharmaceuticals-reports-positive-phase-iii-data-for-covid-19-vaccine-scb-2019/2025-02-06T01:28:26+08:00https://flcube.com/remegen-announces-positive-phase-iii-results-for-telitacicept-in-sle/2025-02-06T01:25:27+08:00https://flcube.com/beigenes-brukinsa-receives-new-eu-and-uk-indications-for-btk-inhibitor/2025-02-06T01:22:33+08:00https://flcube.com/alphamab-oncology-doses-first-patient-in-phase-i-study-for-jskn003-in-australia/2025-02-06T01:17:41+08:00https://flcube.com/beijing-launches-hiv-precision-medicine-standardization-project/2025-02-06T01:15:09+08:00https://flcube.com/fosun-pharma-signs-exclusive-licensing-deal-for-h008-with-carephar/2025-02-06T01:12:23+08:00https://flcube.com/suzhou-weiyou-gene-bio-raises-pre-series-a-funding-for-gene-therapy-pipeline/2025-02-06T01:08:33+08:00https://flcube.com/kamari-pharma-completes-8m-investment-from-chinese-fund-gibf2/2025-02-06T00:50:44+08:00https://flcube.com/joincares-modified-drug-xyp-001-gains-nmpa-approval-for-ipf-trial/2025-02-06T00:45:14+08:00https://flcube.com/koutech-robotics-secures-series-a-funding-for-surgical-innovation/2025-02-06T00:42:37+08:00https://flcube.com/carsgen-therapeutics-presents-positive-phase-ib-ii-data-for-ct053-at-car-tcr-summit/2025-02-06T00:28:57+08:00https://flcube.com/joincare-pharmaceuticals-prices-gdrs-on-six-swiss-exchange/2025-02-06T00:26:14+08:00https://flcube.com/northeast-pharmaceutical-to-invest-in-shanghai-subsidiary-for-adc-and-car-t-development/2025-02-06T00:23:45+08:00https://flcube.com/beijing-designates-923-medical-entities-for-national-reimbursement-drug-list/2025-02-06T00:17:32+08:00https://flcube.com/immuno-cure-biotech-acquires-majority-stake-in-shanghai-teresa-healthcare/2025-02-06T00:15:42+08:00https://flcube.com/takeda-reports-4-5-revenue-growth-in-first-nine-months-of-fiscal-year/2025-02-05T21:42:42+08:00https://flcube.com/tofflon-to-join-shanghai-biomedical-ma-fund-with-leading-firms/2025-02-05T21:32:39+08:00https://flcube.com/becton-dickinson-considers-spinning-off-life-sciences-division/2025-02-05T21:21:53+08:00https://flcube.com/vantive-launches-as-standalone-vital-organ-therapy-company-post-carlyle-acquisition/2025-02-05T21:08:25+08:00https://flcube.com/nona-biosciences-partners-with-invetx-for-animal-health-therapies/2025-02-05T20:41:20+08:00https://flcube.com/abbvie-reports-strong-q4-and-full-year-2024-financials/2025-02-05T20:12:46+08:00https://flcube.com/iaso-bios-car-t-therapy-fucaso-accepted-for-review-in-singapore/2025-02-05T20:06:20+08:00https://flcube.com/novartis-reports-12-yoy-growth-in-full-year-net-sales/2025-02-05T19:57:11+08:00https://flcube.com/daiichi-sankyo-reports-16-6-revenue-growth-in-first-three-quarters-of-fy2024/2025-02-05T18:03:43+08:00https://flcube.com/pfizer-reports-7-revenue-growth-in-2024-expects-steady-performance-in-2025/2025-02-05T17:57:14+08:00https://flcube.com/roche-reports-7-growth-in-full-year-sales-strength-in-pharmaceuticals/2025-02-05T17:24:07+08:00https://flcube.com/sanofi-reports-strong-q4-growth-plans-eur-5-billion-share-buyback/2025-02-05T17:14:01+08:00https://flcube.com/xtalpi-partners-with-jw-pharmaceutical-to-enhance-drug-discovery-with-ai/2025-02-05T02:14:44+08:00https://flcube.com/hengrui-medicines-dexmedetomidine-nasal-spray-gains-priority-review/2025-02-05T02:06:08+08:00https://flcube.com/santen-pharmaceutical-launches-new-plant-construction-in-suzhou/2025-02-05T02:05:23+08:00https://flcube.com/astrazeneca-and-mercks-lynparza-receives-new-approval-in-china/2025-02-05T01:47:03+08:00https://flcube.com/shandong-luoxin-partners-with-shanghai-pharma-for-strategic-services/2025-02-05T01:43:20+08:00https://flcube.com/nhsa-releases-guide-on-volume-based-procurement-drug-equivalents/2025-02-05T01:37:31+08:00https://flcube.com/zelgen-biopharmaceuticals-gains-nmpa-approval-for-jacktinib-clinical-trial-in-sle/2025-02-05T01:35:29+08:00https://flcube.com/f-star-therapeutics-takeover-by-sino-biopharmaceutical-delayed-amid-cfius-review/2025-02-05T01:32:55+08:00https://flcube.com/shenzhen-neuroplus-secures-seed-funding-for-neuromodulation-and-bioelectronic-medicine/2025-02-05T01:28:39+08:00https://flcube.com/merck-kgaa-opens-viral-clearance-lab-in-shanghais-biologics-testing-center/2025-02-05T01:17:56+08:00https://flcube.com/metis-therapeutics-in-licenses-voronois-pan-raf-inhibitor-program/2025-02-05T01:16:02+08:00https://flcube.com/heilongjiang-launches-longjiang-huiminbao-supplementary-health-insurance-scheme/2025-02-05T01:09:35+08:00https://flcube.com/hec-pharma-overturns-patent-decision-against-novartis-gilenya/2025-02-05T01:07:06+08:00https://flcube.com/nerviano-medical-sciences-collaborates-with-merck-on-parp1-inhibitor-nms-293/2025-02-05T01:00:55+08:00https://flcube.com/modernas-cmo-expresses-eagerness-to-bring-mrna-vaccines-to-china/2025-02-05T00:43:58+08:00https://flcube.com/novartis-faces-setback-in-us-patent-battle-over-multiple-sclerosis-drug-gilenya/2025-02-05T00:41:29+08:00https://flcube.com/sino-biopharmaceutical-licenses-lanifibranor-for-nash-treatment-from-inventiva/2025-02-05T00:36:31+08:00https://flcube.com/menarini-and-origimed-partner-on-pan-cancer-single-cell-diagnostic-platform/2025-02-05T00:27:40+08:00https://flcube.com/jenscare-scientific-set-for-ipo-to-fund-structural-heart-disease-solutions/2025-02-05T00:21:51+08:00https://flcube.com/innocare-pharmas-ipo-raises-411m-for-drug-rd-and-platform-upgrade/2025-02-05T00:18:33+08:00https://flcube.com/aim-vaccine-plans-ipo-to-fund-vaccine-rd-and-pipeline-expansion/2025-02-05T00:10:58+08:00https://flcube.com/arctic-vision-administers-first-injection-of-arvn001-for-uveitis-macular-edema/2025-02-04T23:01:50+08:00https://flcube.com/synthgene-partners-with-micornano-for-comprehensive-solutions-in-nucleic-acid-drugs/2025-02-04T22:56:08+08:00https://flcube.com/thunderbio-secures-funding-from-guangzhou-lbp-for-pcr-innovation/2025-02-04T22:47:23+08:00https://flcube.com/fujian-cosunter-receives-nmpa-approval-for-covid-19-drug-candidate-gst-hg171/2025-02-04T22:35:11+08:00https://flcube.com/everest-medicines-gains-cde-approval-for-ever001-phase-ib-study/2025-02-04T22:32:56+08:00https://flcube.com/boston-scientific-completes-first-surgery-with-rotapro-in-china/2025-02-04T22:30:11+08:00https://flcube.com/sihuan-pharmaceutical-reports-decline-in-revenues-amid-covid-19-lockdowns/2025-02-04T22:27:33+08:00https://flcube.com/shuangcheng-pharma-licenses-us-rights-for-paclitaxel-injection-to-meitheal/2025-02-04T22:24:25+08:00https://flcube.com/sino-medical-sciences-gains-approval-for-drug-eluting-stent-system/2025-02-04T17:53:43+08:00https://flcube.com/tris-pharma-and-pediatrix-therapeutics-adhd-drug-gains-priority-review-in-china/2025-02-04T17:51:09+08:00https://flcube.com/angel-pharmaceuticals-gains-cde-approval-for-mupadolimab-phase-i-ib-study/2025-02-04T17:47:56+08:00https://flcube.com/yichang-hec-reports-strong-recovery-in-2022-interim-results/2025-02-04T17:42:43+08:00https://flcube.com/sino-biopharmaceutical-reports-mixed-results-in-2022-interim-report/2025-02-04T17:40:16+08:00https://flcube.com/gluetacs-therapeutics-files-ind-for-molecular-glue-degrading-agent-in-china/2025-02-04T17:17:35+08:00https://flcube.com/global-cord-blood-corporation-appoints-liquidators-amid-shareholder-dispute/2025-02-04T17:10:11+08:00https://flcube.com/hansoh-pharmaceutical-licenses-kiomedine-one-for-osteoarthritis-treatment/2025-02-04T17:05:55+08:00https://flcube.com/ubrigene-raises-hundreds-of-millions-in-series-c-financing-round/2025-02-04T16:58:43+08:00https://flcube.com/chinas-first-proton-therapy-system-approved-by-nmpa/2025-02-04T16:56:14+08:00https://flcube.com/brii-biosciences-publishes-positive-phase-i-results-for-ppd-therapy-brii-296/2025-02-04T16:51:38+08:00https://flcube.com/sino-biopharmaceuticals-tdi01-receives-clinical-trial-approval-for-covid-19/2025-02-04T16:47:26+08:00https://flcube.com/china-resources-pharma-reports-strong-interim-results-amid-covid-19/2025-02-04T16:42:00+08:00https://flcube.com/sciwind-biosciences-partners-with-synerk-for-sirna-therapeutics-development/2025-02-04T16:38:54+08:00https://flcube.com/legend-biotechs-carvykti-approved-in-japan-for-relapsed-multiple-myeloma/2025-02-04T16:30:30+08:00https://flcube.com/eureka-biotech-partners-with-ucello-for-universal-car-t-cell-therapy-development/2025-02-04T16:21:06+08:00https://flcube.com/terumo-blood-and-cell-technologies-partners-with-eurekabio-to-establish-cell-therapy-lab/2025-02-04T16:15:44+08:00https://flcube.com/merck-sharp-dohme-partners-with-sinopharm-for-molnupiravir-in-china/2025-02-04T16:05:43+08:00https://flcube.com/nmpa-releases-59th-batch-of-reference-drugs-for-generic-quality-evaluation/2025-02-04T16:01:45+08:00https://flcube.com/sciclone-pharmaceuticals-reports-10-8-revenue-growth-in-2022-interim-results/2025-02-04T15:59:52+08:00https://flcube.com/harbour-biomed-doses-first-subject-in-phase-i-study-for-hbm9378-in-china/2025-02-04T15:57:17+08:00https://flcube.com/microport-cardioflows-alwide-plus-balloon-catheter-approved-in-colombia/2025-02-04T15:48:40+08:00https://flcube.com/zai-lab-licenses-seagens-tivdak-for-greater-china-development-and-commercialization/2025-02-04T15:43:49+08:00https://flcube.com/telix-pharmaceuticals-gains-ind-approval-for-tlx250-cdx-in-china/2025-02-04T15:40:34+08:00https://flcube.com/fosun-pharma-launches-20ml-spsb-liquid-product-in-us-market/2025-02-04T15:36:51+08:00https://flcube.com/mercks-gabor-outlines-ai-and-biomedicine-strategy-in-china/2025-02-04T15:33:37+08:00https://flcube.com/luye-pharma-grants-ici-pakistan-distribution-rights-for-schizophrenia-drug-seroquel/2025-02-04T15:29:52+08:00https://flcube.com/zelgen-files-nda-for-jacktinib-to-treat-myelofibrosis-in-china/2025-02-04T14:05:37+08:00https://flcube.com/innovent-biologics-reports-15-3-revenue-growth-in-2022-interim-results/2025-02-04T14:03:08+08:00https://flcube.com/neurophth-biotechnology-doses-first-patient-in-phase-iii-trial-for-nr082/2025-02-04T13:54:51+08:00https://flcube.com/bio-thera-solutions-completes-phase-i-study-for-covid-19-antibody-bat2022/2025-02-04T13:25:37+08:00https://flcube.com/allergan-aesthetics-opens-shanghai-innovation-center-for-medical-aesthetics/2025-02-04T13:23:09+08:00https://flcube.com/biosyngen-to-establish-cell-therapy-gmp-facility-in-singapore/2025-02-04T13:21:07+08:00https://flcube.com/luye-pharma-reports-decline-in-h1-revenue-and-profits-amid-market-challenges/2025-02-04T13:18:19+08:00https://flcube.com/parexel-opens-clinical-study-supply-chain-center-in-suzhou/2025-02-04T13:13:28+08:00https://flcube.com/abbisko-therapeutics-doses-first-patient-in-phase-i-study-of-absk043/2025-02-04T13:09:23+08:00https://flcube.com/arctic-vision-enrolls-first-patient-in-phase-iii-study-for-arvn002/2025-02-04T13:03:59+08:00https://flcube.com/bioarctic-ab-secures-global-rights-to-pyroglu-a%ce%b2-antibody-program-in-bms-deal/2025-02-04T13:00:23+08:00https://flcube.com/3d-medicines-partners-with-denfo-medical-for-cancer-therapy-development/2025-02-04T12:57:23+08:00https://flcube.com/simcere-grants-almirall-global-rights-to-autoimmune-drug-sim0278/2025-02-04T12:42:01+08:00https://flcube.com/insight-lifetech-raises-funds-for-cardiovascular-solutions-expansion/2025-02-04T12:35:27+08:00https://flcube.com/biosyngens-first-in-class-drug-candidate-brg01-accepted-for-ind-review/2025-02-04T01:23:47+08:00https://flcube.com/zai-lab-reports-strong-revenue-growth-in-2022-interim-results/2025-02-04T01:21:25+08:00https://flcube.com/alphamab-oncologys-kn019-achieves-primary-endpoint-in-phase-ii-ra-study/2025-02-04T01:18:15+08:00https://flcube.com/wuxi-biologics-partners-with-neox-biotech-to-advance-ai-driven-drug-development/2025-02-04T01:15:56+08:00https://flcube.com/luye-pharmas-shandong-boan-partners-with-shanghai-pharmaceutical-for-biologics-manufacturing/2025-02-04T01:10:05+08:00https://flcube.com/staidsons-stsp-0601-receives-clinical-trial-approval-for-hemophilia-treatment/2025-02-04T01:04:49+08:00https://flcube.com/henlius-biotech-gets-fda-nod-for-hlx07-clinical-study-in-cscc/2025-02-04T01:00:24+08:00https://flcube.com/suzhou-novoprotein-lists-on-shanghais-star-market-for-rd-expansion/2025-02-04T00:57:32+08:00https://flcube.com/rainmed-medicals-caffr-system-receives-tga-approval-for-coronary-disease-diagnosis/2025-02-04T00:53:46+08:00https://flcube.com/neushen-therapeutics-closes-20m-series-pre-a-financing-for-cns-drug-development/2025-02-04T00:51:31+08:00https://flcube.com/boston-scientific-launches-disposable-rf-electrode-for-chronic-pain-in-china/2025-02-04T00:49:03+08:00https://flcube.com/rundo-med-tech-partners-with-baidu-to-advance-digital-clinical-trials/2025-02-04T00:46:29+08:00https://flcube.com/chinas-nmpa-releases-60th-batch-of-reference-drugs-for-generic-quality-evaluation/2025-02-04T00:36:48+08:00https://flcube.com/china-medical-system-licenses-botulinum-toxin-from-south-koreas-bmi-korea/2025-02-04T00:34:43+08:00https://flcube.com/junshi-biosciences-launches-pd-1-inhibitor-tuoyi-for-advanced-nsclc-in-china/2025-02-04T00:32:14+08:00https://flcube.com/betta-pharmaceuticals-raises-140-5m-for-drug-industrialization-base-in-zhejiang/2025-02-04T00:29:19+08:00https://flcube.com/chinas-volume-based-procurement-cuts-high-value-medical-consumables-costs-by-84/2025-02-04T00:26:30+08:00https://flcube.com/everest-medicines-xerava-approved-in-hong-kong-for-complicated-intra-abdominal-infections/2025-02-04T00:24:49+08:00https://flcube.com/ascletis-pharma-doses-first-patient-in-phase-ii-study-of-asc41-for-nash/2025-02-04T00:22:04+08:00https://flcube.com/transcentas-tst004-receives-fda-ind-clearance-for-igan-treatment/2025-02-04T00:18:59+08:00https://flcube.com/connect-biopharmas-cbp-201-shows-positive-results-in-atopic-dermatitis-study/2025-02-04T00:16:31+08:00https://flcube.com/kira-pharmaceuticals-gets-fda-green-light-for-phase-ii-study-of-kp104-in-sle-tma/2025-02-04T00:12:11+08:00https://flcube.com/bgi-genomics-added-to-us-defense-departments-investment-ban-list/2025-02-04T00:02:57+08:00https://flcube.com/convalife-and-jointown-partner-for-global-drug-development-and-commercialization/2025-02-04T00:00:58+08:00https://flcube.com/eli-lillys-retevmo-wins-first-china-approvals-for-ret-driven-cancers/2025-02-03T23:34:17+08:00https://flcube.com/vectorbuilder-raises-56-6m-in-series-c-to-expand-life-science-rd/2025-02-03T23:31:48+08:00https://flcube.com/wuxi-biologics-removed-from-us-unverified-list-amid-ongoing-restrictions/2025-02-03T23:29:13+08:00https://flcube.com/india-launches-anti-dumping-investigation-against-chinese-imports-of-metronidazole/2025-02-03T23:03:22+08:00https://flcube.com/chinas-nmpa-proposes-reforms-to-enhance-radiopharmaceutical-review-and-approval/2025-02-03T21:43:54+08:00https://flcube.com/ark-biosciences-ziresovir-shows-positive-results-in-phase-iii-airflo-study-for-rsv-infection/2025-02-03T21:41:42+08:00https://flcube.com/pfizers-talzenna-shows-positive-results-in-phase-iii-talapro-2-study-for-mcrpc/2025-02-03T21:37:25+08:00https://flcube.com/hua-medicines-dorzagliatin-approved-in-china-for-type-2-diabetes/2025-02-03T21:34:25+08:00https://flcube.com/allergan-aesthetics-launches-juvederm-volite-in-chinas-boao-lecheng/2025-02-03T21:26:47+08:00https://flcube.com/shanghai-lange-medtech-partners-with-yantai-desheng-for-fish-derived-rotator-cuff-patch/2025-02-03T21:21:43+08:00https://flcube.com/roche-boosts-china-investment-with-additional-rmb-250-million/2025-02-03T20:59:29+08:00https://flcube.com/nmpa-approves-jw-therapeutics-carteyva-for-recurrent-follicular-lymphoma/2025-02-03T20:56:13+08:00https://flcube.com/innovents-cyramza-gains-nmpa-approval-for-hepatocellular-carcinoma/2025-02-03T20:51:38+08:00https://flcube.com/sciwind-biosciences-initiates-us-phase-i-study-for-glp-1-agonist-xw014/2025-02-03T20:47:50+08:00https://flcube.com/fujian-cosunter-to-acquire-udca-capsules-technology-from-ruitailai/2025-02-03T20:43:46+08:00https://flcube.com/fujian-cosunter-doses-first-patient-in-phase-i-study-of-covid-19-drug-gst-hg171/2025-02-03T20:33:20+08:00https://flcube.com/salubris-pharmaceuticals-first-in-class-anti-tumor-drug-sal008-accepted-by-nmpa/2025-02-03T20:06:12+08:00https://flcube.com/roches-subcutaneous-herceptin-approved-in-china-for-her2-positive-breast-cancer/2025-02-03T19:32:45+08:00https://flcube.com/cde-releases-63rd-batch-of-chemical-generic-reference-preparations/2025-02-03T19:30:24+08:00https://flcube.com/jiangsu-launches-sunshine-procurement-platform-for-drugs-and-medical-consumables/2025-02-03T19:28:16+08:00https://flcube.com/mercks-keytruda-gains-9th-indication-approval-in-china-for-hepatocellular-carcinoma/2025-02-03T19:26:18+08:00https://flcube.com/pfizers-zavicefta-approved-in-china-for-pediatric-complex-intra-abdominal-infections/2025-02-03T19:16:15+08:00https://flcube.com/hutchmed-initiates-phase-ii-iii-study-of-sovleplenib-for-warm-aiha/2025-02-03T16:48:58+08:00https://flcube.com/harbour-biomed-licenses-batoclimab-to-cspcs-nbp-pharma-for-greater-china/2025-02-03T16:45:06+08:00https://flcube.com/guangdong-zhongsheng-receives-uspto-patent-for-fgfr4-inhibitor-zsp1241/2025-02-03T16:35:54+08:00https://flcube.com/simcere-completes-enrollment-for-phase-iii-study-of-cdk4-6-inhibitor-in-mtnbc/2025-02-03T16:29:30+08:00https://flcube.com/hengrui-medicines-pyrotinib-filing-accepted-for-review-by-nmpa/2025-02-03T16:26:50+08:00https://flcube.com/china-resources-partners-with-fosun-pharma-to-expand-global-healthcare-footprint/2025-02-03T15:58:52+08:00https://flcube.com/azvudine-included-in-chinas-covid-19-treatment-protocol/2025-02-03T15:55:26+08:00https://flcube.com/nmpa-approves-ind-filing-for-henan-genuine-biotechs-long-acting-hiv-drug-cl-197/2025-02-03T15:51:39+08:00https://flcube.com/wuxi-biologics-partners-with-toregem-biopharma-on-anti-usag-1-monoclonal-antibody/2025-02-03T15:48:06+08:00https://flcube.com/beigene-partners-with-amoy-diagnostics-for-companion-diagnostics-development/2025-02-03T15:42:28+08:00https://flcube.com/nmpa-approves-beijing-union-strongs-intracranial-aneurysm-surgical-planning-software/2025-02-03T15:37:30+08:00https://flcube.com/aier-eye-hospital-group-plans-ipo-on-chinext-board/2025-02-03T15:29:03+08:00https://flcube.com/beigene-partners-with-immune-onc-for-clinical-development-of-myeloid-checkpoint-inhibitors/2025-02-03T15:18:31+08:00https://flcube.com/cyagen-biosciences-partners-with-neurophth-for-ophthalmology-aav-capsid-development/2025-02-03T15:08:59+08:00https://flcube.com/iaso-biotherapeutics-licenses-cd19-binder-to-cabaletta-bio-for-autoimmune-diseases/2025-02-03T15:02:31+08:00https://flcube.com/henlius-biotechs-hanbeitai-biosimilar-accepted-for-review-by-cde/2025-02-03T14:58:49+08:00https://flcube.com/shanghai-launches-high-quality-development-pilot-for-public-hospitals/2025-02-03T14:55:15+08:00https://flcube.com/nmpa-introduces-electronic-certificates-for-biologics-and-narcotic-drugs/2025-02-03T14:51:11+08:00https://flcube.com/cde-releases-draft-guidelines-for-tumor-therapeutic-vaccine-clinical-trials/2025-02-03T14:48:41+08:00https://flcube.com/sprintray-raises-over-usd-100m-in-series-d-financing-for-dental-3d-printing/2025-02-03T14:46:34+08:00https://flcube.com/deepseeks-ai-transforming-drug-development-and-healthcare-in-china/2025-02-03T13:57:56+08:00https://flcube.com/remegens-telitacicept-receives-fda-orphan-drug-designation-for-myasthenia-gravis/2025-02-03T13:39:06+08:00https://flcube.com/jacobio-partners-with-merck-kgaa-for-kras-g12c-inhibitor-clinical-study/2025-02-03T13:35:41+08:00https://flcube.com/hotgen-biotech-gains-regulatory-approvals-in-saudi-arabia-and-india/2025-02-03T13:31:31+08:00https://flcube.com/beigenes-brukinsa-outperforms-imbruvica-in-phase-iii-alpine-study/2025-02-03T13:27:37+08:00https://flcube.com/hengrui-medicines-deputy-gm-tao-weikang-resigns-joins-qilu-pharma/2025-02-03T13:24:31+08:00https://flcube.com/proxinse-medtech-raises-series-a-funding-for-endoscope-camera-system/2025-02-03T13:21:36+08:00https://flcube.com/alphalife-sciences-raises-series-a-funding-for-clinical-research-saas/2025-02-03T13:15:56+08:00https://flcube.com/aosaikangs-neratinib-maleate-api-market-filing-accepted-by-nmpa/2025-02-03T12:58:27+08:00https://flcube.com/ausper-biopharma-raises-usd-16m-for-hbv-drug-and-vaccine-development/2025-02-03T12:55:44+08:00https://flcube.com/alioth-biotech-raises-rmb-100m-in-series-a-financing-for-pharma-processing-products/2025-02-03T12:48:52+08:00https://flcube.com/hicomp-microtech-raises-rmb-100m-in-series-b-financing-for-microfluidics-expansion/2025-02-03T12:43:14+08:00https://flcube.com/kintors-dual-c-myc-gspt1-degradation-therapy-gt19715-shows-promise-in-pre-clinical-studies/2025-02-03T12:37:45+08:00https://flcube.com/carsgens-bcma-targeted-car-t-therapy-ct053-gains-priority-review-in-china/2025-02-03T12:35:08+08:00https://flcube.com/lianbio-cancels-phase-iii-trial-for-truseltiq-in-china-amid-global-halt/2025-02-03T12:29:59+08:00https://flcube.com/accutar-biotechnology-initiates-phase-i-trial-for-er%ce%b1-targeting-degradation-molecule-ac0682/2025-02-03T12:25:22+08:00https://flcube.com/cde-releases-draft-guidelines-for-extrapolating-adult-drug-data-to-pediatric-use/2025-02-03T12:23:28+08:00https://flcube.com/kunshi-biotechnology-raises-angel-funding-for-engineered-macrophage-platform/2025-02-03T01:31:32+08:00https://flcube.com/akeso-biopharmas-cadonilimab-recommended-as-first-line-treatment-for-cervical-cancer/2025-02-03T01:29:03+08:00https://flcube.com/fosun-kites-yescarta-gains-priority-review-status-for-r-r-lbcl/2025-02-03T01:25:53+08:00https://flcube.com/genor-biopharma-initiates-first-patient-dosing-for-gb263t-in-china/2025-02-03T01:22:40+08:00https://flcube.com/akeso-biopharma-gains-nmpa-approval-for-ak112-and-ak119-clinical-study/2025-02-03T01:19:34+08:00https://flcube.com/innovent-biologics-publishes-mazdutide-phase-ib-study-results-for-obesity/2025-02-03T01:16:11+08:00https://flcube.com/sihuan-pharma-to-acquire-additional-stake-in-heilongjiang-duoduo-pharma/2025-02-03T01:11:52+08:00https://flcube.com/nhsa-completes-expert-review-for-nrdl-price-negotiation-process/2025-02-03T01:04:55+08:00https://flcube.com/beigenes-brukinsa-receives-positive-chmp-opinion-for-cll-approval/2025-02-03T01:02:18+08:00https://flcube.com/kira-pharmaceuticals-gains-nmpa-approval-for-phase-ii-study-of-kp104-in-pnh/2025-02-03T00:58:07+08:00https://flcube.com/remegens-telitacicept-gains-eu-china-approvals-for-global-phase-iii-study/2025-02-03T00:55:48+08:00https://flcube.com/zelgens-jacktinib-shows-strong-efficacy-in-phase-iii-myelofibrosis-study/2025-02-03T00:53:15+08:00https://flcube.com/ningbo-menovo-to-sell-zhejiang-liaoyuan-pharma-stake-to-jemincare-for-rmb-512-58m/2025-02-03T00:49:55+08:00https://flcube.com/shenzhen-genebiohealth-secures-usd-15m-for-bio-business-expansion/2025-02-03T00:42:47+08:00https://flcube.com/cspcs-generic-xofluza-gains-nmpa-approval-amid-roche-patent-dispute/2025-02-03T00:37:31+08:00https://flcube.com/gracell-biotechnologies-initiates-phase-ii-dosing-for-gc007g-in-b-all-patients/2025-02-03T00:32:19+08:00https://flcube.com/henlius-biotech-gains-nmpa-approval-for-phase-i-trial-of-hlx60-in-solid-tumors-and-lymphomas/2025-02-03T00:28:44+08:00https://flcube.com/pureid-medical-technology-secures-rmb-100m-series-b-funding/2025-02-03T00:26:11+08:00https://flcube.com/sinocelltechs-covid-19-vaccines-sctv01c-and-sctv01e-show-promising-phase-iii-results/2025-02-03T00:22:42+08:00https://flcube.com/jemincares-sonidegib-receives-first-prescriptions-in-china-for-basal-cell-carcinoma/2025-02-03T00:18:46+08:00https://flcube.com/salus-biomed-raises-over-rmb-100m-in-pre-series-a-financing/2025-02-03T00:16:14+08:00https://flcube.com/haisco-pharmas-ciprofol-injection-gains-nmpa-approval-for-gynecology-use/2025-02-03T00:11:33+08:00https://flcube.com/sciencare-pharmas-naltrexone-implant-prioritized-for-review-by-cde/2025-02-03T00:08:50+08:00https://flcube.com/grand-pharmas-tlx591-cdx-approved-for-prostate-cancer-diagnosis-in-china/2025-02-03T00:02:41+08:00https://flcube.com/eucure-biopharma-partners-with-syncromune-on-intratumoral-immunotherapy/2025-02-03T00:00:02+08:00https://flcube.com/abogen-biosciences-receives-uae-clinical-trial-approval-for-omicron-ba-4-5-mrna-vaccine/2025-02-02T23:54:57+08:00https://flcube.com/bayer-to-set-up-shenzhen-unit-to-boost-womens-healthcare-in-south-china/2025-02-02T23:52:37+08:00https://flcube.com/genscripts-legend-biotech-reports-usd-55m-in-carvykti-sales/2025-02-02T23:49:39+08:00https://flcube.com/yichang-hec-changjiang-pharmas-insulin-aspart-gains-nmpa-approval/2025-02-02T23:46:17+08:00https://flcube.com/henlius-biotechs-hanbeitai-gains-nmpa-approval-for-recurrent-glioblastoma/2025-02-02T23:37:41+08:00https://flcube.com/nhsa-responds-to-proposal-on-dental-implants-inclusion-in-nrdl/2025-02-02T23:32:03+08:00https://flcube.com/johnson-johnson-reports-q3-sales-growth-maintains-full-year-guidance/2025-02-02T23:30:12+08:00https://flcube.com/sichuan-biokin-pharma-plans-ipo-on-star-board-to-raise-rmb-1-422-billion/2025-02-02T23:26:49+08:00https://flcube.com/mabwell-biosciences-9mw3011-accepted-for-review-by-chinas-nmpa/2025-02-02T23:21:47+08:00https://flcube.com/zhiyi-biotechnology-receives-fda-clearance-for-sk10-in-chemotherapy-induced-diarrhea/2025-02-02T23:19:02+08:00https://flcube.com/shanghais-hrain-biotechnology-plans-ipo-on-star-board-to-raise-rmb-2-539-billion/2025-02-02T23:13:48+08:00https://flcube.com/hitgen-partners-with-c4x-discovery-to-identify-novel-inflammatory-disease-treatments/2025-02-02T23:10:12+08:00https://flcube.com/abbott-reports-q3-sales-growth-raises-full-year-eps-guidance/2025-02-02T23:03:53+08:00https://flcube.com/shaanxi-releases-notice-for-inter-provincial-orthodontic-brackets-vbp/2025-02-02T23:01:22+08:00https://flcube.com/hainan-poly-pharms-generic-ganciclovir-approved-in-sweden-for-cmv-retinitis/2025-02-02T22:58:52+08:00https://flcube.com/bio-theras-bat1806-biosimilar-accepted-for-review-by-european-medicine-agency/2025-02-02T22:56:21+08:00https://flcube.com/kactus-biosystems-raises-rmb-200m-in-series-b-financing-for-protein-and-enzyme-development/2025-02-02T22:52:38+08:00https://flcube.com/shenzhen-based-pregbio-raises-funds-for-non-invasive-prenatal-gene-detection/2025-02-02T22:50:12+08:00https://flcube.com/shandong-junxiu-biotechnology-secures-rmb-45m-in-series-b-financing/2025-02-02T22:45:09+08:00https://flcube.com/brii-biosciences-reports-positive-phase-i-results-for-hiv-treatments-brii-732-and-brii-778/2025-02-02T22:37:00+08:00https://flcube.com/ambrx-biopharma-halts-development-of-her2-adc-arx788-cuts-workforce/2025-02-02T21:56:14+08:00https://flcube.com/sinopharms-wuhan-institute-isolates-monkeypox-strains-begins-vaccine-research/2025-02-02T21:50:59+08:00https://flcube.com/catug-biotechnology-partners-with-duoning-to-advance-mrna-industrialization/2025-02-02T21:48:50+08:00https://flcube.com/fujian-procurement-center-announces-vbp-for-cardiac-and-laparoscopic-medical-consumables/2025-02-02T21:44:15+08:00https://flcube.com/ortho-k-lenses-included-in-hebeis-volume-based-procurement-list/2025-02-02T21:39:10+08:00https://flcube.com/jiangxi-leads-16-province-vbp-alliance-with-winning-bids-announced/2025-02-02T21:38:53+08:00https://flcube.com/chinas-8th-volume-based-procurement-round-begins-drug-info-filing/2025-02-02T21:38:52+08:00https://flcube.com/china-meheco-keyi-pharmas-ganciclovir-loses-vbp-bid-after-inspection-failure/2025-02-02T21:38:52+08:00https://flcube.com/hebei-leads-sanming-alliance-in-launching-8th-vbp-for-19-medical-consumables/2025-02-02T21:38:51+08:00https://flcube.com/nhsa-releases-guidelines-on-drug-procurement-and-pricing-management/2025-02-02T21:38:51+08:00https://flcube.com/liaoning-led-alliance-launches-volume-based-procurement-tender-for-hernia-and-dural-patches/2025-02-02T21:38:51+08:00https://flcube.com/shanghais-smpa-reduces-ceiling-price-for-non-winning-bids-in-artificial-joint-vbp-tender/2025-02-02T21:38:50+08:00https://flcube.com/fujians-fourth-round-vbp-seeks-public-feedback-on-drug-procurement-list/2025-02-02T21:38:50+08:00https://flcube.com/shanghai-enhances-biomedicine-ip-protection-with-new-procurement-linked-measures/2025-02-02T21:38:49+08:00https://flcube.com/nhsa-launches-service-specifications-for-medical-procurement-platform/2025-02-02T21:38:49+08:00https://flcube.com/chinas-health-authorities-investigate-alleged-price-manipulation-in-pharma-procurement-tenders/2025-02-02T21:38:48+08:00https://flcube.com/guangzhou-and-zhuhai-unveil-measures-to-stimulate-biopharmaceutical-industry-growth/2025-02-02T21:38:48+08:00https://flcube.com/nhsa-unveils-2024-medical-procurement-overhaul-aiming-for-synergy-between-national-and-provincial-levels/2025-02-02T21:38:47+08:00https://flcube.com/chinas-national-procurement-office-announces-continuous-vbp-for-joint-prosthetics/2025-02-02T21:38:47+08:00https://flcube.com/nhsa-mandates-standardized-online-procurement-for-injectable-drugs-to-ensure-pricing-transparency/2025-02-02T21:38:46+08:00https://flcube.com/shenzhens-draft-proposal-for-vbp-drug-procurement-and-medical-insurance-fund-management-released/2025-02-02T21:38:46+08:00https://flcube.com/chinas-nmpa-suspends-dr-reddys-atomoxetine-imports-amid-quality-concerns/2025-02-02T21:38:45+08:00https://flcube.com/hunan-province-launches-pilot-program-for-retail-sales-of-vbp-drugs-with-strict-guidelines/2025-02-02T21:38:45+08:00https://flcube.com/tianjin-healthcare-official-gao-xue-under-investigation/2025-02-02T21:38:44+08:00https://flcube.com/nhsa-seeks-expert-opinions-on-vbp-drug-quality-and-efficacy/2025-02-02T21:38:44+08:00https://flcube.com/nmpa-releases-61st-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2025-02-02T21:36:58+08:00https://flcube.com/betta-pharmaceuticals-bpi-460372-accepted-for-clinical-trial-review-by-nmpa/2025-02-02T21:35:15+08:00https://flcube.com/frontier-biotechnologies-secures-approval-for-hiv-therapy-alfusid/2025-02-02T21:32:49+08:00https://flcube.com/hengruis-camrelizumab-and-akesos-ak112-set-to-receive-breakthrough-designation-in-china/2025-02-02T21:29:50+08:00https://flcube.com/china-approves-gsks-juluca-for-hiv-1-infection/2025-02-02T21:24:41+08:00https://flcube.com/hengrui-medicine-files-for-dalpiciclib-as-initial-therapy-for-breast-cancer/2025-02-02T21:21:40+08:00https://flcube.com/hengrui-medicine-gains-approval-for-phase-ib-ii-study-of-shr-a1811-and-shr-1701-in-her2-positive-gastric-cancer/2025-02-02T21:18:43+08:00https://flcube.com/zhejiang-pushkang-biotech-raises-rmb-100m-in-series-c-financing/2025-02-02T21:16:04+08:00https://flcube.com/sinovac-partners-with-colombia-university-to-boost-vaccine-rd/2025-02-02T21:10:09+08:00https://flcube.com/seeneuro-medical-raises-rmb-100m-in-series-b-funding-for-neural-regulation-devices/2025-02-02T21:06:27+08:00https://flcube.com/micurx-pharmaceuticals-concludes-us-phase-i-study-for-mrx-8/2025-02-02T20:58:11+08:00https://flcube.com/henlius-biotechs-hanbeitai-approved-for-hepatocellular-carcinoma/2025-02-02T20:55:19+08:00https://flcube.com/antengenes-xpovio-receives-taiwan-fda-approval-for-multiple-indications/2025-02-02T20:52:42+08:00https://flcube.com/aim-vaccine-receives-cde-approval-for-serum-free-rabies-vaccine-trial/2025-02-02T20:48:22+08:00https://flcube.com/rici-healthcare-to-acquire-unicorn-ii-holdings-for-rmb-180m/2025-02-02T20:45:56+08:00https://flcube.com/roche-reports-q3-sales-growth-hit-by-covid-19-product-decline/2025-02-02T20:39:15+08:00https://flcube.com/sinovacs-varicella-vaccine-receives-who-pre-qualification/2025-02-02T17:31:41+08:00https://flcube.com/cspc-receives-cde-approval-for-generic-version-of-pfizers-xeljanz/2025-02-02T17:29:57+08:00https://flcube.com/medilink-therapeutics-yl217-receives-fda-ind-clearance-for-novel-adc-targeting-gastrointestinal-cancers/2025-02-02T17:26:29+08:00https://flcube.com/giant-biogene-set-for-ipo-on-hong-kong-stock-exchange-to-raise-funds-for-expansion/2025-02-02T17:04:24+08:00https://flcube.com/bimi-international-medical-to-sell-off-underperforming-subsidiary-chongqing-zhuoda/2025-02-02T16:59:10+08:00https://flcube.com/shandong-branden-medical-devices-files-for-ipo-on-star-board-to-raise-rmb-760m/2025-02-02T16:48:21+08:00https://flcube.com/gan-lee-pharmaceuticals-plans-rmb-814m-private-placement-for-working-capital/2025-02-02T16:43:16+08:00https://flcube.com/rongsheng-bio-set-for-ipo-on-star-board-to-boost-vaccine-rd/2025-02-02T16:40:26+08:00https://flcube.com/daiichi-sankyo-initiates-global-phase-ii-study-of-ds7300-for-small-cell-lung-cancer/2025-02-02T16:27:38+08:00https://flcube.com/abbiskos-absk021-gets-cde-approval-for-phase-iii-study-in-giant-cell-tumor-of-tendon-sheath/2025-02-02T16:25:04+08:00https://flcube.com/livzon-launches-national-rollout-of-covid-19-vaccine-v-01-in-china/2025-02-02T16:22:13+08:00https://flcube.com/venmedtech-raises-series-b-funding-for-iliac-vein-stent-and-product-rd/2025-02-02T16:17:21+08:00https://flcube.com/celgenyx-completes-rmb-100m-series-a-financing-for-next-gen-cell-therapy-development/2025-02-02T16:13:29+08:00https://flcube.com/easy-flow-medical-secures-angel-funding-for-peripheral-device-development/2025-02-02T16:09:02+08:00https://flcube.com/origincells-car-t-therapy-receives-fda-orphan-drug-designation-for-multiple-myeloma/2025-02-02T16:01:48+08:00https://flcube.com/novartis-q3-revenues-rise-4-yoy-china-sales-expand-despite-covid-lockdowns/2025-02-02T15:56:52+08:00https://flcube.com/ascentage-pharma-files-for-phase-ib-ii-study-of-bcl-2-inhibitor-in-systemic-lupus-erythematosus/2025-02-02T15:49:19+08:00https://flcube.com/shanghai-henlius-pd-1-inhibitor-serplulimab-gains-australian-clearance-for-phase-iii-study/2025-02-02T15:46:30+08:00https://flcube.com/ariemedi-secures-series-a-financing-to-expand-precision-navigation-solutions/2025-02-02T15:40:58+08:00https://flcube.com/clinbrain-raises-rmb-200-million-in-series-c-financing-to-boost-medical-big-data/2025-02-02T15:35:59+08:00https://flcube.com/covis-pharmas-copd-therapies-show-positive-results-in-phase-iii-avant-trial/2025-02-02T15:25:18+08:00https://flcube.com/huadong-medicine-reports-10-4-revenue-growth-in-q3-2022/2025-02-02T14:22:51+08:00https://flcube.com/ocumension-initiates-second-phase-iii-denali-study-for-ot-301-in-us/2025-02-02T14:10:47+08:00https://flcube.com/nankai-university-establishes-postgraduate-practice-base-with-china-resources-biopharma/2025-02-02T14:08:01+08:00https://flcube.com/yiming-and-wz-biosciences-collaborate-on-mrna-process-platform/2025-02-02T14:04:03+08:00https://flcube.com/beigenes-brukinsa-receives-multiple-marketing-approvals-in-latin-america/2025-02-02T13:58:35+08:00https://flcube.com/zhaoke-ophthalmology-completes-enrollment-for-intrarosa-phase-iii-trial/2025-02-02T13:55:08+08:00https://flcube.com/jw-therapeutics-partners-with-2seventy-bio-to-develop-cell-therapy-platform/2025-02-02T13:51:55+08:00https://flcube.com/ascletis-pharma-files-ind-for-monkeypox-antiviral-asc10-with-fda/2025-02-02T13:49:05+08:00https://flcube.com/simcere-receives-fda-clearance-for-clinical-study-of-sim0237/2025-02-02T13:45:49+08:00https://flcube.com/ping-an-life-insurance-reports-q3-results-advances-healthcare-strategy/2025-02-02T13:43:30+08:00https://flcube.com/united-labs-gains-nmpa-approval-for-ozempic-biosimilar-ind/2025-02-02T13:40:42+08:00https://flcube.com/chinas-nmpa-issues-new-drug-recall-management-measures/2025-02-02T13:35:05+08:00https://flcube.com/accumedicals-blood-flow-guided-stent-wins-nmpa-approval-for-brain-aneurysms/2025-02-02T13:29:46+08:00https://flcube.com/inxmed-and-huaota-bio-partner-to-develop-novel-solid-tumor-combination-therapy/2025-02-02T13:25:28+08:00https://flcube.com/lepu-scientech-medical-technology-sets-ipo-price-range-ahead-of-hong-kong-listing/2025-02-02T13:20:41+08:00https://flcube.com/wuxi-apptec-posts-stellar-q3-2022-results-with-209-profit-surge/2025-02-02T13:16:52+08:00https://flcube.com/innovents-tyvyt-approved-for-new-gastric-cancer-indication-by-nmpa/2025-02-02T02:06:09+08:00https://flcube.com/zhejiang-huahai-receives-fda-anda-approval-for-generic-tecfidera/2025-02-02T02:02:15+08:00https://flcube.com/novartis-expands-strategic-collaboration-with-boao-lecheng-pilot-zone/2025-02-02T01:59:42+08:00https://flcube.com/salubris-partners-with-alpha-molecular-for-ai-driven-obesity-drug-development/2025-02-02T01:57:02+08:00https://flcube.com/remegen-reports-397-47-yoy-revenue-growth-in-q3-2022/2025-02-02T01:50:05+08:00https://flcube.com/innovents-parsaclisib-filed-for-marketing-approval-in-china/2025-02-02T01:46:34+08:00https://flcube.com/proheal-pharmaceuticals-initiates-clinical-study-for-php1003-in-thyroid-associated-ophthalmopathy/2025-02-02T01:38:16+08:00https://flcube.com/hutchmed-initiates-phase-ii-iii-study-for-elunate-and-tyvyt-in-renal-cell-carcinoma/2025-02-02T01:29:03+08:00https://flcube.com/shanghai-pharmaceuticals-reports-12-86-yoy-revenue-growth-in-q3-2022/2025-02-02T01:25:25+08:00https://flcube.com/recbios-neoadjuvant-hpv-vaccine-accepted-for-review-by-nmpa/2025-02-02T01:21:55+08:00https://flcube.com/kintor-completes-enrollment-for-gt20029-phase-i-study-in-us/2025-02-02T01:17:44+08:00https://flcube.com/alphamab-oncology-gains-nmpa-approval-for-jskn003-clinical-trial/2025-02-02T01:14:56+08:00https://flcube.com/winhealths-ravicti-receives-orphan-drug-designation-in-taiwan/2025-02-02T01:12:00+08:00https://flcube.com/lees-pharmaceuticals-nvk-002-shows-strong-results-in-phase-iii-champ-study/2025-02-02T01:00:05+08:00https://flcube.com/cspcs-antibody-drug-conjugate-sys6002-gains-cde-approval-for-clinical-study/2025-02-02T00:54:28+08:00https://flcube.com/luye-pharmas-long-acting-il-4r%ce%b1-antibody-ba2101-gains-cde-approval/2025-02-02T00:49:57+08:00https://flcube.com/ausper-biopharmas-covid-19-nasal-spray-antibody-gets-nmpa-approval/2025-02-02T00:46:31+08:00https://flcube.com/mercks-q3-sales-rise-on-key-drug-performances-china-growth/2025-02-02T00:39:03+08:00https://flcube.com/salubris-partners-with-anlong-bio-for-small-nucleic-acid-drugs-in-hypertension/2025-02-02T00:36:15+08:00https://flcube.com/shanghai-launches-inhaled-covid-19-vaccine-booster-program/2025-02-02T00:30:54+08:00https://flcube.com/eli-lilly-cancels-licensing-deal-for-fosun-pharmas-fcn-338/2025-02-02T00:25:12+08:00https://flcube.com/junshi-biosciences-reports-55-drop-in-q3-revenues/2025-02-02T00:19:43+08:00https://flcube.com/shanghai-duoning-bio-partners-with-lisure-for-disposable-biopharma-system/2025-02-02T00:17:09+08:00https://flcube.com/santhera-and-reveragen-submit-nda-for-vamorolone-in-duchenne-muscular-dystrophy/2025-02-02T00:10:34+08:00https://flcube.com/chinas-national-plan-to-combat-microbial-drug-resistance-released/2025-02-02T00:03:13+08:00https://flcube.com/sanofis-q3-sales-rise-9-on-dupixent-and-flu-vaccine/2025-02-01T23:58:10+08:00https://flcube.com/novartis-cosentyx-gains-approval-for-new-doses-in-china/2025-02-01T23:55:02+08:00https://flcube.com/xtalpi-partners-with-janssen-to-accelerate-drug-discovery/2025-02-01T23:52:30+08:00https://flcube.com/nmpa-approves-kyowa-hakko-kirins-mogamulizumab-for-sezary-syndrome-and-mycosis-fungoides/2025-02-01T23:50:13+08:00https://flcube.com/nmpa-grants-second-approval-to-henlius-serplulimab-for-lung-cancer/2025-02-01T23:45:51+08:00https://flcube.com/innovents-cldn18-2-adc-ibi343-begins-phase-i-trial-in-australia/2025-02-01T23:41:59+08:00https://flcube.com/ascletis-signs-pact-with-pfizer-china-for-ritonavir-tablets/2025-02-01T23:39:35+08:00https://flcube.com/abbvies-2024-revenue-grows-despite-humira-decline-skyrizi-and-rinvoq-surge/2025-02-01T21:19:03+08:00https://flcube.com/nmpa-suspends-gsks-avodart-amid-inspection-findings/2025-02-01T20:52:10+08:00https://flcube.com/antengenes-atg-017-gets-fda-approval-for-phase-i-clinical-study/2025-02-01T20:48:40+08:00https://flcube.com/china-grands-stc3141-reaches-primary-endpoint-in-ards-phase-ib-study/2025-02-01T20:42:07+08:00https://flcube.com/allogene-overland-biopharm-completes-state-of-the-art-allocar-t-facility-in-shanghai/2025-02-01T20:39:14+08:00https://flcube.com/shandong-buchang-partners-with-remd-bio-for-bispecific-antibody-development/2025-02-01T20:32:43+08:00https://flcube.com/eucure-biopharma-partners-with-isu-abxis-to-develop-tri-specific-antibodies-using-yh003/2025-02-01T20:22:24+08:00https://flcube.com/zhejiang-medicines-arx788-advances-to-phase-ii-study-for-her2-positive-cholangiocarcinoma/2025-02-01T20:15:04+08:00https://flcube.com/simceres-sim0235-begins-us-phase-i-trial-for-anti-tumor-therapy/2025-02-01T20:08:41+08:00https://flcube.com/eli-lillys-peresolimab-and-loxo-783-gain-tacit-clinical-trial-approvals-in-china/2025-02-01T20:05:54+08:00https://flcube.com/novartis-cuts-back-on-us-development-of-beigenes-pd-1-inhibitor-tislelizumab/2025-02-01T20:02:56+08:00https://flcube.com/hua-medicine-launches-dorzagliatin-a-first-in-class-diabetes-drug-in-china/2025-02-01T19:54:45+08:00https://flcube.com/yiming-and-hexaells-hepacure-biocolumn-receives-ind-approval-for-hbv-induced-liver-failure/2025-02-01T19:46:50+08:00https://flcube.com/yiming-and-vitalgens-gene-therapy-vgr-r01-receives-cde-approval-for-bietti-crystalline-dystrophy/2025-02-01T19:36:52+08:00https://flcube.com/lianbios-tp-03-begins-phase-iii-trial-for-demodectic-blepharitis-in-china/2025-02-01T19:22:19+08:00https://flcube.com/ascletis-files-ind-application-for-covid-19-oral-inhibitor-asc11-with-fda/2025-02-01T19:07:40+08:00https://flcube.com/remegens-telitacicept-shows-positive-results-in-phase-ii-myasthenia-gravis-study/2025-02-01T19:04:40+08:00https://flcube.com/immunochina-pharmaceuticals-raises-funds-for-gene-therapy-development/2025-02-01T19:01:53+08:00https://flcube.com/bgi-genomics-receives-nmpa-approval-for-chromosome-aneuploidy-detection-kit/2025-02-01T18:59:03+08:00https://flcube.com/eccogene-gains-fda-approval-for-phase-i-study-of-ecc5004/2025-02-01T18:56:39+08:00https://flcube.com/beigenes-brukinsa-receives-eu-marketing-approval-for-marginal-zone-lymphoma/2025-02-01T16:48:26+08:00https://flcube.com/fosun-pharma-terminates-equity-transfer-deal-with-oncocare-medical/2025-02-01T14:59:11+08:00https://flcube.com/antengenes-cd73-inhibitor-atg-037-greenlit-for-phase-i-study-by-nmpa/2025-02-01T14:53:56+08:00https://flcube.com/sino-medical-sciences-non-compliant-balloon-catheter-approved-by-nmpa/2025-02-01T14:50:30+08:00https://flcube.com/hengruis-pyrotinib-granted-breakthrough-therapy-designation-by-cde/2025-02-01T14:47:52+08:00https://flcube.com/nmpa-approves-luye-pharmas-ly03005-for-depression-treatment/2025-02-01T14:37:18+08:00https://flcube.com/shanghai-smpa-suspends-hecs-linagliptin-procurement-over-patent-infringement/2025-02-01T14:34:50+08:00https://flcube.com/shanghai-pharmaceuticals-gets-nmpa-clearance-for-sublingual-rasagiline/2025-02-01T14:24:50+08:00https://flcube.com/baidu-health-partners-with-shanghai-epiprobe-for-cancer-early-screening/2025-02-01T14:21:37+08:00https://flcube.com/pharmaniaga-partners-with-jd-com-to-enter-china-market/2025-02-01T14:15:58+08:00https://flcube.com/qilu-regors-rgt-264-phosphate-tablets-approved-for-phase-i-study/2025-02-01T14:12:44+08:00https://flcube.com/hainan-free-trade-port-to-simplify-drug-import-procedures-2/2025-02-01T14:08:36+08:00https://flcube.com/hainan-free-trade-port-to-simplify-drug-import-procedures/2025-02-01T14:03:18+08:00https://flcube.com/reforgene-medicine-rm-001-thalassemia-gene-editing/2025-02-01T13:55:35+08:00https://flcube.com/walvax-biotech-launches-phase-iiib-trial-for-mrna-covid-19-vaccine/2025-02-01T13:52:09+08:00https://flcube.com/guangdong-zhongsheng-initiates-phase-iii-study-for-ray1216-in-covid-19/2025-02-01T13:49:05+08:00https://flcube.com/bloomage-biotech-ceo-investigated-over-discounted-share-sales/2025-02-01T13:46:30+08:00https://flcube.com/nmpa-proposes-drug-online-sales-blacklist-for-public-feedback/2025-02-01T13:41:04+08:00https://flcube.com/ascentage-pharma-announces-clinical-advances-for-olverembatinib-at-ash/2025-02-01T13:37:37+08:00https://flcube.com/abbisko-enrolls-first-patient-in-phase-ii-study-for-absk091-in-urothelial-carcinoma/2025-02-01T13:34:00+08:00https://flcube.com/blue-shield-pharmas-ld013-car-t-therapy-approved-for-clinical-trials/2025-02-01T13:30:56+08:00https://flcube.com/blue-shield-pharma-faces-bankruptcy-proceedings-after-missing-debt-payments/2025-02-01T13:29:52+08:00https://flcube.com/biomed-union-raises-rmb-200m-in-series-b-round-for-diagnostic-products/2025-02-01T13:14:52+08:00https://flcube.com/yaguo-technology-secures-series-a-funding-for-airway-management-devices/2025-02-01T13:09:41+08:00https://flcube.com/novatim-immune-therapeutics-raises-rmb-500m-in-first-financing-round/2025-02-01T13:05:19+08:00https://flcube.com/pulnovo-medical-raises-tens-of-millions-in-new-financing-round/2025-02-01T12:47:37+08:00https://flcube.com/akeso-biopharma-completes-enrollment-for-ak112-phase-iii-study/2025-02-01T12:43:10+08:00https://flcube.com/biontechs-comirnaty-gets-limited-authorization-in-china-amid-scholz-visit/2025-02-01T01:55:59+08:00https://flcube.com/organons-q3-results-show-womens-health-segment-outperforms-amid-global-revenue-decline/2025-02-01T01:48:29+08:00https://flcube.com/organon-signs-mou-with-chinas-national-health-commission-at-ciie/2025-02-01T01:39:25+08:00https://flcube.com/ascletis-pharma-presents-phase-i-study-results-for-asc43f-at-aasld/2025-02-01T01:34:46+08:00https://flcube.com/ji-xing-pharmaceuticals-omecamtiv-mecarbil-accepted-for-review-by-cde/2025-02-01T01:31:41+08:00https://flcube.com/sophway-raises-tens-of-millions-in-angel-round-for-endoscope-development/2025-02-01T01:24:37+08:00https://flcube.com/ciie-met-her2-precision-diagnosis-alliance-formed-to-advance-lung-cancer-treatment/2025-02-01T01:18:39+08:00https://flcube.com/ciie-boao-lecheng-zone-announces-partnerships-with-multinationals/2025-02-01T01:13:31+08:00https://flcube.com/cytiva-announces-rmb-60m-investment-for-china-science-innovation-center-at-ciie/2025-02-01T01:10:29+08:00https://flcube.com/innovent-biologics-tafolecimab-shows-strong-ldl-c-reduction-in-phase-iii-study/2025-02-01T01:05:22+08:00https://flcube.com/ascentage-pharma-presents-apg-1387-phase-i-study-results-at-aasld/2025-02-01T01:01:46+08:00https://flcube.com/allergan-aesthetics-partners-with-sinopharm-at-ciie-for-aesthetic-medicine/2025-02-01T00:58:54+08:00https://flcube.com/honeywell-partners-with-anruite-for-smart-manufacturing-in-china/2025-02-01T00:54:55+08:00https://flcube.com/boehringer-ingelheim-launches-rehabilitation-center-in-chengdu-at-ciie/2025-02-01T00:47:11+08:00https://flcube.com/fosun-pharma-partners-with-soong-ching-ling-foundation-for-women-and-childrens-health/2025-02-01T00:44:27+08:00https://flcube.com/jumpcan-partners-with-newsoara-for-pde4-and-protease-inhibitors-in-china/2025-02-01T00:41:44+08:00https://flcube.com/novo-nordisk-to-invest-rmb-400m-in-shanghai-at-ciie/2025-02-01T00:33:17+08:00https://flcube.com/jiangsu-yahong-initiates-phase-iii-study-for-hexvix-in-bladder-cancer-detection/2025-02-01T00:31:22+08:00https://flcube.com/betta-pharmaceuticals-bpi-452080-accepted-for-review-by-nmpa/2025-02-01T00:28:21+08:00https://flcube.com/eli-lilly-partners-with-amoydx-and-burning-rock-for-retevmo-companion-diagnostics/2025-02-01T00:18:42+08:00https://flcube.com/takeda-partners-with-cccmhpie-to-boost-rare-disease-drug-access-in-china/2025-01-31T20:18:02+08:00https://flcube.com/xellsmart-raises-rmb-200m-in-series-a1-round-for-stem-cell-therapies/2025-01-31T20:15:16+08:00https://flcube.com/novo-nordisk-reports-16-yoy-growth-in-q3-raises-full-year-guidance/2025-01-31T20:12:38+08:00https://flcube.com/novo-nordisk-partners-with-shanghai-pharma-for-smart-logistics-at-ciie/2025-01-31T20:07:35+08:00https://flcube.com/simr-biotechnology-raises-rmb-150m-in-series-c1-financing-round/2025-01-31T20:01:17+08:00https://flcube.com/pingan-good-doctor-partners-with-roche-and-origimed-at-ciie/2025-01-31T19:55:01+08:00https://flcube.com/organon-partners-with-alibaba-health-to-enhance-chronic-disease-management/2025-01-31T19:47:22+08:00https://flcube.com/qilu-pharmas-ql1706-shows-promise-in-phase-ii-cervical-cancer-study/2025-01-31T19:43:14+08:00https://flcube.com/organon-sponsors-retail-pharmacy-health-center-at-ciie/2025-01-31T19:40:19+08:00https://flcube.com/sanofi-partners-with-china-resources-sanjiu-at-ciie-for-consumer-healthcare/2025-01-31T19:36:21+08:00https://flcube.com/stada-arzneimittel-ag-partners-with-cr-sanjiu-for-distribution-in-china/2025-01-31T19:33:02+08:00https://flcube.com/cr-sanjiu-to-acquire-significant-stake-in-tasly-pharmaceuticals-in-a-deal-valued-at-870-million/2025-01-31T19:33:01+08:00https://flcube.com/cloudr-inks-deal-with-cr-sanjiu-to-boost-hospital-sales-of-cardiovascular-medicine/2025-01-31T19:33:01+08:00https://flcube.com/cr-pharmas-cr-sanjiu-to-sell-51-stake-in-shenghuo-for-rmb-1-791-billion/2025-01-31T19:33:00+08:00https://flcube.com/sirnaomics-initiates-phase-i-study-of-stp705-for-abdominal-fat-reduction/2025-01-31T19:29:24+08:00https://flcube.com/sumitomo-dainippon-partners-with-profex-to-promote-antipsychotics-in-china/2025-01-31T19:25:14+08:00https://flcube.com/shandong-xinhua-and-bayer-announce-strategic-partnership-at-ciie/2025-01-31T19:04:27+08:00https://flcube.com/medtronic-partners-with-shanghai-jiahui-hospital-at-ciie/2025-01-31T18:59:08+08:00https://flcube.com/chaingen-bio-raises-rmb-45m-in-angel-round-for-x-oligo-conjugates-development/2025-01-31T18:56:08+08:00https://flcube.com/yibao-technology-secures-series-a-funding-to-expand-health-insurance-services/2025-01-31T18:47:21+08:00https://flcube.com/haiscos-hsk16149-accepted-for-review-by-nmpa-for-diabetic-neuropathic-pain/2025-01-31T18:38:29+08:00https://flcube.com/cowell-health-partners-with-astrazeneca-to-enhance-cancer-care-at-ciie/2025-01-31T18:36:01+08:00https://flcube.com/zhaoke-ophthalmology-enrolls-first-patients-for-zky001-in-phase-ii-trials/2025-01-31T18:28:41+08:00https://flcube.com/cde-seeks-public-feedback-on-new-drug-benefit-risk-assessment-guidelines/2025-01-31T18:24:28+08:00https://flcube.com/zhaoke-ophthalmology-licenses-cv-techs-tono-i-tonometer-for-greater-china/2025-01-31T18:22:22+08:00https://flcube.com/cde-releases-draft-guidelines-on-new-drug-benefit-risk-assessment/2025-01-31T18:17:06+08:00https://flcube.com/insilico-medicine-partners-with-sanofi-for-ai-driven-drug-discovery/2025-01-31T18:13:40+08:00https://flcube.com/cde-releases-guidelines-on-pediatric-anti-tumor-drug-development/2025-01-31T18:11:17+08:00https://flcube.com/pfizer-partners-with-card-csaf-and-pingan-good-doctor-at-ciie/2025-01-31T18:08:30+08:00https://flcube.com/pfizer-china-partners-with-alibaba-health-for-disease-education-at-ciie/2025-01-31T18:02:47+08:00https://flcube.com/adicon-partners-with-illumina-to-advance-oncology-detection-assay-tso-500/2025-01-31T17:59:55+08:00https://flcube.com/pfizer-partners-with-china-cardiovascular-association-to-tackle-heart-failure-2/2025-01-31T17:57:22+08:00https://flcube.com/pfizer-partners-with-china-cardiovascular-association-to-tackle-heart-failure/2025-01-31T17:53:33+08:00https://flcube.com/micurx-pharmaceuticals-doses-first-patient-in-china-for-mrx-8-trial/2025-01-31T17:50:52+08:00https://flcube.com/zhifei-bio-initiates-global-study-for-omicron-delta-covid-19-vaccine-in-uzbekistan/2025-01-31T16:56:16+08:00https://flcube.com/mainline-biosciences-raises-rmb-100m-in-series-a-financing-for-peptide-drugs/2025-01-31T16:39:42+08:00https://flcube.com/jiangsu-trausim-raises-rmb-100m-in-series-a-financing-for-dental-implants/2025-01-31T16:33:05+08:00https://flcube.com/cyramza-prescribed-in-china-for-advanced-gastric-cancer/2025-01-31T16:27:56+08:00https://flcube.com/merck-kgaa-collaborates-with-biotheus-to-accelerate-cell-line-characterization/2025-01-31T16:23:36+08:00https://flcube.com/mercks-keytruda-receives-10th-indication-approval-in-china-for-tnbc/2025-01-31T16:19:55+08:00https://flcube.com/3sbios-thrombopoietin-study-in-pediatric-itp-reaches-primary-endpoint/2025-01-31T16:14:55+08:00https://flcube.com/zenas-biopharma-completes-118m-series-b-financing-to-advance-obexelimab/2025-01-31T16:10:37+08:00https://flcube.com/lianbio-initiates-phase-i-study-of-shp2-inhibitor-bbp-398-in-china/2025-01-31T16:03:29+08:00https://flcube.com/innovex-medical-files-for-ipo-in-hong-kong-to-boost-product-development/2025-01-31T16:00:36+08:00https://flcube.com/nmpa-conditionally-approves-yingli-pharmas-linperlisib-for-lymphoma/2025-01-31T15:55:30+08:00https://flcube.com/ascentage-pharma-gains-cde-approval-for-phase-i-study-of-apg-5918/2025-01-31T15:52:53+08:00https://flcube.com/china-releases-14th-five-year-plan-for-national-health-informatization/2025-01-31T15:50:16+08:00https://flcube.com/zai-lab-reports-33-yoy-revenue-growth-in-q3-2022/2025-01-31T15:47:32+08:00https://flcube.com/gsk-partners-with-caspc-to-advance-hiv-sustained-care-advocacy-in-china/2025-01-31T15:44:21+08:00https://flcube.com/3sbio-receives-nmpa-review-for-pediatric-itp-thrombopoietin-filing/2025-01-31T15:40:51+08:00https://flcube.com/boston-scientific-partners-with-omron-for-atrial-fibrillation-management/2025-01-31T15:38:24+08:00https://flcube.com/takeda-partners-with-aws-and-accenture-to-launch-innovation-incubator-at-ciie/2025-01-31T15:35:44+08:00https://flcube.com/betta-pharmaceuticals-bpi-d0316-shows-promise-in-phase-ii-iii-lung-cancer-study/2025-01-31T15:32:21+08:00https://flcube.com/beigene-reports-88-yoy-revenue-growth-in-q3-2022/2025-01-31T15:28:39+08:00https://flcube.com/astrazeneca-reports-19-yoy-revenue-growth-in-q3-2022/2025-01-31T15:25:04+08:00https://flcube.com/fda-approves-phase-ib-study-for-jiangsu-yahongs-apl1401-in-ulcerative-colitis/2025-01-31T15:19:58+08:00https://flcube.com/baheal-partners-with-astrazeneca-for-commercial-rights-to-onglyza/2025-01-31T15:17:22+08:00https://flcube.com/eqrx-shifts-strategy-amid-fda-feedback-on-china-sourced-data/2025-01-31T15:07:39+08:00https://flcube.com/peking-university-study-identifies-liver-cancer-immune-microenvironment-subtypes/2025-01-31T15:04:49+08:00https://flcube.com/cde-prioritizes-review-for-jiedi-pharmas-mitotane-and-other-key-drugs/2025-01-31T15:02:47+08:00https://flcube.com/cansino-biologics-inhalable-covid-19-vaccine-authorized-in-morocco/2025-01-31T14:51:50+08:00https://flcube.com/luye-pharmas-biosimilar-ly06006-ba6101-approved-for-osteoporosis-treatment/2025-01-31T14:49:03+08:00https://flcube.com/lundbecks-eptinezumab-launches-in-boao-lecheng-for-migraine-treatment/2025-01-31T14:46:17+08:00https://flcube.com/novartis-partners-with-alibaba-health-to-enhance-patient-medication-accessibility/2025-01-31T14:42:33+08:00https://flcube.com/remegens-telitacicept-set-for-breakthrough-therapy-designation-in-myasthenia-gravis/2025-01-31T14:39:44+08:00https://flcube.com/harbour-biomed-and-moderna-ink-licensing-deal-for-oncology-immunotherapies/2025-01-31T14:37:19+08:00https://flcube.com/cstones-pd-l1-inhibitor-sugemalimab-achieves-primary-endpoint-in-gastric-cancer-study/2025-01-31T14:34:34+08:00https://flcube.com/beigenes-brukinsa-receives-marketing-approval-in-brazil/2025-01-31T14:32:16+08:00https://flcube.com/fujian-cosunter-receives-multiple-patents-for-cancer-and-hepatitis-drugs/2025-01-31T14:29:44+08:00https://flcube.com/sinocelltechs-sctv01e-vaccine-receives-nmpa-approval-for-phase-ii-study/2025-01-31T14:27:01+08:00https://flcube.com/astrazeneca-to-launch-soliris-in-hangzhou-after-regulatory-approval/2025-01-31T14:04:05+08:00https://flcube.com/akeso-biopharmas-ak112-receives-two-new-breakthrough-therapy-designations/2025-01-31T13:59:21+08:00https://flcube.com/cstone-launches-patient-assistance-program-for-idh1-inhibitor-tibsovo/2025-01-31T13:56:55+08:00https://flcube.com/hutchmed-announces-initial-results-from-frutiga-phase-iii-study/2025-01-31T13:54:39+08:00https://flcube.com/brl-medicine-raises-rmb-200m-in-series-b-financing-for-cgt-development/2025-01-31T13:51:04+08:00https://flcube.com/peijia-medical-enrolls-first-patient-in-highlife-tsmvr-study/2025-01-31T13:48:33+08:00https://flcube.com/acotec-scientific-secures-fda-510k-approval-for-vericor-catheter/2025-01-31T13:45:53+08:00https://flcube.com/cstone-pharmaceuticals-suspends-operations-at-suzhou-plant-to-cut-costs/2025-01-31T13:43:36+08:00https://flcube.com/daxiang-biotech-raises-rmb-100m-in-pre-series-b-financing-for-organoid-on-a-chip/2025-01-31T13:40:53+08:00https://flcube.com/harbin-gloria-pharmaceuticals-faces-change-in-control-amid-bankruptcy/2025-01-31T13:35:06+08:00https://flcube.com/hitgen-partners-with-daewoong-pharmaceutical-for-drug-discovery/2025-01-31T13:28:49+08:00https://flcube.com/astrazeneca-and-cicc-capital-launch-rmb-3-billion-fund-in-hangzhou/2025-01-31T13:25:39+08:00https://flcube.com/henlius-biotechs-braf-v600e-inhibitor-hlx208-approved-for-clinical-study-in-china/2025-01-31T13:21:53+08:00https://flcube.com/china-updates-hypertension-guidelines-lowers-diagnostic-threshold/2025-01-31T13:18:51+08:00https://flcube.com/peru-approves-bmss-reblozyl-and-beigenes-brukinsa/2025-01-31T13:15:43+08:00https://flcube.com/silk-round-fund-and-ina-invest-in-indonesian-pharma-companies/2025-01-31T13:04:05+08:00https://flcube.com/lanova-medicines-gets-nmpa-approval-for-lm-305-clinical-study/2025-01-31T12:59:57+08:00https://flcube.com/everest-medicines-nefecon-nda-accepted-for-iga-nephropathy-in-china/2025-01-31T12:57:03+08:00https://flcube.com/cstone-pharmaceuticals-suspends-suzhou-plant-operations-to-cut-costs/2025-01-31T12:43:18+08:00https://flcube.com/hotgen-receives-nmpa-approval-for-hbv-rna-assay-kit/2025-01-31T12:39:34+08:00https://flcube.com/innovent-biologics-initiates-phase-iii-trial-for-mazdutide-in-obesity/2025-01-31T12:36:56+08:00https://flcube.com/guangdong-zhongsheng-starts-phase-iii-trial-for-covid-19-drug-ray1216/2025-01-31T12:34:18+08:00https://flcube.com/yabao-receives-fda-clearance-for-generic-nexavar/2025-01-31T12:30:22+08:00https://flcube.com/hansoh-pharmaceutical-licenses-biotheus-bispecific-antibody-pm1080-for-greater-china/2025-01-31T12:25:23+08:00https://flcube.com/sansure-biotech-partners-with-ubc-to-manufacture-in-indonesia/2025-01-31T12:19:22+08:00https://flcube.com/hutchmed-shifts-focus-to-late-stage-pipeline-for-regulatory-approvals/2025-01-31T12:16:39+08:00https://flcube.com/harbour-biomed-and-wuxi-biologics-announce-strategic-collaboration/2025-01-31T12:11:19+08:00https://flcube.com/hengruis-pyrotinib-granted-priority-review-for-her2-positive-breast-cancer/2025-01-31T12:07:55+08:00https://flcube.com/cde-issues-guidelines-for-bispecific-antibody-antitumor-drug-development/2025-01-31T12:03:14+08:00https://flcube.com/pegbios-lead-product-pb-119-clears-hkex-hearing-for-type-2-diabetes-and-obesity-treatment/2025-01-31T11:58:29+08:00https://flcube.com/kelun-pharmas-skb264-advances-to-phase-ii-study-for-nsclc/2025-01-31T02:12:23+08:00https://flcube.com/gracells-fastcar-platform-wins-fierce-life-sciences-innovation-award/2025-01-31T02:09:39+08:00https://flcube.com/walvax-biotechnology-expands-manufacturing-partnership-with-etana-for-pcv-and-hpv-vaccines/2025-01-31T02:03:52+08:00https://flcube.com/simcere-pharmaceuticals-licenses-idorsias-insomnia-therapy-daridorexant-for-greater-china/2025-01-31T01:59:44+08:00https://flcube.com/sirnaomics-announces-key-executive-promotions-effective-november-15/2025-01-31T01:54:01+08:00https://flcube.com/hengrui-pharmceuticals-shr0302-achieves-positive-results-in-phase-iii-atopic-dermatitis-study/2025-01-31T01:51:12+08:00https://flcube.com/kanghong-pharma-gains-nmpa-approval-for-innovative-eye-injection-kh631/2025-01-31T01:47:07+08:00https://flcube.com/antengenes-atg-008-shows-promising-results-in-cervical-cancer-and-hepatocellular-carcinoma-studies/2025-01-31T01:43:59+08:00https://flcube.com/cstone-pharmaceuticals-launches-aml-public-welfare-project-with-china-social-welfare-foundation/2025-01-31T01:40:23+08:00https://flcube.com/betta-pharmaceuticals-bpi-d0316-accepted-for-nmpa-review-for-nsclc-adjuvant-therapy/2025-01-31T01:37:43+08:00https://flcube.com/kelun-biotechs-skb264-receives-fda-approval-for-phase-ii-study/2025-01-31T01:35:03+08:00https://flcube.com/junovabio-secures-pre-series-a-funding-for-tumor-molecular-diagnosis/2025-01-31T01:32:44+08:00https://flcube.com/lupeng-pharma-raises-usd-35-million-in-pre-series-b-financing-round/2025-01-31T01:28:26+08:00https://flcube.com/subtle-medical-secures-series-b-funding-for-ai-powered-medical-imaging/2025-01-31T01:23:48+08:00https://flcube.com/hengrui-pharmaceuticals-receives-clinical-trial-approvals-for-three-new-drugs/2025-01-31T01:19:14+08:00https://flcube.com/rainsure-scientific-secures-series-c1-funding-for-digital-pcr-development/2025-01-31T01:15:53+08:00https://flcube.com/cspc-pharmas-rhtnk-tpa-accepted-for-review-by-nmpa-for-stroke-indication/2025-01-31T01:11:40+08:00https://flcube.com/asia-pacific-medical-group-secures-series-a-funding-for-hospital-expansion/2025-01-31T01:09:00+08:00https://flcube.com/haiscos-hsk31858-gains-ethical-approval-for-phase-ii-study-in-ncfbe/2025-01-31T01:03:04+08:00https://flcube.com/canbridges-can106-receives-orphan-drug-designation-for-myasthenia-gravis/2025-01-31T01:00:26+08:00https://flcube.com/hitgen-partners-with-guangzhou-aichemeco-for-automated-synthesis-technology/2025-01-31T00:57:46+08:00https://flcube.com/harbour-biomed-establishes-nona-biosciences-for-next-generation-antibody-development/2025-01-31T00:48:17+08:00https://flcube.com/novartis-considers-sale-of-non-core-units-to-fund-innovation/2025-01-31T00:45:24+08:00https://flcube.com/sequanta-technologies-partners-with-illumina-to-introduce-novaseq-x-series/2025-01-31T00:42:35+08:00https://flcube.com/ascletis-pharmas-pd-l1-inhibitor-asc61-gains-nmpa-ind-approval/2025-01-31T00:39:25+08:00https://flcube.com/microtech-medical-plans-ipo-on-shanghais-star-market/2025-01-31T00:35:39+08:00https://flcube.com/cde-issues-trial-rules-for-nmpa-drug-review-timekeeping-suspension/2025-01-31T00:30:01+08:00https://flcube.com/bio-heart-bio-to-launch-clinical-study-for-rapamycin-drug-eluting-balloon-in-japan/2025-01-31T00:24:18+08:00https://flcube.com/bio-heart-bio-receives-ethical-approval-for-iberis-rdn-system-in-hainan/2025-01-31T00:21:32+08:00https://flcube.com/beigenes-brukinsa-receives-ec-approval-for-cll-treatment/2025-01-31T00:18:42+08:00https://flcube.com/zhangjiang-ai-new-drug-rd-alliance-expands-with-new-members/2025-01-31T00:14:00+08:00https://flcube.com/us-senate-puts-brakes-on-bill-targeting-china-based-cdmos-amid-stock-market-reactions/2025-01-31T00:07:57+08:00https://flcube.com/fapon-biotech-partners-with-roche-diagnostics-at-china-international-import-expo/2025-01-31T00:02:13+08:00https://flcube.com/chinas-jiangsu-bioda-gains-nmpa-approval-for-innovative-artificial-blood-vessel/2025-01-30T23:59:22+08:00https://flcube.com/visen-pharmaceuticals-publishes-phase-iii-data-for-lonapegsomatropin-in-growth-hormone-deficiency/2025-01-30T23:54:27+08:00https://flcube.com/rongcan-biotech-raises-pre-series-a-funding-for-mrna-therapeutics-development/2025-01-30T23:51:32+08:00https://flcube.com/lees-pharmaceutical-reports-q3-2022-financials-with-8-8-revenue-growth/2025-01-30T23:48:55+08:00https://flcube.com/marinus-pharmaceuticals-collaborates-with-tenacia-biotechnology-for-ganaxolone/2025-01-30T23:45:59+08:00https://flcube.com/mirati-therapeutics-sues-inventisbio-over-trade-secret-misappropriation/2025-01-30T23:35:57+08:00https://flcube.com/roche-reports-7-revenue-growth-in-2024-driven-by-oncology-and-ophthalmology/2025-01-30T23:30:52+08:00https://flcube.com/fosun-pharmas-bivalent-covid-19-vaccine-comirnaty-authorized-in-hong-kong/2025-01-30T23:28:52+08:00https://flcube.com/iaso-biotherapeutics-reports-positive-phase-i-results-for-car-t-therapy-in-nmosd/2025-01-30T23:25:45+08:00https://flcube.com/vivest-medical-raises-funds-for-wearable-cardioverter-defibrillator-development/2025-01-30T23:22:06+08:00https://flcube.com/mabwell-receives-approval-for-clinical-study-of-9mw3011-in-polycythemia-vera/2025-01-30T23:08:03+08:00https://flcube.com/chinas-cde-hnmpa-and-boao-lecheng-release-real-world-drug-research-measures/2025-01-30T23:05:00+08:00https://flcube.com/hotgen-biotech-receives-fda-eua-for-covid-19-antigen-home-test/2025-01-30T23:02:47+08:00https://flcube.com/wolters-kluwer-partners-with-chinas-ncid-to-advance-infectious-disease-diagnosis/2025-01-30T23:00:23+08:00https://flcube.com/jiangxi-healthcare-security-administration-launches-new-vbp-tender/2025-01-30T22:55:57+08:00https://flcube.com/fapon-biotech-partners-with-cr-pharma-to-develop-ivd-open-platform-ecosystem/2025-01-30T22:53:32+08:00https://flcube.com/henlius-serplulimab-phase-iii-study-approved-in-spain-for-ls-sclc/2025-01-30T22:47:47+08:00https://flcube.com/hainan-poly-pharm-wins-finland-approval-for-generic-cytovene-iv/2025-01-30T22:44:21+08:00https://flcube.com/kangtai-biological-completes-phase-iii-clinical-data-analysis-for-covid-19-vaccine/2025-01-30T22:41:39+08:00https://flcube.com/jiangxi-leads-22-province-alliance-in-vbp-for-liver-function-test-reagents/2025-01-30T22:38:38+08:00https://flcube.com/ub-biotechnology-secures-series-a-funding-for-flow-cytometry-platform/2025-01-30T22:31:13+08:00https://flcube.com/iaso-biotherapeutics-partners-with-umoja-biopharma-to-evaluate-icil-platform/2025-01-30T22:25:21+08:00https://flcube.com/shanghai-unveils-policies-to-boost-global-biomedical-rd-hub/2025-01-30T22:18:44+08:00https://flcube.com/wuxi-biologics-launches-integrated-biologics-crdmo-center-in-shanghai/2025-01-30T22:15:40+08:00https://flcube.com/nona-biosciences-licenses-hcab-technology-to-dragonfly-therapeutics/2025-01-30T22:12:45+08:00https://flcube.com/salubris-pharmaceuticals-sal0119-accepted-for-cde-review-in-china/2025-01-30T22:06:50+08:00https://flcube.com/aosaikangs-askg915-accepted-for-fda-review-targets-advanced-solid-tumors/2025-01-30T22:04:11+08:00https://flcube.com/legend-biotech-receives-ind-approval-for-lb2102-car-t-therapy/2025-01-30T22:01:26+08:00https://flcube.com/sun-novo-pharma-gains-nmpa-approval-for-stc007-clinical-study-in-ckd-ap/2025-01-30T21:58:35+08:00https://flcube.com/jd-healthcare-partners-with-jiangsu-yuyue-for-medical-device-collaboration/2025-01-30T21:55:04+08:00https://flcube.com/junshi-biosciences-junmaikang-approved-by-nmpa-for-multiple-indications/2025-01-30T21:49:33+08:00https://flcube.com/hengrui-pharmaceuticals-receives-fda-anda-approval-for-gadobutrol-generic/2025-01-30T21:46:08+08:00https://flcube.com/fibrogen-sues-former-employees-and-two-pharma-firms-for-trade-secret-theft/2025-01-30T21:42:20+08:00https://flcube.com/js-innopharm-and-strategia-holdings-form-jsi-ventures-in-boston/2025-01-30T21:16:23+08:00https://flcube.com/jianke-com-files-for-hong-kong-ipo-with-focus-on-chronic-disease-management/2025-01-30T21:09:09+08:00https://flcube.com/chinas-first-gene-therapy-for-deafness-rrg-003-begins-clinical-study/2025-01-30T21:04:30+08:00https://flcube.com/shanghai-hosts-yangtze-river-delta-alliance-vbp-tender-for-44-drugs/2025-01-30T20:57:38+08:00https://flcube.com/beigene-to-present-final-pfs-results-for-brukinsa-at-ash-meeting/2025-01-30T20:53:54+08:00https://flcube.com/kunshi-biotechnology-and-puheng-technology-partner-on-3d-nac-organ-platform-for-car-macrophage-screening/2025-01-30T20:49:51+08:00https://flcube.com/endoso-life-raises-pre-series-a-funding-for-high-end-medical-endoscope-development/2025-01-30T20:40:59+08:00https://flcube.com/vcanbios-vum02-accepted-for-review-by-chinas-center-for-drug-evaluation/2025-01-30T20:33:25+08:00https://flcube.com/fosun-pharmas-human-interferon-gamma-approved-for-new-indication-by-nmpa/2025-01-30T20:30:37+08:00https://flcube.com/innocare-pharmas-hibruka-receives-hsa-approval-for-mantle-cell-lymphoma-in-singapore/2025-01-30T20:27:55+08:00https://flcube.com/sun-novo-pharma-to-acquire-mah-rights-for-azilsartan-from-baiao-pharma/2025-01-30T20:25:02+08:00https://flcube.com/who-approves-sinovacs-coronavac-for-children-aged-3-and-above/2025-01-30T20:10:33+08:00https://flcube.com/anchordxs-urifind-receives-breakthrough-therapy-designation-for-urothelial-carcinoma/2025-01-30T16:51:32+08:00https://flcube.com/visen-pharmaceuticals-files-for-hong-kong-ipo-with-focus-on-growth-hormone/2025-01-30T16:46:41+08:00https://flcube.com/junshi-biosciences-files-for-uk-approval-of-pd-1-inhibitor-tuoyi/2025-01-30T16:41:14+08:00https://flcube.com/cspc-pharmaceutical-reports-q3-2022-financials-with-13-8-revenue-growth/2025-01-30T16:37:14+08:00https://flcube.com/tianjin-tianyao-fined-for-anti-monopoly-violations-in-carmustine-sales/2025-01-30T16:32:00+08:00https://flcube.com/china-releases-third-batch-of-vat-discounts-for-anti-tumor-and-rare-disease-drugs/2025-01-30T16:24:26+08:00https://flcube.com/orbusneich-files-for-ipo-on-hong-kong-stock-exchange/2025-01-30T16:22:15+08:00https://flcube.com/immornas-jcxh-221-mrna-vaccine-cleared-by-fda-for-phase-i-ii-study/2025-01-30T16:17:57+08:00https://flcube.com/henlius-biotech-partners-with-shantou-central-hospital-for-clinical-study-collaboration/2025-01-30T16:14:20+08:00https://flcube.com/anchordx-initiates-us-registrational-study-for-urifind-urothelial-carcinoma-diagnostic/2025-01-30T16:11:11+08:00https://flcube.com/biocytogen-announces-successful-development-of-fully-human-nano-antibody-rennano/2025-01-30T15:49:32+08:00https://flcube.com/kanghong-pharma-receives-fda-approval-for-kh631-gene-therapy-trial/2025-01-30T15:46:47+08:00https://flcube.com/saint-medical-raises-pre-series-b-funding-for-structural-heart-disease-solutions/2025-01-30T15:43:45+08:00https://flcube.com/frontier-biotechnologies-gains-cde-approval-for-fb2001-covid-19-inhalant-study/2025-01-30T15:38:42+08:00https://flcube.com/alphamab-oncology-and-cspc-announce-positive-phase-ii-data-for-kn026-in-her2-positive-gastric-cancer/2025-01-30T15:34:23+08:00https://flcube.com/kintor-pharmas-gt20029-shows-positive-results-in-phase-i-study-for-androgenetic-alopecia-and-acne/2025-01-30T15:25:17+08:00https://flcube.com/fosun-pharmas-henlius-completes-clinical-trial-filing-for-hlx301-in-australia/2025-01-30T14:46:57+08:00https://flcube.com/peijia-medical-announces-first-patient-implant-in-monarq-ttvr-system-clinical-study/2025-01-30T14:41:58+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-chengdu-eastern-new-area-for-ivd-hub/2025-01-30T14:38:38+08:00https://flcube.com/anyeep-raises-rmb-100-million-in-series-a-financing-for-mass-spectrometry-development/2025-01-30T14:35:47+08:00https://flcube.com/shanghai-henlius-biotech-to-provide-rd-services-for-covid-19-therapy-azvudine/2025-01-30T14:29:36+08:00https://flcube.com/china-resources-double-crane-gains-approval-for-definity-in-china/2025-01-30T14:25:32+08:00https://flcube.com/xtalpi-partners-with-ck-life-sciences-to-develop-ai-cancer-vaccine-platform/2025-01-30T14:22:45+08:00https://flcube.com/bliss-bios-bb-1709-accepted-for-review-by-chinas-cde/2025-01-30T14:18:43+08:00https://flcube.com/xiling-lab-raises-rmb-100-million-for-adc-development-and-ind-filing/2025-01-30T14:15:56+08:00https://flcube.com/primelink-bio-raises-funds-for-adc-development-and-rd-expansion/2025-01-30T14:07:57+08:00https://flcube.com/chinas-medical-product-trade-surplus-declines-amid-covid-19-impact/2025-01-30T13:50:08+08:00https://flcube.com/nuance-pharma-partners-with-dksh-to-launch-bentrio-nasal-spray-in-hong-kong-and-macau/2025-01-30T13:47:30+08:00https://flcube.com/biocytogen-and-adc-therapeutics-enter-evaluation-and-option-agreement/2025-01-30T13:43:39+08:00https://flcube.com/lyvgen-biopharma-initiates-phase-ii-study-for-lvgn7409-in-advanced-nsclc/2025-01-30T13:41:07+08:00https://flcube.com/zshk-laboratories-raises-rmb-100-million-in-series-b-financing-round/2025-01-30T13:36:15+08:00https://flcube.com/ascentage-pharma-receives-drug-production-license-for-suzhou-plant/2025-01-30T13:30:00+08:00https://flcube.com/everest-medicines-nefecon-gains-accelerated-approval-in-taiwan-and-south-korea/2025-01-30T13:27:02+08:00https://flcube.com/taizhou-wuxi-lianyungang-biomedicine-hub-launched-at-china-medical-expo/2025-01-30T13:23:45+08:00https://flcube.com/huadong-medicine-partners-with-dongyang-med-for-equity-collaboration/2025-01-30T13:19:47+08:00https://flcube.com/jiangsu-hengrui-gets-nmpa-approval-for-hr20031-clinical-study-in-type-2-diabetes/2025-01-30T13:13:23+08:00https://flcube.com/luye-pharma-launches-toludesvenlafaxine-in-china-for-depression-treatment/2025-01-30T13:10:40+08:00https://flcube.com/hong-kong-researchers-identify-new-target-for-epilepsy-treatment/2025-01-30T13:08:06+08:00https://flcube.com/hope-medicine-gains-global-approval-for-phase-ii-trial-of-hmi-115/2025-01-30T13:06:14+08:00https://flcube.com/full-life-technologies-acquires-focus-x-therapeutics-to-expand-pipeline/2025-01-30T13:01:37+08:00https://flcube.com/nmpa-launches-electronic-certificates-for-api-and-pharmaceutical-product-exports/2025-01-30T12:56:16+08:00https://flcube.com/i-mab-partners-with-wuxi-diagnostics-to-advance-biomarker-driven-clinical-studies/2025-01-30T12:54:13+08:00https://flcube.com/trinomab-biotech-raises-rmb-750-million-in-pre-ipo-financing-round/2025-01-30T12:51:37+08:00https://flcube.com/alibaba-health-reports-22-9-revenue-growth-in-h1-2022/2025-01-30T12:29:35+08:00https://flcube.com/3d-medicines-set-for-ipo-in-hong-kong-aiming-to-raise-up-to-usd-55-million/2025-01-30T12:26:59+08:00https://flcube.com/ascletis-pharmas-covid-19-drug-candidate-asc11-accepted-for-review-by-nmpa/2025-01-30T12:24:23+08:00https://flcube.com/hangzhou-polymed-biopharmaceuticals-raises-funds-for-clinical-pipeline/2025-01-30T12:21:57+08:00https://flcube.com/fosun-pharma-weighs-sale-of-indias-gland-pharma-amid-market-interest/2025-01-30T12:17:06+08:00https://flcube.com/fosun-pharmas-gland-pharma-to-acquire-french-cdmo-cenexi-for-eur-120-million/2025-01-30T12:13:11+08:00https://flcube.com/luye-pharma-initiates-phase-ii-study-for-ly-03014-in-china/2025-01-30T12:09:06+08:00https://flcube.com/chinas-drug-eluting-stent-procurement-results-announced/2025-01-30T12:06:42+08:00https://flcube.com/zhejiang-jiuzhou-pharma-to-raise-rmb-2-5-billion-via-private-placement/2025-01-30T12:03:29+08:00https://flcube.com/frontier-biotechnologies-partners-with-casapc-for-aids-prevention-in-china/2025-01-30T11:58:18+08:00https://flcube.com/henlius-completes-first-dosing-in-head-to-head-study-of-pd-1-inhibitor-hansizhuang/2025-01-30T11:52:46+08:00https://flcube.com/jancsitech-raises-tens-of-millions-in-angel-round-led-by-yuanbio-venture-capital/2025-01-30T11:49:28+08:00https://flcube.com/fda-rejects-spectrums-poziotinib-nda-for-nsclc-treatment/2025-01-30T11:44:24+08:00https://flcube.com/sino-biological-to-invest-rmb-1-billion-in-beijing-bio-pharmaceutical-park/2025-01-30T11:27:02+08:00https://flcube.com/cspc-and-ascletis-get-nmpa-approval-for-covid-19-drug-clinical-trials/2025-01-30T01:39:20+08:00https://flcube.com/fudan-team-presents-ribociclib-phase-ii-bridging-study-results-at-esmo-asia/2025-01-30T01:38:22+08:00https://flcube.com/deepseek-enhances-biopharma-ind-and-nda-processes-with-ai/2025-01-30T01:37:05+08:00https://flcube.com/chinas-nmpa-issues-new-gsp-appendix-for-drug-retailing-quality-management/2025-01-30T01:34:53+08:00https://flcube.com/immuneonco-initiates-phase-ii-clinical-study-for-cd47-antibody-imm01/2025-01-30T01:33:04+08:00https://flcube.com/chinas-nmpa-seeks-feedback-on-drug-quality-management-provisions/2025-01-30T01:30:50+08:00https://flcube.com/luye-pharmas-shandong-boan-bio-files-for-hong-kong-ipo/2025-01-30T01:28:37+08:00https://flcube.com/luca-healthcare-partners-with-cambridge-cognition-to-launch-cognitive-tools-in-china/2025-01-30T01:26:02+08:00https://flcube.com/luye-pharmas-biosimilar-to-amgens-xgeva-launched-in-china/2025-01-30T01:19:50+08:00https://flcube.com/assure-tech-wins-japanese-pdma-approval-for-pen-type-covid-19-antigen-test/2025-01-30T01:16:40+08:00https://flcube.com/lepu-medical-wins-nmpa-approval-for-disposable-pressure-microcatheter/2025-01-30T01:03:46+08:00https://flcube.com/chinas-nmpa-shifts-to-electronic-drug-filings-from-january-2023/2025-01-30T01:00:54+08:00https://flcube.com/hainan-hospital-launches-ibis-smartbone-ortho-for-bone-repair/2025-01-30T00:56:30+08:00https://flcube.com/csl-vifor-and-fresenius-kabi-win-china-approval-for-ferinject/2025-01-30T00:48:47+08:00https://flcube.com/chinas-pharma-firms-collaborate-on-generic-version-of-sun-pharmas-carbamazepine/2025-01-30T00:43:11+08:00https://flcube.com/ethypharm-expands-in-chinas-ibd-market-with-acquisition-of-mesalazine-suppository/2025-01-30T00:41:37+08:00https://flcube.com/youcares-ykyyo17-aerosol-inhalation-agent-approved-for-covid-19-clinical-study/2025-01-30T00:23:08+08:00https://flcube.com/henan-celnovte-biotechnology-raises-rmb-100m-in-new-financing-round/2025-01-30T00:20:10+08:00https://flcube.com/clover-biopharmaceuticals-scb-2019-vaccine-reduces-household-transmission-of-covid-19/2025-01-30T00:14:36+08:00https://flcube.com/ascletis-pharma-completes-enrollment-for-asc40-phase-ii-acne-study/2025-01-30T00:10:13+08:00https://flcube.com/nans-tech-secures-series-a-funding-for-brain-dysfunction-digital-therapies/2025-01-30T00:02:33+08:00https://flcube.com/aclaris-therapeutics-licenses-jak-inhibitor-ati-1777-to-pediatrix-for-greater-china/2025-01-29T23:52:02+08:00https://flcube.com/nmpa-approves-henlius-hlx04-biosimilar-for-lung-and-colorectal-cancer/2025-01-29T23:46:11+08:00https://flcube.com/yifan-pharma-transfers-f-627-distribution-rights-in-germany-to-apogepha/2025-01-29T23:42:32+08:00https://flcube.com/pyxis-oncology-receives-fda-approval-for-biosions-pyx-106-clinical-trials/2025-01-29T23:39:35+08:00https://flcube.com/eli-lilly-ends-license-for-innovents-tyvyt-outside-china/2025-01-29T23:31:51+08:00https://flcube.com/novartis-partners-with-sinopharm-for-commercial-promotion-of-gleevec-and-exjade-in-china/2025-01-29T23:26:57+08:00https://flcube.com/luye-pharma-partners-with-nhwa-and-fine-hin-to-commercialize-toludesvenlafaxine/2025-01-29T23:11:20+08:00https://flcube.com/pediatrix-therapeutics-licenses-tris-pharmas-adhd-portfolio-for-greater-china/2025-01-29T22:57:41+08:00https://flcube.com/hainans-new-regulations-on-medical-devices-in-boao-lecheng-to-take-effect-in-2023/2025-01-29T22:50:49+08:00https://flcube.com/kintors-kx-826-reaches-primary-endpoint-in-phase-ii-study-for-female-aga/2025-01-29T22:44:42+08:00https://flcube.com/sansure-biotechs-pertussis-detection-kit-approved-by-nmpa/2025-01-29T22:42:02+08:00https://flcube.com/simceres-edaravone-borneol-sublingual-tablets-reach-phase-iii-efficacy-endpoint/2025-01-29T22:39:07+08:00https://flcube.com/ai-model-for-early-alzheimers-detection-using-retinal-photographs-published/2025-01-29T22:36:15+08:00https://flcube.com/xjtlu-and-university-of-liverpool-launch-joint-centre-for-pharmacology-and-therapeutics/2025-01-29T22:33:51+08:00https://flcube.com/yifan-pharmaceutical-licenses-f-627-to-acrotech-for-us-distribution/2025-01-29T22:29:06+08:00https://flcube.com/westvac-biopharmas-recombinant-covid-19-vaccine-approved-for-emergency-use-in-china/2025-01-29T21:11:05+08:00https://flcube.com/qilu-pharmaceuticals-ql1604-plus-chemotherapy-shows-promise-in-phase-ii-study/2025-01-29T21:07:48+08:00https://flcube.com/china-health-group-signs-framework-agreement-with-mingcheng-wanda-pharma/2025-01-29T21:05:36+08:00https://flcube.com/hybio-receives-ethical-approval-for-hy3000-covid-19-nasal-spray-phase-ii-study/2025-01-29T20:55:38+08:00https://flcube.com/clover-biopharmaceuticals-covid-19-vaccine-scb-2019-included-in-chinas-emergency-use-program/2025-01-29T20:52:57+08:00https://flcube.com/microport-ep-medtechs-pressure-monitoring-catheter-approved-by-nmpa/2025-01-29T20:50:17+08:00https://flcube.com/henlius-biotech-doses-first-patient-in-phase-i-study-for-hlx60-in-china/2025-01-29T20:47:15+08:00https://flcube.com/hansohs-egfr-inhibitor-ameile-filed-for-ema-review-by-partner-eqrx/2025-01-29T20:36:20+08:00https://flcube.com/sinocelltechs-sctv01c-vaccine-included-in-chinas-emergency-use-program/2025-01-29T20:33:32+08:00https://flcube.com/lynk-pharmaceuticals-doses-first-patient-in-phase-ii-study-for-lnk01003/2025-01-29T20:30:50+08:00https://flcube.com/lavamed-secures-usd-40m-in-angel-and-series-a-financing-rounds/2025-01-29T20:28:27+08:00https://flcube.com/innovent-biologics-doses-first-volunteer-in-orismilast-phase-i-study/2025-01-29T20:22:52+08:00https://flcube.com/daiichi-sankyo-doses-first-patient-in-global-phase-iii-tropion-lung08-study/2025-01-29T19:39:34+08:00https://flcube.com/tsingke-biotech-secures-rmb-400m-series-b-financing-for-expansion/2025-01-29T19:37:02+08:00https://flcube.com/china-medical-system-licenses-opzelura-from-incyte-for-greater-china-and-southeast-asia/2025-01-29T19:32:45+08:00https://flcube.com/safe-raises-rmb-500m-in-series-d-financing-to-expand-cro-services/2025-01-29T19:29:30+08:00https://flcube.com/peijia-medical-enrolls-first-patient-in-geminione-teer-system-study/2025-01-29T19:20:57+08:00https://flcube.com/st-phi-therapeutics-partners-with-azenta-life-sciences-to-advance-cell-therapy/2025-01-29T19:18:16+08:00https://flcube.com/st-phi-therapeutics-universal-cell-therapy-for-solid-tumors-gets-green-light-for-clinical-trial-in-china/2025-01-29T19:16:33+08:00https://flcube.com/beijing-wantais-nasal-spray-covid-19-vaccine-approved-for-emergency-use-in-china/2025-01-29T19:06:50+08:00https://flcube.com/everlife-biomed-raises-pre-series-a-funding-for-immune-exemption-platform/2025-01-29T19:04:10+08:00https://flcube.com/hainans-first-integrated-bladder-cancer-center-launched-at-provincial-urology-meeting/2025-01-29T19:01:51+08:00https://flcube.com/united-family-healthcare-partners-with-hss-for-orthopedic-collaboration/2025-01-29T18:59:53+08:00https://flcube.com/microport-medbots-orthopedic-surgery-robot-receives-ce-certification/2025-01-29T18:55:19+08:00https://flcube.com/junshi-biosciences-files-for-ema-approval-of-tuoyi-for-nasopharyngeal-and-esophageal-cancers/2025-01-29T18:08:24+08:00https://flcube.com/akeso-biopharma-plans-ipo-on-shanghais-star-market/2025-01-29T18:05:17+08:00https://flcube.com/novo-nordisk-and-atlatl-announce-winners-of-entrestar-program-for-pharma-start-ups/2025-01-29T18:02:32+08:00https://flcube.com/shaanxi-panlong-pharma-partners-with-porton-pharma-solutions-for-drug-development/2025-01-29T17:38:45+08:00https://flcube.com/akesos-ivonescimab-secures-record-breaking-out-license-deal-with-summit-therapeutics/2025-01-29T17:29:22+08:00https://flcube.com/qihui-biopharmaceuticals-raises-series-a-funding-for-microbubbles-technology/2025-01-29T17:24:47+08:00https://flcube.com/westgene-biopharma-secures-rmb-150m-series-a-financing-for-mrna-drug-development/2025-01-29T17:19:34+08:00https://flcube.com/huihe-healthcare-secures-hundreds-of-millions-in-series-c1-and-c2-financing/2025-01-29T17:12:17+08:00https://flcube.com/chaomu-technology-raises-series-a-funding-for-eye-disease-treatments/2025-01-29T17:07:32+08:00https://flcube.com/nhsa-delays-nrdl-negotiations-due-to-covid-19-disruptions/2025-01-29T17:02:26+08:00https://flcube.com/maxhealth-biotechnology-completes-series-b-financing-round/2025-01-29T17:00:00+08:00https://flcube.com/micurx-pharmaceuticals-gains-clinical-trial-approvals-for-mrx-4-in-europe/2025-01-29T16:54:43+08:00https://flcube.com/f-star-therapeutics-takeover-by-sino-biopharmaceutical-delayed-again/2025-01-29T16:52:40+08:00https://flcube.com/exoneuglia-secures-angel-funding-for-ipsc-based-cell-therapy/2025-01-29T16:49:07+08:00https://flcube.com/jacobios-kras-g12c-inhibitor-jab-21822-receives-breakthrough-therapy-designation/2025-01-29T16:44:26+08:00https://flcube.com/24-provinces-form-alliances-for-volume-based-procurement-of-medical-consumables/2025-01-29T16:37:40+08:00https://flcube.com/yuanmai-cell-biotechnology-secures-angel-funding-for-macrophage-immunotherapy/2025-01-29T16:35:25+08:00https://flcube.com/yantai-dongcheng-pharma-acquires-rights-to-18f-apn-1607-from-aprinoia-therapeutics/2025-01-29T16:30:09+08:00https://flcube.com/shanghai-hantong-medtech-raises-angel-funding-for-ultrasound-platform/2025-01-29T16:25:04+08:00https://flcube.com/genassist-therapeutics-secures-series-a-funding-for-gene-therapy-development/2025-01-29T16:19:37+08:00https://flcube.com/hansohs-generic-firazyr-approved-for-marketing-in-china-by-nmpa/2025-01-29T16:17:05+08:00https://flcube.com/nmpa-approves-viatris-symfi-lo-for-hiv-1-treatment-in-china/2025-01-29T16:07:04+08:00https://flcube.com/sciclones-danyelza-approved-for-marketing-in-china-by-nmpa/2025-01-29T16:01:55+08:00https://flcube.com/enhertu-confirmed-as-new-standard-of-care-for-breast-cancer-in-phase-iii-study/2025-01-29T15:58:20+08:00https://flcube.com/remegens-rc118-receives-orphan-drug-designations-for-gastric-and-pancreatic-cancers/2025-01-29T15:54:10+08:00https://flcube.com/innovent-biologics-presents-clinical-study-results-at-esmo-io-2022/2025-01-29T15:48:27+08:00https://flcube.com/nmpa-extends-validation-period-for-covid-19-antigen-detection-reagents/2025-01-29T15:45:26+08:00https://flcube.com/science-standard-medical-testing-raises-pre-series-a-funding/2025-01-29T15:39:51+08:00https://flcube.com/phanes-therapeutics-and-beigene-partner-on-phase-i-study-of-pt199/2025-01-29T15:31:55+08:00https://flcube.com/xtalpi-partners-with-cttq-for-ai-driven-small-molecule-drug-development/2025-01-29T15:27:57+08:00https://flcube.com/harbour-biomed-concludes-phase-i-study-for-hbm4003-in-advanced-melanoma/2025-01-29T15:25:18+08:00https://flcube.com/frontier-biotechnologies-partners-with-yuyue-med-for-fb2001-atomizer/2025-01-29T15:21:53+08:00https://flcube.com/harbour-biomeds-nona-biosciences-licenses-antibody-platform-to-kelun-biotech/2025-01-29T15:18:07+08:00https://flcube.com/enhertu-approved-by-fda-for-hr-positive-her2-low-breast-cancer/2025-01-29T15:04:27+08:00https://flcube.com/hitgen-and-nitrase-therapeutics-enter-research-agreement/2025-01-28T16:40:29+08:00https://flcube.com/sequanta-technologies-and-iomics-bio-collaborate-on-multi-omics-research/2025-01-28T16:33:21+08:00https://flcube.com/innoforce-partners-with-rnaimmune-for-mrna-development-and-production/2025-01-28T16:26:40+08:00https://flcube.com/nmpa-approves-covid-19-antigen-detection-reagents-from-four-companies/2025-01-28T16:20:58+08:00https://flcube.com/biozon-partners-with-agilent-technologies-to-boost-icp-ms-in-china-clinics/2025-01-28T16:06:44+08:00https://flcube.com/sino-biopharmaceuticals-atr-kinase-inhibitor-tcc1727-accepted-for-fda-review/2025-01-28T16:00:40+08:00https://flcube.com/acotec-scientific-and-boston-scientific-enter-acquisition-and-collaboration-agreement/2025-01-28T15:58:25+08:00https://flcube.com/biogens-aducanumab-administered-to-chinese-patient-for-first-time/2025-01-28T15:55:43+08:00https://flcube.com/stemirna-therapeutics-covid-19-mrna-vaccine-gets-eua-in-laos/2025-01-28T15:53:23+08:00https://flcube.com/medbanks-set-for-ipo-on-hong-kong-stock-exchange/2025-01-28T15:51:10+08:00https://flcube.com/fujian-cosunter-completes-enrollment-for-phase-i-study-of-gst-hg171/2025-01-28T15:30:45+08:00https://flcube.com/alphamab-oncology-updates-clinical-studies-for-kn046-and-kn026-at-sabcs-2022/2025-01-28T15:27:20+08:00https://flcube.com/roche-and-zhongshan-hospital-collaborate-on-clinical-studies-and-innovation-center/2025-01-28T15:22:33+08:00https://flcube.com/ash-2022-china-biotechs-showcase-latest-clinical-trial-results/2025-01-28T15:19:13+08:00https://flcube.com/merck-partners-with-tsinghua-shenzhen-for-organoid-3d-printing-system/2025-01-28T15:09:28+08:00https://flcube.com/luye-pharma-group-hands-over-seroquel-distribution-rights-to-dch-auriga-in-singapore/2025-01-28T15:07:19+08:00https://flcube.com/beijing-releases-covid-19-infection-drug-list-to-address-stocking-issues/2025-01-28T15:02:19+08:00https://flcube.com/cutia-therapeutic-plans-ipo-on-hong-kong-stock-exchange/2025-01-28T14:59:40+08:00https://flcube.com/chinas-state-council-boosts-internet-medical-services-amid-covid-19/2025-01-28T14:55:32+08:00https://flcube.com/asieris-pharmaceuticals-enrolls-first-patient-in-phase-ii-study-for-apl-1202/2025-01-28T14:53:10+08:00https://flcube.com/jiangsu-yahong-administers-first-dose-of-hexvix-in-hainan-pilot-zone/2025-01-28T14:50:39+08:00https://flcube.com/ascletis-pharma-announces-positive-phase-i-results-for-asc10-in-covid-19-treatment/2025-01-28T14:47:44+08:00https://flcube.com/yantai-dongcheng-to-acquire-us-firm-xingimaging-for-30-2m/2025-01-28T14:36:10+08:00https://flcube.com/hotgen-biotechs-covid-19-antigen-home-test-approved-in-russia/2025-01-28T14:32:30+08:00https://flcube.com/angel-pharmaceuticals-presents-cpi-818-data-at-ash-2022-annual-meeting/2025-01-28T13:45:08+08:00https://flcube.com/clinbrain-and-wch-establish-joint-laboratory-for-geriatric-information-platform/2025-01-28T13:39:25+08:00https://flcube.com/wuhan-yzy-biopharma-files-for-ipo-on-hong-kong-stock-exchange/2025-01-28T13:31:12+08:00https://flcube.com/jw-therapeutics-presents-carteyva-data-at-ash-annual-meeting/2025-01-28T13:27:14+08:00https://flcube.com/4b-technologies-raises-rmb-100m-in-pre-series-b-financing-round/2025-01-28T13:24:18+08:00https://flcube.com/gaush-meditech-ipos-on-hong-kong-stock-exchange-at-hkd-21-4-per-share/2025-01-28T13:20:49+08:00https://flcube.com/northeast-pharmaceutical-fined-rmb-133m-for-monopoly-selling/2025-01-28T13:15:58+08:00https://flcube.com/dizal-pharma-presents-golidocitinib-data-at-ash-annual-meeting/2025-01-28T13:13:37+08:00https://flcube.com/vigonvita-life-sciences-targets-hkex-ipo-with-integrated-biopharma-model/2025-01-28T12:47:57+08:00https://flcube.com/hengruis-generic-cyclophosphamide-capsules-approved-by-chinas-nmpa/2025-01-28T02:08:19+08:00https://flcube.com/suzhou-therys-generic-nilotinib-approved-by-chinas-nmpa/2025-01-28T02:07:47+08:00https://flcube.com/biontech-ships-first-covid-19-vaccine-batches-to-china/2025-01-28T02:07:07+08:00https://flcube.com/abcam-and-wuxi-diagnostics-expand-partnership-into-companion-diagnostics/2025-01-28T02:06:26+08:00https://flcube.com/shanghai-pharmaceuticals-partners-with-hkstp-for-biomedicine-cultivation-program/2025-01-28T02:04:49+08:00https://flcube.com/111-inc-begins-online-sales-of-pfizers-paxlovid-in-china/2025-01-28T01:59:19+08:00https://flcube.com/biosion-and-immunogen-collaborate-on-cancer-adcs/2025-01-28T01:55:41+08:00https://flcube.com/henlius-biotech-partners-with-medilink-for-global-adc-development/2025-01-28T01:46:36+08:00https://flcube.com/ascentage-pharmas-apg-2575-shows-promising-results-in-global-phase-ii-study/2025-01-28T01:44:04+08:00https://flcube.com/lifetech-scientific-completes-enrollment-for-ibs-coronary-stent-phase-ii-study/2025-01-28T01:41:12+08:00https://flcube.com/chinas-covid-19-vaccination-second-booster-shot-plan-released/2025-01-28T01:36:53+08:00https://flcube.com/immuneoncos-imm2520-receives-fda-clinical-trial-approval/2025-01-28T01:34:49+08:00https://flcube.com/jiangsu-recbios-covid-19-vaccine-recov-shows-superiority-in-phase-ii-trial/2025-01-28T01:32:31+08:00https://flcube.com/treadwell-therapeutics-presents-plk4-inhibitor-data-at-ash-annual-meeting/2025-01-28T01:29:37+08:00https://flcube.com/cryofocus-biotechnologys-rdn-system-gains-fda-breakthrough-therapy-designation/2025-01-28T01:27:04+08:00https://flcube.com/cryofocus-biotechnology-partners-with-boston-scientific-for-respiratory-products-distribution-in-china/2025-01-28T01:26:11+08:00https://flcube.com/cryofocus-biotechnology-receives-nmpa-approval-for-complete-cardiac-cryoablation-system/2025-01-28T01:25:24+08:00https://flcube.com/cryofocus-biotechnology-secures-nmpa-approval-for-cryotherapy-equipmen/2025-01-28T01:24:12+08:00https://flcube.com/cryofocus-biotechnology-partners-with-guangzhou-medical-university-hospital-for-cryoballoon-ablation-rd/2025-01-28T01:21:55+08:00https://flcube.com/boehringer-ingelheims-spevigo-approved-by-nmpa-for-generalized-pustular-psoriasis/2025-01-28T01:14:55+08:00https://flcube.com/cosmo-pharmaceuticals-lumeblue-completes-phase-iii-trial-in-china/2025-01-28T01:12:47+08:00https://flcube.com/acotec-scientifics-neo-skater-balloon-approved-by-nmpa-for-intracranial-vessels/2025-01-28T00:58:02+08:00https://flcube.com/tracon-pharmaceuticals-provides-positive-update-on-envafolimab-phase-ii-trial/2025-01-28T00:53:14+08:00https://flcube.com/sirnaomics-announces-interim-results-for-stp705-in-phase-iib-study-for-isscc/2025-01-28T00:48:59+08:00https://flcube.com/henlius-biotech-initiates-phase-i-trial-for-hlx60-in-australia/2025-01-28T00:45:42+08:00https://flcube.com/china-meheco-to-import-and-distribute-pfizers-paxlovid-in-mainland-china/2025-01-28T00:42:48+08:00https://flcube.com/zylox-tonbridge-receives-nmpa-approval-for-zylox-octoplus-vena-cava-filter/2025-01-28T00:40:13+08:00https://flcube.com/innovent-biologics-collaborates-with-lg-chem-for-tigulixostat-in-china/2025-01-28T00:32:41+08:00https://flcube.com/everest-medicines-achieves-preclinical-milestone-for-mrna-rabies-vaccine/2025-01-28T00:26:33+08:00https://flcube.com/alternative-bio-completes-15m-seed-round-to-advance-cancer-therapeutics/2025-01-28T00:23:49+08:00https://flcube.com/liaoning-publishes-fourth-round-of-volume-based-procurement-winning-bids/2025-01-28T00:18:59+08:00https://flcube.com/cryofocus-medtech-set-for-ipo-on-hong-kong-stock-exchange/2025-01-28T00:16:42+08:00https://flcube.com/nmpa-approves-sonoscape-and-acoustic-lifes-intravascular-ultrasound-products/2025-01-28T00:10:45+08:00https://flcube.com/henlius-serplulimab-receives-orphan-drug-designation-in-europe-for-sclc/2025-01-28T00:00:22+08:00https://flcube.com/xingimaging-and-mitro-biotech-partner-for-contract-research-services-in-china/2025-01-27T23:57:02+08:00https://flcube.com/doer-bio-and-msd-collaborate-on-clinical-trial-for-anti-claudin18-2-antibody-dr30303/2025-01-27T23:47:30+08:00https://flcube.com/wuxi-biologics-shanghai-subsidiary-removed-from-us-uvl/2025-01-27T23:44:24+08:00https://flcube.com/luye-pharmas-shandong-boan-biotechnology-ipos-on-hong-kong-stock-exchange/2025-01-27T23:41:09+08:00https://flcube.com/simcere-pharmaceutical-completes-enrollment-for-sim0417-covid-19-drug-trial/2025-01-27T23:26:18+08:00https://flcube.com/neurophths-nfs-02-gene-therapy-gets-fda-ind-approval-for-lhon-treatment/2025-01-27T23:22:43+08:00https://flcube.com/tg-immunopharma-gains-fda-approval-for-phase-i-study-of-anti-pvrig-antibody/2025-01-27T23:18:24+08:00https://flcube.com/adagene-initiates-international-study-for-adg126-in-hepatocellular-carcinoma/2025-01-27T23:09:11+08:00https://flcube.com/jiangsu-recbios-herpes-zoster-vaccine-rec610-gets-clinical-trial-approval-in-philippines/2025-01-27T23:04:59+08:00https://flcube.com/endo-international-licenses-tlcs-phase-iii-nanomedicine-for-oa-knee-pain/2025-01-27T23:02:10+08:00https://flcube.com/genfleet-and-merck-kgaa-partner-on-european-clinical-study-for-kras-g12c-inhibitor/2025-01-27T22:56:40+08:00https://flcube.com/blue-sail-medicals-microcatheter-receives-nmpa-marketing-approval/2025-01-27T22:53:18+08:00https://flcube.com/blue-sail-medical-subsidiary-secures-rmb-100-million-investment-to-expand-operations/2025-01-27T22:31:59+08:00https://flcube.com/meihua-medtech-secures-over-rmb-100m-in-series-b-financing-led-by-eight-roads-and-sunland/2025-01-27T22:24:37+08:00https://flcube.com/innermedical-secures-rmb-300m-in-series-d-funding-led-by-green-pine-and-simiao/2025-01-27T22:20:25+08:00https://flcube.com/novartis-china-establishes-health-development-fund-in-boao-lecheng/2025-01-27T22:15:28+08:00https://flcube.com/towardpi-raises-rmb-300-million-in-series-c-financing-round/2025-01-27T22:10:23+08:00https://flcube.com/towardpi-medical-secures-rmb-200-million-in-series-d-financing-led-by-matrix-partners/2025-01-27T22:07:33+08:00https://flcube.com/towardpi-medical-partners-with-oculus-iberia-to-introduce-advanced-octa-technology-to-spain/2025-01-27T22:07:32+08:00https://flcube.com/aosaikang-receives-fda-approval-for-askg915-clinical-trial/2025-01-27T22:03:45+08:00https://flcube.com/pfizer-exercises-option-for-sisunatovir-rights-with-lianbio/2025-01-27T22:00:17+08:00https://flcube.com/fosun-pharma-registers-comirnaty-vaccines-in-hong-kong/2025-01-27T21:56:13+08:00https://flcube.com/xtalpi-partners-with-singapores-eddc-to-develop-lung-cancer-treatments/2025-01-27T21:52:49+08:00https://flcube.com/prenetics-acquires-majority-stake-in-act-genomics-to-boost-oncology-services/2025-01-27T21:50:11+08:00https://flcube.com/cstones-sugemalimab-maa-accepted-by-uk-mhra-for-nsclc-treatment/2025-01-27T21:37:47+08:00https://flcube.com/ascletis-pharma-receives-uspto-notice-for-asc10-patent/2025-01-27T21:34:00+08:00https://flcube.com/hutchmed-initiates-rolling-nda-submission-for-elunate-to-us-fda/2025-01-27T21:28:20+08:00https://flcube.com/pcaob-report-signals-relief-for-us-listed-chinese-biotechs/2025-01-27T21:24:41+08:00https://flcube.com/sibionics-raises-rmb-500-million-in-series-d-financing-round/2025-01-27T21:21:25+08:00https://flcube.com/waker-bioscience-raises-angel-funding-for-isa-technology-upgrades/2025-01-27T21:15:41+08:00https://flcube.com/innocare-receives-cde-approval-for-phase-ii-trial-of-orelabrutinib-combination/2025-01-27T21:10:25+08:00https://flcube.com/ronovo-surgical-raises-pre-series-b-funding-for-surgical-robot-development/2025-01-27T21:06:15+08:00https://flcube.com/pingan-good-doctor-partners-to-establish-lifestyle-medicine/2025-01-27T21:01:42+08:00https://flcube.com/jw-therapeutics-collaborates-with-juno-for-dll3-car-t-therapy-development/2025-01-27T20:58:05+08:00https://flcube.com/mabwell-bioscience-licenses-biosimilars-to-russian-firm-binnopharm/2025-01-27T20:54:50+08:00https://flcube.com/sirnaomics-lead-candidate-stp707-shows-promising-phase-i-data/2025-01-27T20:51:23+08:00https://flcube.com/kira-pharmaceuticals-gains-nmpa-and-tga-approvals-for-kp104-phase-ii-study/2025-01-27T20:48:12+08:00https://flcube.com/merck-launches-noxafil-in-china-for-antifungal-treatment/2025-01-27T18:51:31+08:00https://flcube.com/hinovas-protac-drug-hp518-accepted-for-fda-review-in-mcrpc/2025-01-27T18:48:42+08:00https://flcube.com/fosun-kites-car-t-therapy-fkc889-approved-for-clinical-trials-in-china/2025-01-27T18:46:02+08:00https://flcube.com/shanghai-outlines-plans-to-boost-healthcare-and-pharma-industry/2025-01-27T18:42:17+08:00https://flcube.com/yantai-dongcheng-receives-nmpa-approval-for-f18-pet-imaging-study/2025-01-27T18:38:36+08:00https://flcube.com/biomica-raises-funds-for-tumor-immunity-and-ibd-drug-development/2025-01-27T18:34:49+08:00https://flcube.com/redpine-medical-raises-hundreds-of-millions-in-series-c-financing-round/2025-01-27T18:18:25+08:00https://flcube.com/yipinhongs-ar882-receives-nmpa-approval-for-gout-clinical-trial/2025-01-27T18:11:40+08:00https://flcube.com/shaanxi-panlong-receives-patents-for-coronavirus-3cl-protease-inhibitor/2025-01-27T18:08:22+08:00https://flcube.com/nhsa-orders-investigation-into-unreasonable-medical-insurance-restrictions/2025-01-27T18:03:47+08:00https://flcube.com/fosun-pharmas-avatrombopag-receives-nmpa-review-for-chronic-itp-indication/2025-01-27T18:00:56+08:00https://flcube.com/nanjing-pharmaceutical-to-acquire-majority-stakes-in-three-jiangsu-subsidiaries/2025-01-27T17:56:43+08:00https://flcube.com/msd-and-kelun-biotech-ink-record-breaking-adc-deal/2025-01-27T16:32:45+08:00https://flcube.com/nmpa-and-gac-release-notification-on-import-and-export-management-of-narcotic-drugs/2025-01-27T16:28:00+08:00https://flcube.com/shyndecs-generic-cytosar-u-gains-marketing-approval-in-china/2025-01-27T16:24:44+08:00https://flcube.com/sino-medical-sciences-nc-rockstar-catheter-approved-by-us-fda/2025-01-27T16:17:26+08:00https://flcube.com/antengene-files-for-xpovio-approval-in-macau-malaysia-and-thailand/2025-01-27T16:14:33+08:00https://flcube.com/eisai-and-biogen-initiate-bla-in-china-for-alzheimers-therapy-lecanemab/2025-01-27T16:11:56+08:00https://flcube.com/qitan-tech-raises-rmb-700-million-in-series-c-financing-led-by-meituan/2025-01-27T16:04:45+08:00https://flcube.com/kanghongs-escitalopram-oral-solution-receives-nmpa-marketing-approval/2025-01-27T15:57:45+08:00https://flcube.com/tonghua-dongbao-receives-nmpa-approval-for-thdbh151-clinical-study-in-gout-and-hyperuricemia/2025-01-27T15:53:06+08:00https://flcube.com/innovent-biologics-announces-strategic-partnerships-to-form-tumor-diagnosis-and-treatment-alliance/2025-01-27T15:49:43+08:00https://flcube.com/microports-fireliums-receives-nmpa-approval-for-coronary-bifurcation-stenosis-treatment/2025-01-27T15:34:41+08:00https://flcube.com/microports-tomahawk-intravascular-shock-wave-therapy-device-approved-by-nmpa/2025-01-27T14:30:14+08:00https://flcube.com/fda-clears-sbla-for-eisai-and-biogens-leqembi-maintenance-dosing/2025-01-27T13:32:16+08:00https://flcube.com/jiangsu-yuyue-partners-with-inogen-for-international-distribution-and-rd/2025-01-27T13:18:21+08:00https://flcube.com/guangzhou-innogens-efsubaglutide-alfa-approved-by-nmpa-for-type-2-diabetes/2025-01-27T12:57:20+08:00https://flcube.com/cspcs-nbl-020-receives-fda-ind-approval-for-advanced-solid-tumors/2025-01-27T01:24:04+08:00https://flcube.com/jiangsu-chia-tai-tianqings-tqb2102m-gains-nmpa-clinical-approval/2025-01-27T01:21:05+08:00https://flcube.com/wuxi-xdc-partners-with-genequantum-for-adc-development/2025-01-27T01:18:53+08:00https://flcube.com/neurophth-partners-with-apellis-for-gene-therapy-development-in-amd/2025-01-27T01:10:57+08:00https://flcube.com/jing-medicines-hjm-353-gains-clinical-trial-approvals-in-us-and-china/2025-01-27T01:04:16+08:00https://flcube.com/jiangsu-vcare-pharmatech-raises-rmb-200-million-in-series-b-financing-round/2025-01-27T00:58:03+08:00https://flcube.com/mindrank-ai-receives-fda-approval-for-mdr-001-clinical-study-in-obesity/2025-01-27T00:55:15+08:00https://flcube.com/hangzhou-biotest-receives-fda-eua-for-covid-19-antigen-self-testing-reagent/2025-01-27T00:51:33+08:00https://flcube.com/junshi-biosciences-licenses-pd-1-inhibitor-tuoyi-to-hikma-mena-fze/2025-01-27T00:46:38+08:00https://flcube.com/shanghai-pharmaceuticals-secures-exclusive-rights-for-shionogis-ensitrelvir-in-china/2025-01-27T00:43:25+08:00https://flcube.com/junshi-biosciences-pd-1-inhibitor-tuoyi-faces-fda-review-delay/2025-01-27T00:39:30+08:00https://flcube.com/huadong-medicines-lanluma-v-and-x-approved-for-use-in-hainan/2025-01-27T00:35:10+08:00https://flcube.com/antengene-and-msd-collaborate-on-global-clinical-study-for-atg-037/2025-01-27T00:32:07+08:00https://flcube.com/iaso-biotherapeutics-receives-fda-approval-for-ct103a-ind-application/2025-01-27T00:27:31+08:00https://flcube.com/shenzhen-wurzburg-dynamics-raises-rmb-100-million-in-series-a-financing-round/2025-01-27T00:23:52+08:00https://flcube.com/acornmed-raises-rmb-200-million-in-series-b-financing-led-by-yikai-venture-capital/2025-01-27T00:08:11+08:00https://flcube.com/elpiscience-receives-ind-approval-for-es014-in-china/2025-01-27T00:03:00+08:00https://flcube.com/ablaze-pharma-and-yonghe-partner-for-targeted-radiotherapy-development/2025-01-26T23:57:01+08:00https://flcube.com/innocare-pharmas-orelabrutinib-placed-on-partial-clinical-hold-by-fda/2025-01-26T23:50:38+08:00https://flcube.com/hainan-poly-pharm-receives-fda-approval-for-generic-lincomycin/2025-01-26T23:46:35+08:00https://flcube.com/innovent-biologics-gfh925-receives-breakthrough-therapy-designation/2025-01-26T23:43:46+08:00https://flcube.com/sichuan-healthcare-security-administration-announces-vbp-for-oral-implant-systems/2025-01-26T23:40:03+08:00https://flcube.com/wuxi-biologics-receives-first-gmp-certificate-from-ireland-hpra/2025-01-26T23:37:45+08:00https://flcube.com/carsgen-develops-new-car-t-technique-to-enhance-anti-tumor-activity/2025-01-26T23:35:08+08:00https://flcube.com/sciclone-pharmaceuticals-vaborem-ind-filing-accepted-by-nmpa/2025-01-26T23:32:09+08:00https://flcube.com/luye-pharmas-paliperidone-palmitate-accepted-for-nmpa-review/2025-01-26T23:29:09+08:00https://flcube.com/china-downgrades-covid-19-from-class-a-to-class-b-infectious-disease/2025-01-26T23:26:36+08:00https://flcube.com/carrier-biomed-raises-tens-of-millions-in-series-a-financing-round/2025-01-26T23:24:18+08:00https://flcube.com/everest-medicines-launches-first-phase-of-global-mrna-vaccine-manufacturing-site/2025-01-26T23:18:16+08:00https://flcube.com/innocare-pharma-receives-hong-kong-approval-for-tafasitamab-in-dlbcl/2025-01-26T23:15:46+08:00https://flcube.com/leadart-biotechnologies-raises-usd-6-million-in-pre-series-a-round/2025-01-26T23:12:03+08:00https://flcube.com/simcere-receives-nmpa-clearance-for-sim0237-clinical-study/2025-01-26T23:05:39+08:00https://flcube.com/cstone-pharmaceuticals-publishes-ayvakit-study-results-on-oncologist-website/2025-01-26T23:02:58+08:00https://flcube.com/biosion-completes-series-b-financing-round-led-by-guangfa-xinde-investment/2025-01-26T22:59:56+08:00https://flcube.com/bgi-genomics-receives-anvisa-approval-for-colorectal-cancer-detection-kit/2025-01-26T22:57:22+08:00https://flcube.com/inflarx-and-staidson-amend-deal-to-advance-vilobelimab-regulatory-filing-in-china/2025-01-26T22:54:22+08:00https://flcube.com/junshi-biosciences-jt001-vv116-shows-non-inferiority-to-paxlovid-in-covid-19-trial/2025-01-26T22:20:43+08:00https://flcube.com/hainan-shuangcheng-files-paragraph-iv-patent-declaration-for-paclitaxel-albumin-bound/2025-01-26T22:16:53+08:00https://flcube.com/grand-pharmas-covid-19-therapy-gs221-shows-promising-safety-profile/2025-01-26T22:07:55+08:00https://flcube.com/fosun-pharma-launches-online-registration-for-biontech-covid-19-vaccine-in-hong-kong/2025-01-26T22:03:56+08:00https://flcube.com/immunotech-biopharms-car-t-19-d2-ind-filing-accepted-by-nmpa/2025-01-26T21:59:15+08:00https://flcube.com/acotec-scientific-holdings-receives-nmpa-approvals-for-yan-and-p-conic-balloon/2025-01-26T21:55:52+08:00https://flcube.com/cansino-biologics-updates-data-from-covid-19-vaccine-clinical-studies/2025-01-26T21:53:13+08:00https://flcube.com/fortune-care-raises-over-rmb-100-million-in-series-c-financing-round/2025-01-26T21:49:30+08:00https://flcube.com/guangzhou-mygene-raises-hundreds-of-millions-in-series-c-financing-led-by-efund-capital/2025-01-26T21:39:15+08:00https://flcube.com/nmpa-approves-172-medical-devices-for-marketing-in-november-2022/2025-01-26T21:05:48+08:00https://flcube.com/mercks-lagevrio-receives-emergency-conditional-approval-from-chinas-nmpa/2025-01-26T21:03:06+08:00https://flcube.com/nhsa-and-cnipa-issue-opinions-on-strengthening-ip-protection-in-drug-procurement/2025-01-26T20:59:14+08:00https://flcube.com/legend-biotechs-carvykti-accepted-for-review-by-chinas-cde/2025-01-26T20:56:14+08:00https://flcube.com/f-star-therapeutics-and-sino-biopharmaceutical-face-delays-in-proposed-acquisition/2025-01-26T20:52:32+08:00https://flcube.com/cspcs-almb-0168-receives-nmpa-approval-for-osteoarthritis-clinical-study/2025-01-26T20:48:31+08:00https://flcube.com/remegens-rc108-receives-fda-go-ahead-for-phase-i-clinical-study/2025-01-26T20:44:59+08:00https://flcube.com/simcere-receives-nmpa-clearance-for-sim0348-clinical-study/2025-01-26T20:42:06+08:00https://flcube.com/skynor-medical-raises-rmb-100-million-in-financing-round-for-market-expansion/2025-01-26T20:39:08+08:00https://flcube.com/sichuan-kelun-completes-rmb-1-5-billion-financing-round-for-kelun-biotech/2025-01-26T20:33:17+08:00https://flcube.com/everest-medicines-nefecon-receives-priority-review-recommendation-from-cde/2025-01-26T20:29:04+08:00https://flcube.com/brightgene-receives-nmpa-approval-for-bgm0504-clinical-trial/2025-01-26T20:25:45+08:00https://flcube.com/anhui-anke-biotechnology-receives-nmpa-approval-for-ak2017-clinical-study/2025-01-26T20:21:20+08:00https://flcube.com/astrazenecas-nexium-approved-by-nmpa-for-adolescent-gerd-treatment/2025-01-26T20:15:49+08:00https://flcube.com/sino-biopharmaceutical-secures-rights-to-shionogis-covid-19-therapy-ensitrelvir/2025-01-26T20:12:12+08:00https://flcube.com/shenzhen-core-medical-raises-hundreds-of-millions-in-series-c-financing/2025-01-26T20:06:28+08:00https://flcube.com/sinovac-reports-h1-2022-financials-amid-covid-19-vaccine-demand-decline/2025-01-26T20:03:12+08:00https://flcube.com/staidsons-anti-c5a-monoclonal-antibody-stsa-1002-accepted-for-nmpa-review/2025-01-26T19:59:29+08:00https://flcube.com/guangdong-raynovent-biotech-secures-rmb-370-million-in-series-c-financing/2025-01-26T19:56:15+08:00https://flcube.com/hengrui-pharmaceuticals-appoints-dr-jiang-ningjun-as-deputy-general-manager-and-cso/2025-01-26T19:48:57+08:00https://flcube.com/junshi-biosciences-cgrp-monoclonal-antibody-js010-accepted-for-nmpa-review/2025-01-26T19:36:06+08:00https://flcube.com/beigenes-tislelizumab-receives-nmpa-review-for-first-line-hcc-indication/2025-01-26T19:32:34+08:00https://flcube.com/immunohead-biotech-raises-rmb-200-million-in-series-a-financing-round/2025-01-26T19:27:21+08:00https://flcube.com/biocytogen-and-hansoh-enter-antibody-collaboration-and-licensing-agreement/2025-01-26T19:19:36+08:00https://flcube.com/cstone-pharmaceuticals-achieves-primary-endpoint-in-gemstone-304-study-for-sugemalimab/2025-01-26T19:14:00+08:00https://flcube.com/3d-medicines-gains-fda-approval-for-phase-ii-study-of-envafolimab-in-dmmr-tumors/2025-01-26T19:11:08+08:00https://flcube.com/changzhou-qianhong-completes-phase-i-study-of-qhrd107-for-acute-myeloid-leukemia/2025-01-26T19:03:16+08:00https://flcube.com/guangdong-zhongsheng-completes-enrollment-for-ray1216-phase-iii-study-in-covid-19/2025-01-26T19:00:28+08:00https://flcube.com/cde-releases-65th-batch-of-chemical-generic-reference-preparations/2025-01-26T18:54:52+08:00https://flcube.com/viking-therapeutics-sues-ascletis-pharma-over-alleged-trade-secret-theft/2025-01-26T18:52:35+08:00https://flcube.com/shuwen-biotech-partners-with-nottingham-university-hospitals-for-mammatyper/2025-01-26T18:47:57+08:00https://flcube.com/chinagene-techs-zvs101e-receives-fda-ind-approval-for-biettis-crystalline-dystrophy/2025-01-26T18:41:54+08:00https://flcube.com/canbridge-secures-global-rights-to-second-generation-gene-therapy-for-sma/2025-01-26T16:39:29+08:00https://flcube.com/transcentas-tst003-receives-clinical-trial-approval-in-china-and-us/2025-01-26T16:12:08+08:00https://flcube.com/henlius-hanbeitai-gains-nmpa-approval-for-expanded-indications/2025-01-26T16:09:05+08:00https://flcube.com/sihuans-hui-sheng-bio-completes-series-a-financing-for-diabetes-pipeline/2025-01-26T16:02:53+08:00https://flcube.com/hutchmed-completes-enrollment-for-phase-iii-eslim-01-study-of-sovleplenib-in-itp/2025-01-26T15:59:30+08:00https://flcube.com/remegens-rc48-gains-nmpa-approval-for-phase-ii-study-in-bladder-cancer/2025-01-26T15:48:41+08:00https://flcube.com/apeloa-and-simcere-partner-for-cdmo-services-and-rd-collaboration/2025-01-26T15:45:28+08:00https://flcube.com/sino-biopharmaceuticals-cttq-partners-with-protelight-for-antibacterial-peptide-pl-5/2025-01-26T15:40:40+08:00https://flcube.com/protelight-pharmas-peceleganan-pl-5-accepted-for-review-by-chinas-cde/2025-01-26T15:39:00+08:00https://flcube.com/inscinstech-raises-rmb-150-million-in-series-a-b-and-b-rounds/2025-01-26T15:34:03+08:00https://flcube.com/everest-medicines-outlines-strategic-plans-for-expansion-and-growth/2025-01-26T15:24:56+08:00https://flcube.com/zai-lab-appoints-dr-rafael-amado-as-president-of-cancer-rd/2025-01-26T15:22:16+08:00https://flcube.com/jiangxi-jemincare-gains-fda-approval-for-clinical-trial-of-jyb1907-in-solid-tumors/2025-01-26T15:18:42+08:00https://flcube.com/mabwell-receives-nmpa-approval-for-clinical-trial-of-9mw3011-in-rare-diseases/2025-01-26T15:15:41+08:00https://flcube.com/msd-and-eisais-keytruda-lenvima-combo-shows-promise-in-gastroesophageal-cancer-study/2025-01-26T15:04:17+08:00https://flcube.com/nhsa-targets-low-volume-drugs-in-national-reimbursement-list/2025-01-26T14:35:12+08:00https://flcube.com/novo-nordisks-amycretin-shows-promising-weight-loss-results-in-phase-ib-iia-study/2025-01-26T14:25:53+08:00https://flcube.com/jiangsu-vcare-pharmatech-secures-rmb200-million-in-series-c-financing/2025-01-26T14:12:49+08:00https://flcube.com/genequantum-secures-13-billion-deals-with-biohaven-and-aimedbio-for-adc-development/2025-01-26T13:24:15+08:00https://flcube.com/sinopharm-partners-with-biogen-for-comprehensive-service-agreement/2025-01-26T13:11:54+08:00https://flcube.com/boehringer-ingelheims-nerandomilast-granted-priority-review-for-ipf-in-china/2025-01-26T13:05:56+08:00https://flcube.com/mirxes-holding-files-for-hong-kong-ipo-with-focus-on-mirna-test-kits/2025-01-26T12:54:41+08:00https://flcube.com/shenzhen-kangtai-halts-covid-19-vaccine-development-amid-market-shifts/2025-01-26T12:44:25+08:00https://flcube.com/huadong-medicines-ellanse-m-filing-accepted-by-chinas-nmpa/2025-01-26T12:32:07+08:00https://flcube.com/china-medical-system-partners-with-mabgeek-for-innovative-drug-mg-k10/2025-01-26T10:58:01+08:00https://flcube.com/jiangsu-aideas-acc007-approved-by-nmpa-for-hiv-1-treatment/2025-01-26T02:00:34+08:00https://flcube.com/wuxi-biologics-and-gsk-ink-licensing-agreement-for-t-cell-engaging-antibodies/2025-01-26T01:57:17+08:00https://flcube.com/antengene-acquires-full-rights-to-calitheras-cd73-inhibitor-cb-708/2025-01-26T01:53:04+08:00https://flcube.com/haiscos-egfr-protac-hsk40118-accepted-for-review-by-chinas-nmpa/2025-01-26T01:47:14+08:00https://flcube.com/nmpa-strengthens-oversight-of-covid-19-drugs-and-home-treatment-guidelines/2025-01-26T01:41:41+08:00https://flcube.com/nmpa-approves-chinabridges-ecmo-equipment-for-emergency-use/2025-01-26T01:38:36+08:00https://flcube.com/eoc-pharmas-entinostat-nda-accepted-by-chinas-nmpa-for-breast-cancer/2025-01-26T01:31:53+08:00https://flcube.com/hightide-therapeutics-completes-107-million-series-c-and-c-financing-rounds/2025-01-26T01:28:44+08:00https://flcube.com/biogen-and-tsinghua-university-launch-three-year-neuroscience-collaboration/2025-01-26T01:25:28+08:00https://flcube.com/chinas-nhc-and-natcm-launch-integrated-pain-management-pilot-plan/2025-01-26T01:22:31+08:00https://flcube.com/zhongchao-partners-with-natco-pharma-to-distribute-drugs-in-china/2025-01-26T01:18:42+08:00https://flcube.com/by-health-to-establish-nutrition-research-center-with-shanghai-institute/2025-01-26T01:11:18+08:00https://flcube.com/hutchmeds-sovleplenib-administered-to-first-patient-in-phase-ii-covid-19-study/2025-01-26T01:06:46+08:00https://flcube.com/zai-lab-and-novocures-ttfields-device-shows-survival-benefit-in-lung-cancer-study/2025-01-26T01:02:43+08:00https://flcube.com/salubris-pharmaceuticals-gains-nmpa-approval-for-phase-i-study-of-sal0133/2025-01-26T00:56:06+08:00https://flcube.com/immune-onc-therapeutics-completes-131-million-series-b-financing/2025-01-26T00:46:01+08:00https://flcube.com/henlius-completes-first-dosing-in-global-phase-iii-study-for-hansizhuang-in-ls-sclc/2025-01-26T00:42:29+08:00https://flcube.com/singular-medical-secures-series-b-funding-for-cardiac-device-development/2025-01-26T00:38:31+08:00https://flcube.com/boehringer-ingelheim-enrolls-first-patient-in-phase-ii-iii-study-for-bi-907828/2025-01-26T00:33:43+08:00https://flcube.com/vcanbios-stem-cell-therapy-vum02-accepted-for-clinical-trial-review/2025-01-26T00:31:07+08:00https://flcube.com/cansino-biologics-mrna-vaccine-cs-2034-shows-positive-safety-and-immunogenicity-data/2025-01-26T00:28:13+08:00https://flcube.com/mindray-partners-with-bomimed-for-exclusive-canadian-sales-and-service/2025-01-26T00:25:12+08:00https://flcube.com/simnova-partners-with-orna-therapeutics-for-in-situ-car-therapies/2025-01-26T00:20:28+08:00https://flcube.com/aurisco-partners-with-cytiva-to-build-oligonucleotide-production-plant/2025-01-26T00:15:49+08:00https://flcube.com/dizals-sunvozertinib-and-golidocitinib-combo-gets-nmpa-approval-for-phase-ii-study/2025-01-26T00:10:32+08:00https://flcube.com/luye-pharmas-ba1301-receives-cde-approval-for-clinical-trials/2025-01-26T00:07:39+08:00https://flcube.com/chinas-national-health-commission-releases-updated-covid-19-treatment-plan/2025-01-26T00:04:37+08:00https://flcube.com/jiangxi-jemincares-jmkx003142-gets-fda-nod-for-clinical-study/2025-01-26T00:01:39+08:00https://flcube.com/pfizers-paxlovid-excluded-from-chinas-nrdl-amid-price-dispute/2025-01-25T23:58:56+08:00https://flcube.com/china-strengthens-covid-19-prevention-and-control-in-rural-areas/2025-01-25T23:55:32+08:00https://flcube.com/eli-lillys-donanemab-set-to-gain-breakthrough-therapy-designation-in-china/2025-01-25T23:53:05+08:00https://flcube.com/changzhou-sifary-medtech-secures-series-b-funding-for-global-expansion/2025-01-25T23:50:19+08:00https://flcube.com/zhifei-biological-products-bcg-vaccine-filing-accepted-by-chinas-nmpa/2025-01-25T23:35:31+08:00https://flcube.com/yantai-dongcheng-pharma-gets-fda-go-ahead-for-177lu-lnc1004-clinical-trial/2025-01-25T23:32:41+08:00https://flcube.com/vivavision-biotech-partners-with-everads-therapy-for-retinal-disease-therapies/2025-01-25T23:29:27+08:00https://flcube.com/shenzhen-based-rhegen-bio-raises-rmb-100-million-in-pre-series-b-round/2025-01-25T23:20:02+08:00https://flcube.com/hainan-poly-pharms-generic-ganciclovir-approved-in-denmark/2025-01-25T23:14:36+08:00https://flcube.com/jacobio-pharma-doses-first-patient-in-us-phase-i-iia-study-for-jab-2485/2025-01-25T23:08:27+08:00https://flcube.com/vacsera-in-talks-with-sinovac-to-establish-integrated-vaccine-plant/2025-01-25T23:05:16+08:00https://flcube.com/eisai-ceo-outlines-ambitions-for-alzheimers-drug-leqembi-after-fda-approval/2025-01-25T23:01:07+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-phase-iii-study-for-mazdutide/2025-01-25T22:56:28+08:00https://flcube.com/nmpa-releases-63rd-batch-of-reference-drugs-for-generic-quality-evaluation/2025-01-25T21:55:03+08:00https://flcube.com/cosunters-covid-19-drug-gst-hg171-shows-superior-efficacy-in-trial/2025-01-25T21:52:53+08:00https://flcube.com/fosun-foundation-donates-covid-19-therapy-azvudine-to-rural-china/2025-01-25T21:14:36+08:00https://flcube.com/nmpa-approves-expanded-production-for-covid-19-symptom-treatments/2025-01-25T21:06:38+08:00https://flcube.com/roches-glofitamab-and-dizals-sunvozertinib-enter-priority-review/2025-01-25T21:03:12+08:00https://flcube.com/yinjia-biosciences-raises-rmb-100-million-in-series-a-financing-round/2025-01-25T20:59:23+08:00https://flcube.com/china-optimizes-medical-insurance-policies-for-covid-19-treatment/2025-01-25T20:52:25+08:00https://flcube.com/china-resources-biopharmaceutical-secures-rmb-600-million-in-series-b-funding/2025-01-25T20:48:25+08:00https://flcube.com/adagenes-adg126-shows-promise-in-combination-with-anti-pd-1-therapy/2025-01-25T20:44:50+08:00https://flcube.com/pfizer-ceo-denies-licensing-paxlovid-to-chinese-generics-firms/2025-01-25T20:37:08+08:00https://flcube.com/legend-biotech-receives-nasdaq-notice-regarding-listing-compliance/2025-01-25T20:33:26+08:00https://flcube.com/biocity-biopharma-launches-phase-iii-study-for-kidney-disease-drug-sc0062/2025-01-25T10:58:18+08:00https://flcube.com/evopoint-biosciences-licenses-sos1-inhibitor-to-metis-therapeutics/2025-01-25T01:47:06+08:00https://flcube.com/pfizers-nurtec-odt-launches-in-china-via-hainans-boao-lecheng-zone/2025-01-25T01:42:59+08:00https://flcube.com/hkex-2022-annual-report-ipo-activity-declines-amid-global-challenges/2025-01-25T01:40:27+08:00https://flcube.com/konruns-initiates-phase-ii-study-for-kc1036-in-advanced-thymic-tumors/2025-01-25T01:34:40+08:00https://flcube.com/dizals-sunvozertinib-nda-accepted-for-review-by-chinas-nmpa/2025-01-25T01:32:16+08:00https://flcube.com/hightide-therapeutics-doses-first-patient-in-phase-iib-study-for-htd1801-in-nash/2025-01-25T01:30:07+08:00https://flcube.com/msd-submits-initial-quotation-for-molnupiravir-in-china-amid-new-covid-19-rules/2025-01-25T01:28:07+08:00https://flcube.com/treadwell-therapeutics-cfi-402257-granted-fast-track-status-by-fda/2025-01-25T01:25:22+08:00https://flcube.com/cde-releases-66th-batch-of-chemical-generic-reference-preparations/2025-01-25T01:21:02+08:00https://flcube.com/jiangsu-kanions-kys202002a-greenlit-for-clinical-study-in-multiple-myeloma/2025-01-25T01:18:57+08:00https://flcube.com/gaoling-medical-secures-funding-for-infrared-thermotherapy-technology/2025-01-25T01:16:19+08:00https://flcube.com/yiling-pharmaceuticals-bio-008-accepted-for-review-by-chinas-nmpa/2025-01-25T01:11:52+08:00https://flcube.com/sino-biopharmaceutical-secures-rights-to-biosimilar-of-amgens-xgeva-in-china/2025-01-25T01:09:17+08:00https://flcube.com/cansino-biologics-to-issue-gdrs-on-swx-swiss-exchange-to-boost-globalization/2025-01-25T01:05:21+08:00https://flcube.com/luye-pharma-launches-named-patient-program-for-lurbinectedin-in-hong-kong/2025-01-25T01:02:34+08:00https://flcube.com/msd-china-to-take-legal-action-against-market-infringement-of-molnupiravir/2025-01-25T00:59:12+08:00https://flcube.com/med-vision-secures-series-a-funding-to-expand-digital-therapy-portfolio/2025-01-25T00:56:20+08:00https://flcube.com/bioantibody-bio-raises-rmb-100-million-in-series-a-funding-round/2025-01-25T00:49:50+08:00https://flcube.com/meihua-partners-with-getein-biotech-to-manufacture-covid-19-antigen-tests/2025-01-25T00:45:36+08:00https://flcube.com/cspcs-cleviprex-approved-for-clinical-study-by-chinas-nmpa/2025-01-25T00:42:20+08:00https://flcube.com/chinas-dental-implant-vbp-tender-results-in-significant-price-cuts/2025-01-25T00:40:08+08:00https://flcube.com/takedas-mobocertinib-approved-in-china-for-egfr-exon20ins-nsclc/2025-01-25T00:37:55+08:00https://flcube.com/meditrust-health-secures-series-c-funding-with-hsbc-as-strategic-investor/2025-01-25T00:34:00+08:00https://flcube.com/kelun-biotechs-skb264-approved-for-phase-ii-study-in-egfr-mutant-nsclc/2025-01-25T00:29:32+08:00https://flcube.com/beigene-outlines-global-rd-strategy-at-j-p-morgan-healthcare-summit/2025-01-25T00:25:22+08:00https://flcube.com/roches-polivy-approved-by-chinas-nmpa-for-lymphoma-treatment/2025-01-25T00:20:28+08:00https://flcube.com/china-launches-eighth-round-of-national-volume-based-procurement-for-41-drugs/2025-01-25T00:16:43+08:00https://flcube.com/eyougene-raises-hundreds-of-millions-in-series-b-funding-for-expansion/2025-01-25T00:01:08+08:00https://flcube.com/lepure-bio-secures-hundreds-of-millions-in-series-c-funding-for-expansion/2025-01-24T23:56:15+08:00https://flcube.com/shenzhen-keyto-fluid-control-secures-series-c-funding-for-expansion/2025-01-24T23:49:43+08:00https://flcube.com/xinhua-pharmas-oab-14-receives-nmpa-approval-for-phase-i-alzheimers-study/2025-01-24T23:45:42+08:00https://flcube.com/cii-tech-secures-tens-of-millions-in-pre-series-a-funding-for-mass-spectrometry/2025-01-24T23:43:25+08:00https://flcube.com/technoderma-raises-series-a-funding-to-advance-dermatology-pipeline/2025-01-24T23:08:49+08:00https://flcube.com/konruns-kc1036-advances-to-phase-ii-study-for-lung-adenocarcinoma/2025-01-24T23:01:55+08:00https://flcube.com/harbour-biomeds-hbm1020-receives-fda-approval-for-us-phase-i-study/2025-01-24T22:59:26+08:00https://flcube.com/porton-pharma-solutions-to-invest-eur-50-million-in-slovenia-bio-industry-park/2025-01-24T22:57:18+08:00https://flcube.com/cloudr-partners-with-shaanxi-pharmaceutical-firms-for-integrated-healthcare-solutions/2025-01-24T22:54:59+08:00https://flcube.com/syneos-health-partners-with-fosun-pharma-to-commercialize-serplulimab-in-us/2025-01-24T22:32:25+08:00https://flcube.com/sanofis-iglarlixi-approved-in-china-for-type-2-diabetes-management/2025-01-24T22:28:38+08:00https://flcube.com/3d-medicines-3d185-receives-orphan-drug-designation-for-gastric-cancer/2025-01-24T22:25:00+08:00https://flcube.com/china-medical-systems-opzelura-cream-filing-for-vitiligo-accepted-by-nmpa/2025-01-24T22:16:07+08:00https://flcube.com/ascletis-pharma-initiates-dosing-in-phase-i-trial-for-covid-19-treatment-asc11/2025-01-24T22:11:19+08:00https://flcube.com/base-therapeutics-secures-series-a1-funding-to-advance-gene-editing-pipelines/2025-01-24T22:08:47+08:00https://flcube.com/luye-pharmas-rykindo-receives-fda-approval-for-schizophrenia-and-bipolar-i-disorder/2025-01-24T22:00:09+08:00https://flcube.com/wuxi-biologics-ceo-outlines-growth-amid-global-challenges-at-j-p-morgan-conference/2025-01-24T21:57:48+08:00https://flcube.com/relive-biotechnologies-acquires-co-don-ag-secures-usd-36-million-for-expansion/2025-01-24T21:46:15+08:00https://flcube.com/akesos-penpulimab-secures-new-approval-for-lung-cancer-indication/2025-01-24T21:35:36+08:00https://flcube.com/clover-biopharmaceuticals-plans-covid-19-vaccine-scb-2019-launch-in-china-for-2023/2025-01-24T21:33:02+08:00https://flcube.com/amoytops-ak0706-receives-clinical-trial-approval-for-hepatitis-b-treatment/2025-01-24T21:30:34+08:00https://flcube.com/shanghai-ark-biopharmaceutical-partners-with-wuxi-sta-for-commercial-supply-of-ziresovir/2025-01-24T21:29:52+08:00https://flcube.com/arkbio-partners-with-sdodt-to-boost-adhd-treatment-marketing-and-commercialization/2025-01-24T21:29:51+08:00https://flcube.com/jhm-biopharma-raises-rmb100-million-to-expand-protein-drug-pipeline/2025-01-24T21:23:48+08:00https://flcube.com/sino-biopharmas-pd-l1-combo-with-anlotinib-accepted-for-review-by-chinas-cde/2025-01-24T21:18:48+08:00https://flcube.com/mehecos-genertec-partners-with-astrazeneca-for-covid-19-antibody-evusheld-in-china/2025-01-24T21:15:52+08:00https://flcube.com/guangzhous-overseas-pharma-wins-china-clinical-trial-approval-for-opl-038/2025-01-24T21:00:57+08:00https://flcube.com/conjustar-raises-rmb100-million-to-advance-x-drug-conjugates-pipeline/2025-01-24T20:47:56+08:00https://flcube.com/hengruis-long-acting-insulin-analogue-accepted-for-review-by-chinas-nmpa/2025-01-24T20:34:01+08:00https://flcube.com/abbvie-partners-with-neomorph-on-molecular-glue-degraders-for-oncology-and-immunology/2025-01-24T20:26:10+08:00https://flcube.com/sino-medical-sciences-wins-peru-approval-for-coronary-balloon-catheter/2025-01-24T19:53:13+08:00https://flcube.com/shenzhen-beike-initiates-first-chinese-stem-cell-study-for-systemic-lupus-erythematosus/2025-01-24T19:41:36+08:00https://flcube.com/accurays-tomo-c-system-completes-treatment-of-first-100-patients-in-china/2025-01-24T18:56:05+08:00https://flcube.com/ascentage-pharma-prices-us-ipo-at-usd-17-25-per-ads/2025-01-24T18:49:07+08:00https://flcube.com/united-laboratories-biosimilar-semaglutide-accepted-for-review-by-chinas-nmpa/2025-01-24T18:41:00+08:00https://flcube.com/beijing-aosaikangs-askb589-shows-promise-in-phase-i-ii-study-for-gastric-cancer/2025-01-24T18:30:22+08:00https://flcube.com/biogens-higher-dose-spinraza-regimen-under-review-by-fda-and-ema/2025-01-24T18:21:31+08:00https://flcube.com/novo-nordisk-partners-with-immvention-on-bach1-program-for-sickle-cell-disease/2025-01-24T18:15:19+08:00https://flcube.com/bristol-myers-squibbs-opdivo-secures-two-new-approvals-for-esophageal-cancer-in-china/2025-01-24T12:12:07+08:00https://flcube.com/henlius-pd-1-inhibitor-hansizhuang-approved-for-first-line-sclc-indication/2025-01-24T12:10:05+08:00https://flcube.com/agilis-robotics-completes-successful-animal-testing-for-surgical-robot/2025-01-24T12:07:18+08:00https://flcube.com/carsgen-and-huadong-medicine-partner-to-commercialize-bcma-car-t-product-ct053-in-china/2025-01-24T12:02:29+08:00https://flcube.com/tongshu-gene-partners-with-lc-gene-to-distribute-gene-mutation-detection-kit-in-china/2025-01-24T11:59:01+08:00https://flcube.com/bristol-myers-squibbs-opdivo-gains-new-indication-for-nsclc-neoadjuvant-therapy-in-china/2025-01-23T18:24:40+08:00https://flcube.com/daiichi-sankyos-mirogabalin-nears-china-market-entry-with-cde-review/2025-01-23T18:22:02+08:00https://flcube.com/bio-theras-biosimilar-bat1806-passes-nmpa-review-targets-roches-actemra/2025-01-23T18:20:08+08:00https://flcube.com/abbiskos-absk021-gains-nmpa-approval-for-phase-ii-study-in-cgvhd/2025-01-23T18:15:40+08:00https://flcube.com/affamed-secures-china-rights-to-eli-lillys-migraine-drug-galcanezumab/2025-01-23T18:13:27+08:00https://flcube.com/chinas-nhc-releases-second-national-drug-use-monitoring-list/2025-01-23T18:11:21+08:00https://flcube.com/suzhou-powersite-electric-secures-series-b-funding-for-x-ray-imaging-expansion/2025-01-23T18:09:45+08:00https://flcube.com/beijing-interbio-secures-pre-series-a-funding-for-spr-technology-expansion/2025-01-23T18:03:11+08:00https://flcube.com/cstones-ret-inhibitor-gavreto-approved-in-taiwan-for-lung-and-thyroid-cancers/2025-01-23T17:58:17+08:00https://flcube.com/ascletis-partners-with-simcere-for-ritonavir-supply-in-covid-19-drug-development/2025-01-23T17:55:37+08:00https://flcube.com/simceres-covid-19-drug-sim0417-accepted-for-special-review-by-nmpa/2025-01-23T17:52:29+08:00https://flcube.com/nhsa-completes-2022-nrdl-update-with-111-new-listings-focus-on-covid-19-treatments/2025-01-23T17:26:33+08:00https://flcube.com/cde-grants-priority-review-to-takedas-vonicog-alfa-zhongmeis-rilonacept-and-zai-labs-sul-dur/2025-01-23T17:23:47+08:00https://flcube.com/immunofocos-cldn18-2-targeted-car-t-therapy-imc002-accepted-for-cde-review/2025-01-23T17:19:38+08:00https://flcube.com/keymed-biosciences-cmg901-shows-promising-results-in-phase-ia-study-for-solid-tumors/2025-01-23T17:07:29+08:00https://flcube.com/mdhc-group-raises-hundreds-of-millions-in-third-financing-round/2025-01-23T17:04:06+08:00https://flcube.com/staidsons-stsp-0601-begins-phase-ii-study-for-hemophilia-treatment/2025-01-23T16:57:14+08:00https://flcube.com/everest-medicines-ever206-shows-positive-phase-i-results-in-china/2025-01-23T16:54:44+08:00https://flcube.com/bliss-bio-raises-rmb-100-million-in-series-b-financing-for-oncology-pipeline/2025-01-23T16:51:58+08:00https://flcube.com/blissbio-secures-nmpa-approval-for-bb-1712-pioneering-adc-therapy/2025-01-23T16:49:48+08:00https://flcube.com/junshi-biosciences-neotorch-study-achieves-superiority-in-lung-cancer-trial/2025-01-23T16:44:25+08:00https://flcube.com/hengruis-ezh2-inhibitor-shr2554-nears-breakthrough-therapy-designation/2025-01-23T16:40:43+08:00https://flcube.com/henlius-terminates-trop2-antibody-licensing-deal-with-chiome-bioscience/2025-01-23T16:37:25+08:00https://flcube.com/structure-therapeutics-files-for-ipo-on-nasdaq-to-raise-119m/2025-01-23T16:32:07+08:00https://flcube.com/hansohs-hs-10517-greenlit-for-covid-19-clinical-study-by-nmpa/2025-01-23T16:27:10+08:00https://flcube.com/cowell-health-partners-with-gilead-sciences-to-enhance-drug-accessibility/2025-01-23T16:24:31+08:00https://flcube.com/iaso-bio-raises-rmb-500-million-in-series-c1-funding-for-cell-therapy-pipeline/2025-01-23T16:21:08+08:00https://flcube.com/junshi-biosciences-covid-19-drug-jt001-vv116-accepted-for-nmpa-review/2025-01-23T16:18:31+08:00https://flcube.com/amcor-acquires-shanghai-based-mdk-to-expand-asia-pacific-footprint/2025-01-23T16:15:29+08:00https://flcube.com/simnova-orna-expand-partnership-to-develop-bcma-targeted-rna-therapies/2025-01-23T16:04:55+08:00https://flcube.com/zai-labs-zl-1310-granted-orphan-drug-designation-by-fda-for-sclc/2025-01-23T16:04:24+08:00https://flcube.com/simcere-affiliate-xianbo-biotech-gets-china-nod-for-car-t-therapy-snc109/2025-01-23T15:51:12+08:00https://flcube.com/simnova-secures-rmb-200-million-in-series-a-funding-to-advance-car-therapy-pipeline/2025-01-23T15:48:32+08:00https://flcube.com/johnson-johnson-reports-q4-growth-projects-2025-sales-outlook/2025-01-23T15:18:38+08:00https://flcube.com/yoltech-initiates-study-for-yolt-204-in-transfusion-dependent-beta-thalassemia/2025-01-23T15:04:59+08:00https://flcube.com/haichang-bios-sirna-drug-hc016-cleared-for-us-clinical-trials/2025-01-23T14:57:58+08:00https://flcube.com/imbioray-raises-rmb-100-million-in-series-a-for-nk-cell-therapies/2025-01-23T14:47:32+08:00https://flcube.com/abbott-labs-posts-q4-growth-projects-strong-2025-outlook/2025-01-23T14:31:27+08:00https://flcube.com/shenzhen-targetrx-raises-50m-in-series-c-financing-for-global-clinical-trials/2025-01-23T14:23:15+08:00https://flcube.com/haiscos-hsk44459-approved-for-clinical-trials-in-behcets-disease/2025-01-23T14:14:04+08:00https://flcube.com/fosuns-plan-to-take-henlius-private-fails-after-shareholder-vote/2025-01-23T13:59:45+08:00https://flcube.com/belief-biomeds-bbm-d101-receives-fda-approval-for-dmd-clinical-trial/2025-01-23T13:38:14+08:00https://flcube.com/roches-cobas-liat-sti-assay-panels-gain-fda-approval-and-clia-waiver/2025-01-23T13:15:28+08:00https://flcube.com/united-laboratories-ubt251-approved-for-phase-ii-trials-in-chronic-kidney-disease/2025-01-23T13:03:03+08:00https://flcube.com/sanofis-sarclisa-approved-in-eu-for-newly-diagnosed-multiple-myeloma/2025-01-23T12:55:08+08:00https://flcube.com/eli-lilly-and-merck-launch-consortium-for-innovative-drug-manufacturing/2025-01-23T12:48:49+08:00https://flcube.com/shanghai-bao-pharmaceuticals-launches-ipo-to-advance-biopharmaceutical-pipeline/2025-01-22T15:25:17+08:00https://flcube.com/degron-therapeutics-secures-20m-series-a-for-molecular-glue-drug-development/2025-01-22T15:06:32+08:00https://flcube.com/fda-lifts-clinical-hold-on-sanofis-cialis-over-the-counter-trial/2025-01-22T14:40:42+08:00https://flcube.com/johnson-johnsons-spravato-approved-as-monotherapy-for-major-depressive-disorder/2025-01-22T14:18:46+08:00https://flcube.com/cd-biopharma-initiates-phase-i-trial-for-cd-001-in-advanced-solid-tumors/2025-01-22T14:11:38+08:00https://flcube.com/kehua-bioengineering-gains-nmpa-approval-for-gene-polymorphism-detection-kits/2025-01-22T13:48:38+08:00https://flcube.com/sichuan-biokin-re-submits-ipo-application-to-hong-kong-stock-exchange/2025-01-22T13:11:08+08:00https://flcube.com/acotecs-vericor-s2-coronary-microcatheter-approved-by-nmpa/2025-01-22T12:47:33+08:00https://flcube.com/ascentage-pharma-raises-hkd-550-million-in-secondary-offering-for-pipeline-expansion/2025-01-21T23:56:05+08:00https://flcube.com/bmss-opdivo-approved-in-china-for-neoadjuvant-therapy-in-urothelial-carcinoma/2025-01-21T23:54:00+08:00https://flcube.com/nhsa-updates-2022-national-reimbursement-drug-list-with-2967-drug-varieties/2025-01-21T23:51:25+08:00https://flcube.com/harbour-biomed-receives-fda-approval-for-hbm1007-clinical-study/2025-01-21T23:35:29+08:00https://flcube.com/joincares-biosimilar-tocilizumab-approved-for-marketing-in-china/2025-01-21T23:24:53+08:00https://flcube.com/canbridge-pharmaceuticals-initiates-phase-ii-dosing-for-can103-in-gaucher-disease/2025-01-21T23:14:27+08:00https://flcube.com/genscript-probio-closes-220m-series-c-financing-for-biologics-and-gene-therapy-expansion/2025-01-21T23:11:31+08:00https://flcube.com/roche-and-hkstp-collaborate-to-boost-life-sciences-in-greater-bay-area/2025-01-21T23:06:22+08:00https://flcube.com/burning-rock-upgrades-2022-revenue-growth-forecast-to-10-yoy/2025-01-21T23:03:36+08:00https://flcube.com/pasithea-therapeutics-partners-with-wuxi-apptec-for-api-manufacturing-of-pas-004/2025-01-21T23:00:57+08:00https://flcube.com/cspcs-octreotide-long-acting-injection-approved-for-acromegaly-clinical-study/2025-01-21T22:56:11+08:00https://flcube.com/beigenes-brukinsa-approved-by-fda-for-chronic-lymphocytic-leukemia/2025-01-21T22:41:31+08:00https://flcube.com/dartsbio-pharmaceuticals-secures-rmb-100-million-in-series-b-financing/2025-01-21T22:38:31+08:00https://flcube.com/cnbg-virogins-omicron-targeted-mrna-vaccine-approved-for-clinical-trials/2025-01-21T22:35:54+08:00https://flcube.com/cngb-virogins-vg161-on-track-for-breakthrough-designation-in-china-for-advanced-liver-cancer/2025-01-21T22:35:07+08:00https://flcube.com/hepagenes-fxr-agonist-hpg1860-shows-positive-phase-iia-data-in-nash-study/2025-01-21T22:31:41+08:00https://flcube.com/novartis-kisqali-receives-nmpa-approval-for-premenopausal-breast-cancer/2025-01-21T22:27:24+08:00https://flcube.com/fosun-pharmas-comirnaty-bivalent-vaccine-approved-in-macau-for-booster-shots/2025-01-21T22:25:02+08:00https://flcube.com/huidagene-receives-fda-ind-approval-for-ophthalmology-gene-therapy-hg004/2025-01-21T22:21:16+08:00https://flcube.com/yinghe-brain-science-raises-rmb-100-million-in-angel-financing-round/2025-01-21T22:17:39+08:00https://flcube.com/hutchmed-signs-licensing-deal-with-takeda-for-global-fruquintinib-development/2025-01-21T22:12:37+08:00https://flcube.com/tianjin-based-protein-t-raises-rmb-100-million-in-series-a-financing/2025-01-21T22:08:09+08:00https://flcube.com/ascletis-receives-ind-approval-for-asc10-in-monkeypox-treatment/2025-01-21T22:03:57+08:00https://flcube.com/legend-biotechs-carvykti-meets-primary-endpoint-in-cartitude-4-phase-iii-study/2025-01-21T22:01:52+08:00https://flcube.com/nmpa-approves-two-china-developed-covid-19-small-molecule-therapies/2025-01-21T21:59:21+08:00https://flcube.com/chinas-nhc-issues-guidelines-to-improve-pediatric-medication-management/2025-01-21T21:57:15+08:00https://flcube.com/chinas-multi-bureau-plan-aims-to-eradicate-cervical-cancer-by-2030/2025-01-21T21:54:01+08:00https://flcube.com/js-innopharms-us-subsidiary-initiates-phase-i-trial-for-aurka-inhibitor-vic-1911/2025-01-21T21:51:12+08:00https://flcube.com/akeso-receives-first-300m-installment-from-summit-for-bispecific-antibody-ivonescimab/2025-01-21T21:45:33+08:00https://flcube.com/nmpa-proposes-emergency-use-management-measures-for-medical-devices/2025-01-21T21:42:30+08:00https://flcube.com/innocares-gunagratinib-shows-promising-data-in-cholangiocarcinoma-at-asco-gi-2023/2025-01-21T21:40:45+08:00https://flcube.com/exegenesis-bio-gains-fda-approval-for-gene-therapy-exg102-031-in-wet-amd/2025-01-21T21:37:53+08:00https://flcube.com/simceres-cosela-receives-first-prescription-in-china-for-cdk4-6-inhibition/2025-01-21T21:33:24+08:00https://flcube.com/china-updates-export-controls-on-technologies-adds-gene-editing-to-list/2025-01-21T21:31:15+08:00https://flcube.com/china-unveils-measures-to-boost-foreign-investment-in-rd-centers/2025-01-21T21:29:01+08:00https://flcube.com/haiscos-prostate-cancer-drug-hsk38008-and-dpp-4-inhibitor-hsk7653-accepted-for-review/2025-01-21T21:26:56+08:00https://flcube.com/remegen-and-allist-partner-to-assess-adc-and-egfr-inhibitor-combination-in-nsclc/2025-01-21T21:24:23+08:00https://flcube.com/healzen-therapeutics-gains-nmpa-approval-for-hz-a-018-clinical-study-in-autoimmune-diseases/2025-01-21T21:21:26+08:00https://flcube.com/betta-pharmaceuticals-bpi-d0316-accepted-for-review-by-cde-for-first-line-nsclc/2025-01-21T21:15:38+08:00https://flcube.com/jiangsu-alpha-biopharmas-zorifertinib-nda-accepted-for-review-by-cde/2025-01-21T21:12:46+08:00https://flcube.com/grand-pharmas-jext-auto-injector-approved-for-import-into-greater-bay-area/2025-01-21T21:06:37+08:00https://flcube.com/abbiskos-absk021-receives-fda-breakthrough-therapy-designation-for-tgct/2025-01-21T21:04:14+08:00https://flcube.com/cde-grants-priority-review-status-to-kechows-hl-085-for-melanoma-treatment/2025-01-21T21:02:10+08:00https://flcube.com/zhifei-renews-vaccine-supply-agreement-with-merck-sharp-dohme/2025-01-21T21:00:01+08:00https://flcube.com/abbotts-q4-sales-dip-amid-covid-19-testing-decline-china-market-updates/2025-01-21T18:56:51+08:00https://flcube.com/keluns-skb264-receives-breakthrough-therapy-designation-for-lung-cancer/2025-01-21T18:53:55+08:00https://flcube.com/hengruis-camrelizumab-apatinib-combo-approved-for-liver-cancer-in-china/2025-01-21T18:51:15+08:00https://flcube.com/yiling-pharmaceuticals-g201-na-accepted-for-review-by-chinas-nmpa-for-prostate-cancer/2025-01-21T18:47:56+08:00https://flcube.com/zhaoke-ophthalmologys-cyclosporine-a-eye-gel-nears-market-approval-in-china/2025-01-21T18:45:15+08:00https://flcube.com/sciwind-biosciences-initiates-phase-iii-trial-for-ecnoglutide-in-type-2-diabetes/2025-01-21T18:41:46+08:00https://flcube.com/beijing-hsa-sets-price-for-hainan-simceres-covid-19-therapy-sim0417/2025-01-21T18:38:17+08:00https://flcube.com/qilu-pharmaceuticals-biosimilar-lucentis-accepted-for-review-by-chinas-cde/2025-01-21T18:36:02+08:00https://flcube.com/remegens-telitacicept-gains-fda-approval-for-phase-iii-study-in-myasthenia-gravis/2025-01-21T18:33:12+08:00https://flcube.com/luye-pharma-gains-cde-approval-for-goserelin-acetate-microspheres-clinical-study/2025-01-21T18:30:30+08:00https://flcube.com/enkang-pharma-secures-series-b-funding-for-drips-targeted-cancer-therapy/2025-01-21T18:27:54+08:00https://flcube.com/carsgen-and-roche-partner-on-clinical-study-for-gastric-cancer-treatment/2025-01-21T18:21:59+08:00https://flcube.com/zennova-pharmaceuticals-completes-phase-1-of-chengdu-manufacturing-and-rd-center/2025-01-21T18:19:08+08:00https://flcube.com/tigermed-completes-acquisition-of-croatia-based-cro-marti-farm/2025-01-21T18:14:53+08:00https://flcube.com/trump-signs-executive-order-to-withdraw-from-who-drawing-criticism/2025-01-21T17:41:07+08:00https://flcube.com/douyin-gains-approval-to-establish-hospital-in-beijings-zhongguancun/2025-01-21T17:37:03+08:00https://flcube.com/nmpa-approves-synaptic-medicals-cryoablation-device-and-gene-methylation-detection-kit/2025-01-21T17:31:05+08:00https://flcube.com/huadong-medicines-medibeacon-tgfr-system-receives-fda-marketing-clearance/2025-01-21T17:06:00+08:00https://flcube.com/medilinks-yl201-receives-breakthrough-therapy-designation-for-nasopharyngeal-carcinoma/2025-01-21T16:32:24+08:00https://flcube.com/jiangsu-lianhuan-completes-enrollment-for-phase-iii-study-of-lh-1801-in-type-2-diabetes/2025-01-21T16:20:57+08:00https://flcube.com/arrowheads-plozasiran-accepted-for-fda-review-in-familial-chylomicronemia-syndrome/2025-01-21T16:09:04+08:00https://flcube.com/keymed-and-innocare-announce-licensing-deal-for-cd20xcd3-bispecific-antibody-with-prolium/2025-01-21T15:57:28+08:00https://flcube.com/gsks-jemperli-approved-for-first-line-endometrial-cancer-treatment-in-eu/2025-01-21T15:41:02+08:00https://flcube.com/kelun-biotechs-tagitanlimab-receives-nmpa-clearance-for-nasopharyngeal-carcinoma/2025-01-21T15:31:56+08:00https://flcube.com/junshi-biosciences-licenses-toripalimab-to-leo-pharma-for-eu-and-uk-markets/2025-01-21T15:16:01+08:00https://flcube.com/carsgen-therapeutics-initiates-trial-for-universal-car-t-therapy-kj-c2320-in-aml/2025-01-21T15:07:20+08:00https://flcube.com/chongqing-genrixs-xeligekimab-approved-for-ankylosing-spondylitis-by-nmpa/2025-01-21T14:48:23+08:00https://flcube.com/takeda-to-establish-china-innovation-center-in-chengdu-focusing-on-digital-health/2025-01-21T14:38:50+08:00https://flcube.com/junshi-biosciences-js401-accepted-for-review-by-chinas-nmpa-for-hyperlipidemia/2025-01-20T23:17:35+08:00https://flcube.com/pfizer-reports-record-revenues-as-covid-19-sales-soar-2023-guidance-amid-market-shifts/2025-01-20T23:14:47+08:00https://flcube.com/junshi-biosciences-partners-with-huahai-for-production-of-covid-19-drug-vv116/2025-01-20T23:10:37+08:00https://flcube.com/ocumension-completes-enrollment-for-global-phase-iii-study-of-myopia-treatment-ot-101/2025-01-20T23:01:49+08:00https://flcube.com/rb-bio-raises-rmb-200-million-in-series-a-round-to-advance-gene-therapy-pipeline/2025-01-20T22:59:38+08:00https://flcube.com/hengruis-her2-targeted-adc-shr-a1811-gains-nmpa-clearance-for-clinical-trial/2025-01-20T22:53:26+08:00https://flcube.com/hengruis-lutetium-177lu-oxy-octreotide-gains-clinical-clearance-in-china/2025-01-20T22:50:37+08:00https://flcube.com/changchun-bcht-gains-nmpa-approval-for-herpes-zoster-vaccine/2025-01-20T22:48:03+08:00https://flcube.com/jemincares-avatrombopag-market-filing-accepted-for-review-by-chinas-cde/2025-01-20T22:45:28+08:00https://flcube.com/ascletis-receives-fda-approval-for-phase-iia-trial-of-asc10-in-rsv-infection/2025-01-20T22:43:07+08:00https://flcube.com/daewoong-pharmaceutical-licenses-bersiporocin-to-csp-for-greater-china-development/2025-01-20T22:38:00+08:00https://flcube.com/sirnaomics-accelerates-stp705-development-after-positive-skin-cancer-trial-results/2025-01-20T22:33:29+08:00https://flcube.com/betta-pharmaceuticals-gains-fda-approval-for-clinical-trial-of-bpi-460372/2025-01-20T22:31:15+08:00https://flcube.com/novartis-q4-results-show-growth-in-innovative-medicines-amid-sandoz-spin-off-plans/2025-01-20T22:28:52+08:00https://flcube.com/virpax-pharmaceuticals-seeks-china-licensing-partner-for-non-opioid-pain-drug-envelta/2025-01-20T22:25:44+08:00https://flcube.com/novo-nordisk-posts-strong-2022-results-glp-1-therapies-drive-growth/2025-01-20T22:21:43+08:00https://flcube.com/antengene-launches-phase-i-clinch-study-for-atg-022-in-australia/2025-01-20T22:19:08+08:00https://flcube.com/henlius-begins-phase-i-trial-for-biosimilar-hlx15-targeting-multiple-myeloma/2025-01-20T22:17:00+08:00https://flcube.com/neushen-therapeutics-partners-with-umass-chan-for-als-gene-therapy-development/2025-01-20T21:51:24+08:00https://flcube.com/f-star-therapeutics-and-sino-biopharmaceutical-seek-cfius-approval-with-extended-deadline/2025-01-20T21:48:57+08:00https://flcube.com/jiangsu-hengruis-shr8058-accepted-for-review-by-chinas-nmpa-for-dry-eye-disease/2025-01-20T21:45:41+08:00https://flcube.com/nanjing-based-frontier-biotechnologies-secures-full-approval-for-albuvirtide-in-china/2025-01-20T21:42:28+08:00https://flcube.com/chinas-nmpa-releases-64th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2025-01-20T18:44:34+08:00https://flcube.com/bristol-myers-squibbs-ozanimod-approved-in-china-for-multiple-sclerosis/2025-01-20T18:41:34+08:00https://flcube.com/roche-reports-2-yoy-growth-in-2022-ocrevus-and-hemlibra-drive-sales/2025-01-20T18:38:14+08:00https://flcube.com/merck-co-posts-22-yoy-sales-growth-keytruda-and-gardasil-drive-revenues/2025-01-20T18:34:42+08:00https://flcube.com/takeda-posts-strong-q3-results-announces-pipeline-advances-in-oncology-and-rare-diseases/2025-01-20T18:31:45+08:00https://flcube.com/genscripts-car-t-therapy-carvykti-achieves-55m-in-sales-awaits-china-approval/2025-01-20T18:27:28+08:00https://flcube.com/zhejiang-gongdong-to-acquire-trademark-plastics-for-overseas-expansion/2025-01-20T18:22:36+08:00https://flcube.com/innovent-biologics-posts-strong-q4-revenues-amid-covid-19-challenges/2025-01-20T18:11:05+08:00https://flcube.com/shanghai-weimu-medical-raises-pre-series-a-funding-for-clinical-development/2025-01-20T18:08:29+08:00https://flcube.com/microport-endovascular-plans-rmb-2-55-billion-private-placement/2025-01-20T18:03:23+08:00https://flcube.com/ocumensions-phase-i-study-for-dry-eye-treatment-ot-202-concludes/2025-01-20T18:01:02+08:00https://flcube.com/eli-lilly-reports-q4-financials-with-covid-19-impact-and-market-performers/2025-01-20T17:58:43+08:00https://flcube.com/nhsa-outlines-2025-work-plan-and-2024-medical-insurance-status/2025-01-20T17:48:09+08:00https://flcube.com/fda-approves-astrazenecas-calquence-for-mantle-cell-lymphoma/2025-01-20T17:37:34+08:00https://flcube.com/namsa-to-acquire-wuxi-apptecs-us-medical-device-testing-business/2025-01-20T17:29:24+08:00https://flcube.com/mhra-approves-gileads-livdelzi-for-primary-biliary-cholangitis/2025-01-20T17:14:02+08:00https://flcube.com/us-bis-imposes-export-controls-on-biotech-lab-instruments/2025-01-20T16:32:05+08:00https://flcube.com/junshi-biosciences-forecasts-29-71-revenue-growth-for-2024/2025-01-20T16:21:49+08:00https://flcube.com/fda-clears-amgens-lumakras-and-vectibix-combo-for-kras-g12c-mutated-mcrc/2025-01-20T16:13:39+08:00https://flcube.com/luye-pharma-launches-erzofri-in-us-market/2025-01-20T16:04:50+08:00https://flcube.com/novo-nordisks-semaglutide-7-2-mg-shows-superior-weight-loss-in-phase-iii-study/2025-01-20T15:55:44+08:00https://flcube.com/xinzeyuan-medical-raises-series-b-funding-for-surgical-supply-chain/2025-01-20T15:47:27+08:00https://flcube.com/xinzeyuan-medical-technology-secures-over-rmb-100-million-in-series-b-financing/2025-01-20T15:41:12+08:00https://flcube.com/zai-labs-karxt-nda-accepted-by-nmpa-for-schizophrenia-treatment/2025-01-20T15:35:02+08:00https://flcube.com/frontier-biotechnologies-gains-nmpa-approval-for-albuvirtide-phase-ii-study/2025-01-20T15:26:22+08:00https://flcube.com/wanbangdes-huperzine-a-receives-fda-clearance-for-hie-study/2025-01-20T15:19:53+08:00https://flcube.com/fda-approves-datroway-for-hr-her2-breast-cancer-treatment/2025-01-20T15:04:40+08:00https://flcube.com/allist-pharmaceuticals-gains-nmpa-approval-for-furmonertinib-clinical-study/2025-01-20T14:52:24+08:00https://flcube.com/junshi-biosciences-toripalimab-gains-tga-approval-for-nasopharyngeal-carcinoma/2025-01-20T14:38:27+08:00https://flcube.com/gilead-sciences-reports-q4-and-full-year-2022-financial-results/2025-01-20T13:58:26+08:00https://flcube.com/sanofi-reports-strong-q4-and-full-year-2022-financials-with-7-growth/2025-01-20T13:55:19+08:00https://flcube.com/sanner-group-prepares-to-open-second-manufacturing-facility-in-china/2025-01-20T13:52:32+08:00https://flcube.com/insilico-medicine-opens-ai-biotech-research-center-in-abu-dhabi/2025-01-20T13:46:19+08:00https://flcube.com/vertexs-modas-system-gains-nmpa-approval-for-movement-disorder-assessment/2025-01-20T13:44:09+08:00https://flcube.com/beigene-launches-mental-health-program-for-cancer-patients/2025-01-20T13:41:28+08:00https://flcube.com/anheart-therapeutics-partners-with-guardant-health-for-taletrectinib-diagnostics/2025-01-20T13:38:04+08:00https://flcube.com/grand-pharmas-tlx101-accepted-for-nmpa-review-for-glioblastoma-treatment/2025-01-20T13:34:38+08:00https://flcube.com/forlong-biotechnology-secures-series-a-funding-for-protein-drug-development/2025-01-20T13:31:40+08:00https://flcube.com/zhimeng-biopharma-signs-global-licensing-deal-with-gsk-for-tlr8-agonist-cb06/2025-01-20T13:28:03+08:00https://flcube.com/haisco-pharmaceutical-announces-public-offering-for-clinical-studies/2025-01-20T13:22:50+08:00https://flcube.com/bdgenes-crispr-cas9-therapy-bd111-accepted-for-cde-review/2025-01-20T13:20:15+08:00https://flcube.com/juntop-biosciences-covid-19-therapy-mindewei-priced-at-rmb-795-per-course/2025-01-20T13:15:51+08:00https://flcube.com/ji-xing-pharmaceuticals-acquires-global-rights-to-phasebios-pb6440/2025-01-20T12:44:31+08:00https://flcube.com/mabwells-novel-adc-9mw2921-accepted-for-nmpa-review/2025-01-20T12:39:51+08:00https://flcube.com/amgen-reports-q4-and-full-year-2022-financials-with-global-sales-growth/2025-01-20T12:37:11+08:00https://flcube.com/gsk-reports-strong-q4-and-full-year-2022-financials-amid-strategic-shift/2025-01-20T12:09:48+08:00https://flcube.com/siemens-healthineers-reports-q1-revenue-drop-amid-covid-19-impact/2025-01-20T12:05:56+08:00https://flcube.com/astellas-pharma-reports-strong-q3-results-with-17-3-revenue-growth/2025-01-20T12:02:50+08:00https://flcube.com/fujian-cosunters-hbv-therapy-gst-hg141-begins-phase-ii-trial/2025-01-20T11:59:25+08:00https://flcube.com/harbour-biomeds-anti-ccr8-monoclonal-antibody-hbm1022-receives-fda-ind-approval/2025-01-20T11:56:48+08:00https://flcube.com/eli-lillys-tirzepatide-achieves-primary-endpoints-in-chinese-obesity-study/2025-01-20T11:54:26+08:00https://flcube.com/lifetech-partners-with-jenscare-for-structural-heart-disease-devices/2025-01-20T11:48:08+08:00https://flcube.com/gracells-car-t-therapy-gc012f-receives-fda-ind-approval/2025-01-20T11:45:06+08:00https://flcube.com/junshi-biosciences-covid-19-therapy-faces-supply-issues-partners-with-sihuan-pharma/2025-01-20T11:38:08+08:00https://flcube.com/macrolux-raises-over-rmb-100-million-in-series-b-financing/2025-01-20T11:33:31+08:00https://flcube.com/macrolux-secures-series-a-funding-for-endoscopy-solutions/2025-01-20T11:26:55+08:00https://flcube.com/hua-medicine-receives-milestone-payment-from-bayer-for-dorzagliatin/2025-01-20T11:20:41+08:00https://flcube.com/sciclone-pharmaceuticals-files-for-hong-kong-market-approval-of-danyelza/2025-01-20T11:17:17+08:00https://flcube.com/asia-regenerative-medicine-raises-pre-series-a-funding-for-bioartificial-organs/2025-01-20T11:09:35+08:00https://flcube.com/beijing-smart-beam-raises-series-a-funding-for-ct-x-ray-tube-development/2025-01-20T11:03:44+08:00https://flcube.com/asieris-partners-with-revir-therapeutics-for-urogenital-cancer-research/2025-01-20T10:57:20+08:00https://flcube.com/qilu-pharmaceuticals-qls12004-gains-tacit-clinical-trial-approval/2025-01-19T23:10:23+08:00https://flcube.com/sino-biopharmaceutical-terminates-ipo-pre-listing-process-for-star-board/2025-01-19T23:05:26+08:00https://flcube.com/shanghai-pinnacles-partners-with-sysmex-for-biochemical-immune-diagnosis-solutions/2025-01-19T23:00:34+08:00https://flcube.com/genscript-probio-partners-with-bio-immunitas-for-hrpp-platform/2025-01-19T22:53:25+08:00https://flcube.com/hemay-pharma-completes-series-d-financing-for-autoimmune-and-oncology-drugs/2025-01-19T22:45:24+08:00https://flcube.com/neurodawn-completes-series-a-financing-for-cns-drug-development/2025-01-19T22:39:20+08:00https://flcube.com/grand-pharma-completes-patient-enrollment-for-stc3141-sepsis-study/2025-01-19T22:33:48+08:00https://flcube.com/eyebright-medical-gains-six-swiss-exchange-approval-for-gdr-offering/2025-01-19T22:09:31+08:00https://flcube.com/teddy-clinical-research-lab-partners-with-cerba-research-for-global-services/2025-01-19T22:06:48+08:00https://flcube.com/joincares-generic-seretide-accepted-for-nmpa-review/2025-01-19T21:57:22+08:00https://flcube.com/nona-biosciences-partners-with-mythic-therapeutics-for-next-gen-adcs/2025-01-19T21:54:01+08:00https://flcube.com/everest-medicines-nefecon-included-in-south-koreas-gift-program/2025-01-19T21:51:38+08:00https://flcube.com/hinovas-hp530s-accepted-for-nmpa-review-as-fak-inhibitor-for-solid-tumors/2025-01-19T21:42:08+08:00https://flcube.com/astrazeneca-reports-q4-and-full-year-2022-results-with-strong-revenue-growth/2025-01-19T21:31:02+08:00https://flcube.com/roche-returns-global-rights-to-blueprints-ret-inhibitor-gavreto/2025-01-19T17:27:27+08:00https://flcube.com/hengrui-pharmaceuticals-licenses-shr2554-to-treeline-biosciences/2025-01-19T17:25:55+08:00https://flcube.com/cspc-pharmaceutical-licenses-adc-sys6002-to-corbus-pharmaceuticals/2025-01-19T17:21:43+08:00https://flcube.com/mingche-biotechnology-secures-pre-series-a-funding-for-medical-device-innovation/2025-01-19T17:17:51+08:00https://flcube.com/dessight-biomedical-secures-pre-series-a-funding-for-ophthalmic-innovations/2025-01-19T17:09:29+08:00https://flcube.com/luye-pharma-initiates-phase-i-study-for-ba1106-a-cd25-monoclonal-antibody/2025-01-19T17:03:37+08:00https://flcube.com/zelgens-zggs15-accepted-for-nmpa-review-as-first-global-bsab-filing/2025-01-19T17:01:12+08:00https://flcube.com/kintors-gt20029-shows-positive-results-in-us-phase-i-study-for-aga-and-acne/2025-01-19T16:59:00+08:00https://flcube.com/hengruis-her2-targeted-adc-shr-a1811-aims-for-breakthrough-designation/2025-01-19T16:56:43+08:00https://flcube.com/eoc-pharmas-cdk7-inhibitor-eoc237-accepted-for-cde-review/2025-01-19T16:53:50+08:00https://flcube.com/harbour-biomed-licenses-hbm7008-to-cullinan-oncology-for-us-development/2025-01-19T16:44:27+08:00https://flcube.com/kangtai-biological-begins-phase-i-trial-for-tetravalent-influenza-vaccine/2025-01-19T16:41:32+08:00https://flcube.com/jiangsu-recbio-completes-first-tranche-enrollment-for-shingles-vaccine-rec610/2025-01-19T16:39:20+08:00https://flcube.com/beijing-wantai-initiates-phase-i-study-for-20-valent-pneumonia-vaccine/2025-01-19T16:37:02+08:00https://flcube.com/gracell-biotechnologies-gains-ind-approval-for-gc012f-in-china/2025-01-19T16:34:40+08:00https://flcube.com/chinas-ministries-release-plan-for-urban-medical-group-pilots/2025-01-19T16:32:31+08:00https://flcube.com/thinmedtech-partners-with-west-china-hospital-for-ckd-digital-therapy/2025-01-19T16:29:33+08:00https://flcube.com/remegen-gains-nmpa-approval-for-rc48-and-pyrotinib-clinical-study/2025-01-19T16:25:31+08:00https://flcube.com/clover-biopharmaceuticals-administers-first-dose-of-covid-19-vaccine-scb-2019-in-zhejiang/2025-01-19T16:21:59+08:00https://flcube.com/brii-biosciences-publishes-positive-phase-ii-results-for-hbv-treatment/2025-01-19T16:16:58+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-shr-a1921-clinical-study/2025-01-19T16:13:18+08:00https://flcube.com/grand-pharma-completes-first-atrial-fibrillation-treatment-with-heartlight-x3/2025-01-19T16:10:07+08:00https://flcube.com/zelgens-zg2001-and-zg0895-clinical-trials-approved-by-nmpa/2025-01-19T16:07:35+08:00https://flcube.com/innovent-biologics-initiates-phase-ii-study-for-ibi311-in-thyroid-associated-ophthalmopathy/2025-01-19T16:04:50+08:00https://flcube.com/hygea-medtech-secures-series-d-funding-for-oncology-device-expansion/2025-01-19T16:02:22+08:00https://flcube.com/hygea-medicals-subsidiary-gets-green-light-for-innovative-intrahepatic-puncture-instrument-in-china/2025-01-19T15:59:58+08:00https://flcube.com/cti-acquires-vectoring-pharmatech-to-expand-pharmacy-cmc-research/2025-01-19T15:56:44+08:00https://flcube.com/shenzhen-united-family-hospital-partners-with-gba-medical-delegation/2025-01-19T15:48:39+08:00https://flcube.com/vincentage-raises-rmb-100-million-for-innovative-drug-development/2025-01-19T15:46:31+08:00https://flcube.com/sequanta-and-grandomics-collaborate-on-ultra-high-throughput-sequencing-lab/2025-01-19T15:40:39+08:00https://flcube.com/luzhu-biotech-files-for-ipo-in-hong-kong-sponsored-by-cicc/2025-01-19T15:35:52+08:00https://flcube.com/chinas-nrdl-update-new-drugs-available-for-online-procurement/2025-01-19T15:33:50+08:00https://flcube.com/mindray-launches-first-wireless-handheld-ultrasound-system-te-air/2025-01-19T15:30:57+08:00https://flcube.com/inscinstech-secures-c-series-financing-for-biopharma-expansion/2025-01-19T15:23:38+08:00https://flcube.com/winhealth-pharma-taps-baidus-ernie-bot-for-rare-disease-services/2025-01-19T14:52:25+08:00https://flcube.com/eppendorf-to-start-construction-on-new-shanghai-production-site/2025-01-19T14:49:25+08:00https://flcube.com/innocare-regains-rights-to-orelabrutinib-as-biogen-terminates-licensing-agreement/2025-01-19T14:43:53+08:00https://flcube.com/aim-vaccine-gains-approvals-for-covid-19-mrna-vaccine-trials-in-pakistan/2025-01-19T14:40:49+08:00https://flcube.com/innovent-biologics-initiates-phase-iii-clear-study-for-picankibart-in-psoriasis/2025-01-19T14:38:10+08:00https://flcube.com/frontera-therapeutics-initiates-ft-002-clinical-study-for-x-linked-retinitis-pigmentosa/2025-01-19T14:35:55+08:00https://flcube.com/kanghongs-kh617-receives-orphan-drug-designation-for-glioblastoma/2025-01-19T14:33:28+08:00https://flcube.com/luye-pharmas-ba2101-begins-phase-i-clinical-trial-for-allergic-diseases/2025-01-19T14:28:28+08:00https://flcube.com/cde-accepts-clinical-trial-filing-for-ranoks-first-in-class-brd4-degradation-drug-rnk05047/2025-01-19T14:26:05+08:00https://flcube.com/junshi-biosciences-and-coherus-report-positive-jupiter-02-trial-results-for-npc-treatment/2025-01-19T14:21:20+08:00https://flcube.com/eyenovia-partners-with-formosa-pharmaceuticals-for-ophthalmic-therapeutics/2025-01-19T14:17:55+08:00https://flcube.com/cspcs-nbl-020-gets-nmpa-approval-for-clinical-study-in-advanced-solid-tumors/2025-01-19T14:12:35+08:00https://flcube.com/kelun-pharmas-generic-jardiance-gains-new-indication-in-china/2025-01-19T14:09:49+08:00https://flcube.com/hangzhou-singclean-stripped-of-vbp-status-for-artificial-lenses/2025-01-19T14:06:39+08:00https://flcube.com/topgen-biopharm-partners-with-fudan-university-for-breast-cancer-gene-detection/2025-01-19T13:58:35+08:00https://flcube.com/by-health-partners-with-meituans-drug-purchase-app-for-new-retail-expansion/2025-01-19T13:37:06+08:00https://flcube.com/kangtai-biological-partners-with-pakistani-firm-for-pneumonia-vaccine-expansion/2025-01-19T13:30:35+08:00https://flcube.com/shanghai-based-remd-raises-series-a-funding-for-electroporation-device-expansion/2025-01-19T13:27:52+08:00https://flcube.com/organon-reports-q4-and-full-year-2022-financials-with-revenue-declines/2025-01-19T13:16:08+08:00https://flcube.com/nmpa-approves-keverprazan-for-duodenal-ulcers-and-reflux-esophagitis/2025-01-19T13:15:40+08:00https://flcube.com/chinas-2022-western-medicine-trade-analysis-growth-and-challenges/2025-01-19T00:26:34+08:00https://flcube.com/wuhan-binhuis-oncolytic-virus-therapy-awarded-breakthrough-designation-by-cde/2025-01-19T00:21:25+08:00https://flcube.com/cde-awards-priority-review-to-eisais-lecanemab-for-early-alzheimers-disease/2025-01-19T00:17:07+08:00https://flcube.com/chunlizhengda-to-acquire-majority-stake-in-surgimaster-for-medical-power-tools/2025-01-19T00:13:47+08:00https://flcube.com/duoning-biotech-secures-global-rights-to-junzhens-cell-counter-products/2025-01-19T00:08:08+08:00https://flcube.com/sansure-biotech-partners-with-hunan-normal-university-for-research-and-talent-development/2025-01-19T00:00:27+08:00https://flcube.com/biosyngens-brg01-gets-fda-nod-for-npc-clinical-study/2025-01-18T23:57:49+08:00https://flcube.com/cde-issues-guidelines-for-real-world-drug-research-and-evidence-framework/2025-01-18T23:54:14+08:00https://flcube.com/brl-medicine-achieves-first-cure-of-thalassemia-major-with-brl-101/2025-01-18T23:49:54+08:00https://flcube.com/immuno-cure-biotech-launches-phase-i-hiv-aids-vaccine-study/2025-01-18T23:46:02+08:00https://flcube.com/clover-biopharmaceuticals-secures-exclusive-deal-for-adimflu-s-distribution-in-china/2025-01-18T23:40:50+08:00https://flcube.com/hainan-honz-partners-with-gpi-for-pediatric-and-maternity-medicine-expansion/2025-01-18T23:37:54+08:00https://flcube.com/moleculemind-raises-over-rmb-100-million-for-ai-protein-design-platform/2025-01-18T23:33:43+08:00https://flcube.com/zhejiang-suspends-generic-nesina-trading-due-to-ip-disputes/2025-01-18T23:19:21+08:00https://flcube.com/junshi-biosciences-pd-1-inhibitor-tuoyi-shows-promise-in-phase-iii-tnbc-study/2025-01-18T23:03:16+08:00https://flcube.com/abbott-partners-with-sinopharm-for-expanded-medical-solutions-in-china/2025-01-18T23:00:28+08:00https://flcube.com/luoxins-tegoprazan-gains-nmpa-review-for-duodenal-ulcer-treatment/2025-01-18T22:42:29+08:00https://flcube.com/shanghai-pharmaceuticals-x842-accepted-for-nmpa-review-for-reflux-esophagitis/2025-01-18T22:39:49+08:00https://flcube.com/we-linking-raises-tens-of-millions-in-angel-round-for-brain-computer-interface/2025-01-18T22:36:09+08:00https://flcube.com/we-linking-secures-angel-financing-for-implantable-brain-computer-interface-development/2025-01-18T22:21:31+08:00https://flcube.com/hybio-pharma-and-cr-medicine-collaborate-on-market-expansion/2025-01-18T22:16:03+08:00https://flcube.com/junshi-biosciences-seeks-uk-mhra-approval-for-pd-1-inhibitor-tuoyi/2025-01-18T22:01:37+08:00https://flcube.com/chinagene-tech-initiates-zvs101e-gene-therapy-trial-for-biettis-crystalline-dystrophy/2025-01-18T21:58:31+08:00https://flcube.com/ascletis-pharmas-asc10-shows-promising-phase-i-results-at-croi-2023/2025-01-18T21:53:04+08:00https://flcube.com/beijing-huashen-shengdian-secures-angel-funding-for-pelvic-surgery-monitor-rd/2025-01-18T21:49:47+08:00https://flcube.com/zhaokes-generic-bimatoprost-timolol-maleate-eye-drops-approved-in-china/2025-01-18T21:40:34+08:00https://flcube.com/sino-biopharmaceuticals-limaprost-approved-by-nmpa-for-lumbar-spinal-stenosis-treatment/2025-01-18T21:36:29+08:00https://flcube.com/biocytogens-nano-100-project-aims-to-develop-over-100-fully-human-nanobody-drugs/2025-01-18T21:34:08+08:00https://flcube.com/suzhou-porton-biologics-partners-with-yinjia-biosciences-for-cgt-development/2025-01-18T21:29:35+08:00https://flcube.com/legend-biotech-no-longer-faces-delisting-from-nasdaq/2025-01-18T16:27:10+08:00https://flcube.com/abbiskos-absk121-greenlit-for-phase-i-clinical-study-by-nmpa/2025-01-18T16:24:14+08:00https://flcube.com/microport-cardioflows-tavi-product-approved-in-thailand/2025-01-18T16:21:15+08:00https://flcube.com/transthera-biosciences-completes-series-d-financing-round/2025-01-18T16:17:44+08:00https://flcube.com/shanghai-pharmaceuticals-wst01-receives-fda-clinical-clearance/2025-01-18T16:13:58+08:00https://flcube.com/huahai-pharma-raises-funds-for-digital-manufacturing-and-api-platform/2025-01-18T16:11:33+08:00https://flcube.com/zai-lab-partners-with-sir-run-run-shaw-hospital-for-medical-innovation-center/2025-01-18T16:08:28+08:00https://flcube.com/huadong-medicines-patent-challenge-against-novo-nordisks-ozempic-heads-to-hearing/2025-01-18T16:05:04+08:00https://flcube.com/neurophths-nr082-gene-therapy-completes-phase-iii-enrollment/2025-01-18T15:58:41+08:00https://flcube.com/sinovacs-hepatitis-a-vaccine-healive-approved-in-egypt/2025-01-18T15:56:16+08:00https://flcube.com/asieris-uro-g-bladder-endoscope-catheter-awaits-nmpa-approval/2025-01-18T15:52:51+08:00https://flcube.com/merck-kgaa-partners-with-beijing-for-drug-imports-via-beijing-ports/2025-01-18T15:47:15+08:00https://flcube.com/insilico-medicines-covid-19-drug-ism3312-enters-clinical-trials/2025-01-18T15:44:25+08:00https://flcube.com/meihua-international-partners-with-hainan-for-medical-tech-park-and-rd-center/2025-01-18T15:41:52+08:00https://flcube.com/kactus-biosystems-and-levinthal-biotech-deepen-strategic-partnership/2025-01-18T15:38:07+08:00https://flcube.com/cde-releases-67th-batch-of-chemical-generic-reference-preparations/2025-01-18T15:29:40+08:00https://flcube.com/cde-releases-guidelines-for-chemically-synthesized-peptide-research/2025-01-18T15:27:12+08:00https://flcube.com/guangdong-adds-hospitals-to-gba-drug-and-device-green-channel/2025-01-18T15:24:40+08:00https://flcube.com/zai-lab-to-present-zejula-os-study-results-at-esmo-congress/2025-01-18T15:21:44+08:00https://flcube.com/huadong-medicine-expands-global-partnership-with-scohia-pharma-for-sco-094/2025-01-18T15:17:25+08:00https://flcube.com/zai-labs-sul-dur-nda-accepted-for-review-by-nmpa/2025-01-18T15:10:12+08:00https://flcube.com/changchun-bcht-biotechnology-and-imb-cams-enter-five-year-research-pact/2025-01-18T15:06:40+08:00https://flcube.com/raytone-bio-completes-angel-round-to-advance-isus-platform/2025-01-18T14:41:10+08:00https://flcube.com/aosaikangs-limertinib-approved-for-egfr-t790m-mutated-nsclc/2025-01-18T13:10:30+08:00https://flcube.com/johnson-johnson-submits-nda-for-tar-200-in-high-risk-bladder-cancer/2025-01-17T23:28:34+08:00https://flcube.com/eli-lillys-omvoh-approved-by-fda-for-crohns-disease-treatment/2025-01-17T23:05:07+08:00https://flcube.com/iview-therapeutics-secures-series-a-funding-for-ophthalmology-pipeline/2025-01-17T22:55:45+08:00https://flcube.com/boehringer-ingelheims-iclepertin-fails-to-meet-phase-iii-study-endpoints/2025-01-17T22:37:32+08:00https://flcube.com/telix-pharmaceuticals-tlx591-cdx-approved-in-europe-via-decentralized-procedure/2025-01-17T21:43:29+08:00https://flcube.com/nmpa-implements-regulatory-reforms-for-drug-and-medical-device-industries/2025-01-17T21:32:49+08:00https://flcube.com/daiichi-sankyo-acquires-gatipotuzumab-ip-rights-for-132-5m/2025-01-17T21:18:20+08:00https://flcube.com/nhsa-pushes-for-real-time-settlement-reform-in-basic-medical-insurance/2025-01-17T18:49:40+08:00https://flcube.com/a16z-bio-health-launches-biotech-ecosystem-venture-fund/2025-01-17T18:41:30+08:00https://flcube.com/impact-therapeutics-senaparib-cleared-by-nmpa-for-ovarian-cancer-therapy/2025-01-17T18:23:57+08:00https://flcube.com/siemens-lays-foundation-for-new-medical-equipment-base-in-shenzhen/2025-01-17T18:11:05+08:00https://flcube.com/fujian-haixi-pharmaceuticals-files-for-hong-kong-ipo/2025-01-17T17:55:04+08:00https://flcube.com/sciclone-and-menarini-submit-nda-for-vaborem-in-china/2025-01-17T17:40:37+08:00https://flcube.com/servier-and-google-cloud-extend-partnership-to-advance-ai-in-drug-development/2025-01-17T17:23:45+08:00https://flcube.com/cathay-biotech-plans-901m-private-placement-to-boost-bio-based-materials/2025-01-17T16:38:11+08:00https://flcube.com/simcere-licenses-fermions-ai-enabled-painkiller-fz002-037/2025-01-17T16:24:50+08:00https://flcube.com/boston-scientifics-farapulse-and-watchman-flx-studies-show-positive-results/2025-01-17T15:48:12+08:00https://flcube.com/asieris-usp1-inhibitor-apl-2302-cleared-for-clinical-trials/2025-01-17T15:36:21+08:00https://flcube.com/zhejiang-huahais-hb0056-approved-for-us-phase-i-asthma-trial/2025-01-17T14:34:31+08:00https://flcube.com/hengruis-her2-targeted-adc-and-antibody-drug-combo-approved-for-trials/2025-01-17T12:31:00+08:00https://flcube.com/cspcs-sys-6043-receives-fda-approval-for-clinical-trials/2025-01-17T11:55:36+08:00https://flcube.com/innovents-limertinib-wins-nmpa-approval-for-nsclc-treatment/2025-01-17T11:15:03+08:00https://flcube.com/conjustar-completes-15-million-pre-a-financing-round/2025-01-17T00:24:54+08:00https://flcube.com/conjustar-peptide-drug-conjugate-angel-financing/2025-01-17T00:13:39+08:00https://flcube.com/zhongchao-and-johnson-johnson-renew-partnership-for-digital-health-services/2025-01-17T00:06:59+08:00https://flcube.com/cstones-sugemalimab-accepted-for-eu-marketing-authorization-by-ema/2025-01-16T23:58:12+08:00https://flcube.com/danatlas-raises-pre-series-a-funding-for-synthetic-lethality-drug-development/2025-01-16T23:55:41+08:00https://flcube.com/cde-signals-priority-review-for-sanofis-dupixent-and-other-drugs/2025-01-16T23:23:21+08:00https://flcube.com/innocare-and-keymed-announce-first-dosing-of-icp-b05-clinical-study/2025-01-16T23:13:59+08:00https://flcube.com/luye-pharmas-paliperidone-palmitate-approved-for-european-clinical-trials/2025-01-16T23:10:12+08:00https://flcube.com/bio-thera-solutions-partners-with-china-resource-medicine-for-integrated-collaboration/2025-01-16T23:05:54+08:00https://flcube.com/nmpa-approves-stmeds-ecmo-product-for-market/2025-01-16T23:02:39+08:00https://flcube.com/johnson-johnson-medtechs-qdot-catheter-approved-in-china-for-atrial-fibrillation/2025-01-16T22:54:02+08:00https://flcube.com/sanofis-vaxigriptetra-approved-for-pediatric-influenza-vaccination-in-china/2025-01-16T22:49:37+08:00https://flcube.com/enhertu-approved-in-china-for-her2-positive-breast-cancer/2025-01-16T22:32:17+08:00https://flcube.com/novartis-revolade-approved-for-severe-aplastic-anemia-in-china/2025-01-16T22:28:10+08:00https://flcube.com/kelun-biotech-files-for-hong-kong-ipo-with-goldman-sachs-and-citic-securities/2025-01-16T22:09:49+08:00https://flcube.com/accutar-biotech-begins-phase-i-trial-for-ac0176-in-china/2025-01-16T22:05:55+08:00https://flcube.com/beigenes-tislelizumab-approved-for-gastric-tumors-in-china/2025-01-16T22:00:40+08:00https://flcube.com/sciclone-partners-with-cowell-health-to-enhance-cancer-treatment-accessibility/2025-01-16T21:56:00+08:00https://flcube.com/baheal-pharmaceutical-partners-with-novartis-for-votrient-commercialization/2025-01-16T21:48:36+08:00https://flcube.com/grand-pharmas-first-in-class-rdc-itm-11-accepted-for-ind-review/2025-01-16T21:45:09+08:00https://flcube.com/jacobio-pharma-partners-with-westchina-frontier-for-preclinical-safety-studies/2025-01-16T21:41:53+08:00https://flcube.com/mabwells-il-11-monoclonal-antibody-9mw3811-approved-for-australian-clinical-trial/2025-01-16T21:25:47+08:00https://flcube.com/astrazenecas-calquence-administered-in-hainan-ahead-of-official-approval/2025-01-16T21:20:34+08:00https://flcube.com/carsgen-therapeutics-partners-with-jinshan-hospital-for-car-t-research/2025-01-16T21:16:38+08:00https://flcube.com/sansure-biotech-partners-with-shanghai-tenth-peoples-hospital-for-genomics-center/2025-01-16T21:11:35+08:00https://flcube.com/ge-healthcare-and-sutter-health-form-1b-care-alliance/2025-01-16T18:42:06+08:00https://flcube.com/hutchmeds-orpathys-approved-for-expanded-nsclc-indication-in-china/2025-01-16T18:29:42+08:00https://flcube.com/innovents-ibi343-receives-breakthrough-therapy-designation-for-pancreatic-cancer/2025-01-16T18:18:21+08:00https://flcube.com/wepon-medicals-wp107-receives-fda-approval-for-gmg-clinical-trial/2025-01-16T18:06:50+08:00https://flcube.com/fosun-pharma-initiates-phase-ii-study-for-glomerular-disease-treatment/2025-01-16T17:47:24+08:00https://flcube.com/hengruis-shr-9839-receives-nmpa-clearance-for-advanced-tumors/2025-01-16T17:35:23+08:00https://flcube.com/topchoice-medical-to-acquire-19-stake-in-heren-health-for-72-2m/2025-01-16T17:15:00+08:00https://flcube.com/chipscreens-epidaza-patent-faces-invalidation-request-review/2025-01-16T17:13:53+08:00https://flcube.com/eluminex-biosciences-closes-40m-series-b-for-ophthalmic-innovations/2025-01-16T16:28:38+08:00https://flcube.com/rinuagene-raises-14-4m-in-pre-series-a-for-mrna-drug-development/2025-01-16T16:21:00+08:00https://flcube.com/junshi-biosciences-reports-2022-preliminary-earnings-with-revenue-decline/2025-01-16T16:17:23+08:00https://flcube.com/chipscreen-biosciences-licenses-first-in-class-bsab-yh008-from-eucure/2025-01-16T16:12:40+08:00https://flcube.com/novartis-lnp023-and-janssens-tremfya-on-track-for-breakthrough-designations/2025-01-16T16:06:53+08:00https://flcube.com/suzhou-porton-biologics-partners-with-corrgene-for-cell-and-gene-therapy/2025-01-16T16:01:19+08:00https://flcube.com/sanofis-sarclisa-approved-for-import-in-shenzhen-via-greater-bay-area-scheme/2025-01-16T15:51:42+08:00https://flcube.com/innovent-biologics-begins-phase-i-trial-for-ibi333-in-neovascular-amd/2025-01-16T14:17:51+08:00https://flcube.com/hybios-covid-19-nasal-spray-hy3000-gets-fda-clinical-trial-approval/2025-01-16T14:06:19+08:00https://flcube.com/junshi-biosciences-pcsk9-inhibitor-ongericimab-meets-phase-iii-endpoints/2025-01-16T14:02:19+08:00https://flcube.com/oricell-therapeutics-closes-45m-series-b1-round-for-cellular-immunotherapy/2025-01-16T13:56:25+08:00https://flcube.com/cstones-pd-l1-inhibitor-sugemalimab-accepted-for-review-in-gastric-cancer/2025-01-16T13:50:43+08:00https://flcube.com/immorna-therapeutics-enrolls-first-patient-in-phase-i-study-of-jcxh-211-for-malignant-tumors/2025-01-16T13:42:50+08:00https://flcube.com/immorna-therapeutics-earns-fda-approval-for-phase-i-ii-clinical-trial-of-self-replicating-rna-cancer-therapy/2025-01-16T13:36:55+08:00https://flcube.com/beigene-reports-outstanding-q4-and-full-year-2022-financial-results/2025-01-15T22:48:36+08:00https://flcube.com/viatris-reports-q4-2022-results-highlights-china-growth/2025-01-15T22:43:33+08:00https://flcube.com/china-performs-first-ab-bnct-procedures-outside-japan/2025-01-15T22:39:50+08:00https://flcube.com/hutchmed-reports-2022-financial-results-with-revenue-growth/2025-01-15T22:31:26+08:00https://flcube.com/3sbios-nalfurafine-tablets-accepted-for-review-by-nmpa-for-chronic-liver-disease/2025-01-15T22:26:50+08:00https://flcube.com/3sbio-terminates-distribution-agreement-with-astrazeneca-for-byetta/2025-01-15T22:22:52+08:00https://flcube.com/jw-therapeutics-initiates-clinical-study-for-jwatm214-in-advanced-hepatocellular-carcinoma/2025-01-15T22:18:54+08:00https://flcube.com/fibrogen-reports-q4-2022-financial-results-with-revenue-growth/2025-01-15T22:14:48+08:00https://flcube.com/china-issues-new-ethical-review-measures-for-life-sciences-and-medical-research/2025-01-15T22:10:49+08:00https://flcube.com/bayer-reports-2022-sales-growth-highlights-new-drug-performances/2025-01-15T22:03:19+08:00https://flcube.com/chinas-nrdl-update-and-expansion-of-dual-channel-drug-access/2025-01-15T21:59:12+08:00https://flcube.com/chinas-state-council-unveils-plan-for-tcm-revitalization-and-development/2025-01-15T21:54:03+08:00https://flcube.com/kinnjiu-biopharma-initiates-global-phase-i-study-for-exarafenib/2025-01-15T21:39:20+08:00https://flcube.com/zai-lab-reports-2022-financial-results-with-revenue-growth/2025-01-15T21:32:14+08:00https://flcube.com/pengyang-yiliao-raises-series-b-funds-for-cardiovascular-product-development/2025-01-15T21:27:54+08:00https://flcube.com/zhejiang-medicines-arx788-shows-positive-results-in-breast-cancer-study/2025-01-15T21:20:21+08:00https://flcube.com/glowe-raises-series-a-funding-to-expand-aigc-in-mental-health/2025-01-15T21:16:03+08:00https://flcube.com/geneus-tech-secures-funding-for-gseq500-gene-sequencer-production/2025-01-15T21:08:40+08:00https://flcube.com/alphamab-oncology-partners-with-stemirna-for-bsab-and-mrna-vaccine-development/2025-01-15T21:02:06+08:00https://flcube.com/cansino-biologics-inhalable-covid-19-vaccine-gets-eua-in-indonesia/2025-01-15T20:57:59+08:00https://flcube.com/beigene-ltd-acquires-global-rights-to-cspcs-mat2a-inhibitor-syh2039/2025-01-15T17:56:54+08:00https://flcube.com/biogen-proposes-to-acquire-sage-therapeutics-for-469m/2025-01-15T13:37:24+08:00https://flcube.com/medtronic-secures-exclusive-distribution-rights-for-contegos-neuroguard-and-excipio/2025-01-15T13:16:38+08:00https://flcube.com/eli-lilly-to-acquire-scorpion-therapeutics-stx-478-for-2-5b/2025-01-15T12:08:02+08:00https://flcube.com/johnson-johnson-to-acquire-intra-cellular-therapies-for-14-6b/2025-01-15T11:48:53+08:00https://flcube.com/gsk-acquires-idrx-for-1b-to-boost-gist-treatment-pipeline/2025-01-15T11:27:46+08:00https://flcube.com/autobio-diagnostics-partners-with-boditech-med-for-korean-ivd-market/2025-01-15T11:12:46+08:00https://flcube.com/henlius-and-abbott-sign-license-agreement-for-biosimilars-and-biologic-drug/2025-01-15T10:49:22+08:00https://flcube.com/chongqing-genrixs-silevimig-nda-accepted-for-rabies-immunization-review/2025-01-15T10:36:54+08:00https://flcube.com/novartis-to-defend-entresto-patent-after-cafc-ruling/2025-01-14T22:00:15+08:00https://flcube.com/bristol-myers-squibb-exercises-license-for-arsenalbios-ab-4000-series/2025-01-14T21:47:27+08:00https://flcube.com/hengrui-and-kailera-announce-positive-phase-ii-results-for-hrs9531-in-weight-loss/2025-01-14T21:30:01+08:00https://flcube.com/gentize-biopharma-raises-13-64m-in-pre-series-a-for-vaccine-development/2025-01-14T21:21:22+08:00https://flcube.com/roches-ventana-kappa-and-lambda-dual-ish-test-gains-fda-clearance/2025-01-14T21:03:59+08:00https://flcube.com/illumina-partners-with-nvidia-to-advance-multiomic-data-analysis/2025-01-14T20:47:24+08:00https://flcube.com/leqembi-autoinjector-advances-with-fda-review-for-alzheimers-treatment/2025-01-14T20:25:40+08:00https://flcube.com/mediar-therapeutics-and-eli-lilly-ink-deal-for-ipf-drug-mtx-463/2025-01-14T20:11:43+08:00https://flcube.com/cornerstone-robotics-raises-68-2m-in-series-c-to-advance-surgical-robots/2025-01-14T19:03:02+08:00https://flcube.com/mgi-techs-dnbseq-e25-receives-nmpa-license-as-worlds-first-self-luminescent-sequencer/2025-01-14T17:48:33+08:00https://flcube.com/medtronics-brainsense-technologies-win-eu-uk-ce-mark-for-parkinsons-treatment/2025-01-14T17:35:24+08:00https://flcube.com/sansure-biotech-to-acquire-sinobioway-hygene-for-110m-to-boost-product-pipeline/2025-01-14T17:12:37+08:00https://flcube.com/simcere-zaiming-and-abbvie-ink-1-055b-license-deal-for-mm-drug-sim0500/2025-01-14T16:54:47+08:00https://flcube.com/novo-nordisk-launches-rybelsus-in-china-worlds-first-oral-glp-1ra/2025-01-14T16:51:57+08:00https://flcube.com/mercks-keytruda-gains-nmpa-approval-for-hnscc-indication-in-china/2025-01-14T16:43:04+08:00https://flcube.com/huadong-medicine-gets-fda-nod-for-phase-i-study-of-hdm2006-in-solid-tumors/2025-01-14T16:18:32+08:00https://flcube.com/zhaoke-ophthalmology-partners-with-aft-for-brimochol-pf-distribution-in-anz/2025-01-14T16:00:06+08:00https://flcube.com/tonghua-dongbao-begins-phase-ii-trial-for-glp-1-gip-agonist-thdbh120-in-weight-loss/2025-01-14T15:34:05+08:00https://flcube.com/neo-modulus-secures-40-9m-series-c-funding-for-regenerative-medical-devices/2025-01-14T15:15:24+08:00https://flcube.com/medilink-therapeutics-and-astrazeneca-collaborate-on-yl201-and-imfinzi-combo-for-solid-tumors/2025-01-14T15:05:23+08:00https://flcube.com/cspcs-prusogliptin-approved-in-china-for-type-2-diabetes-treatment/2025-01-14T14:44:41+08:00https://flcube.com/cbc-groups-r-bridge-healthcare-fund-boosts-mirxes-with-40m-for-cancer-detection-expansion/2025-01-14T14:02:48+08:00https://flcube.com/china-releases-blue-book-on-medical-insurance-fund-supervision/2025-01-13T23:49:59+08:00https://flcube.com/nhc-recommends-simcere-and-junshi-covid-19-therapies-in-updated-guidelines/2025-01-13T23:47:15+08:00https://flcube.com/atom-biosciences-abp-671-shows-positive-phase-iia-results-in-gout-treatment/2025-01-13T23:35:45+08:00https://flcube.com/echo-biotech-secures-series-a-funding-for-exosomes-drug-development/2025-01-13T23:32:42+08:00https://flcube.com/affamed-technologies-completes-first-patient-implantation-for-mini-well-iol/2025-01-13T23:27:46+08:00https://flcube.com/cspc-pharmaceutical-initiates-phase-iii-study-for-mitoxantrone-liposome-in-nasopharyngeal-carcinoma/2025-01-13T23:24:57+08:00https://flcube.com/national-vbp-tender-round-8-to-be-held-in-hainan-with-40-drugs-bidding/2025-01-13T23:22:20+08:00https://flcube.com/tinker-bio-raises-series-a-funding-for-microfluidic-chip-expansion/2025-01-13T23:19:30+08:00https://flcube.com/ocumension-therapeutics-initiates-phase-ii-study-for-dry-eye-treatment-ot-202/2025-01-13T23:14:24+08:00https://flcube.com/hexin-medical-technology-raises-series-a-funding-for-radionuclide-therapy/2025-01-13T23:11:23+08:00https://flcube.com/shanghai-pharmaceuticals-partners-with-baiyun-district-for-health-initiative/2025-01-13T23:04:59+08:00https://flcube.com/tandemai-secures-35m-series-a-to-expand-drug-discovery-platform/2025-01-13T23:01:43+08:00https://flcube.com/merck-reports-12-9-sales-growth-in-2022-annual-report/2025-01-13T22:56:15+08:00https://flcube.com/jw-therapeutics-carteyva-granted-breakthrough-therapy-designation-by-cde/2025-01-13T22:37:44+08:00https://flcube.com/cspc-pharmaceuticals-adc-pipeline-advances-with-sys-6041-approval/2025-01-13T22:27:24+08:00https://flcube.com/suzhou-ribo-and-boehringer-ingelheim-reach-pre-clinical-milestone-in-nash-mash-partnership/2025-01-13T22:20:30+08:00https://flcube.com/johnson-johnson-medtechs-dual-energy-catheter-gains-ce-mark/2025-01-13T22:13:08+08:00https://flcube.com/henlius-biotech-gains-nmpa-clearance-for-hlx43-adc-study/2025-01-13T22:06:57+08:00https://flcube.com/mabworks-biotech-licenses-anti-april-mab-to-climb-bio-for-global-development/2025-01-13T21:57:01+08:00https://flcube.com/gilead-sciences-and-leo-pharma-alliance-targets-inflammatory-diseases/2025-01-13T21:45:54+08:00https://flcube.com/junshi-biosciences-mindewei-receives-full-approval-in-china/2025-01-13T21:37:41+08:00https://flcube.com/ucello-biotechs-uc101-receives-fda-ind-clearance-for-anti-cd19-therapy/2025-01-13T21:30:43+08:00https://flcube.com/harbour-biomed-and-kelun-biotech-license-tslp-monoclonal-antibody-to-windward-bio/2025-01-13T21:15:08+08:00https://flcube.com/hengruis-recaticimab-approved-for-hypercholesterolemia-treatment/2025-01-13T20:58:43+08:00https://flcube.com/healzen-and-johnson-johnson-partner-on-btk-degradation-therapeutics/2025-01-13T20:49:20+08:00https://flcube.com/hengrui-pharmaceuticals-gets-nmpa-approval-for-shr-1819-phase-ii-study/2025-01-13T20:39:06+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-approval-for-shr-4375-clinical-trial/2025-01-13T20:32:53+08:00https://flcube.com/ouro-medicines-launches-with-120m-series-a-financing-for-cm336-development/2025-01-13T20:27:10+08:00https://flcube.com/menarini-group-expands-oncology-pipeline-with-insilico-medicine-license/2025-01-13T20:15:30+08:00https://flcube.com/zai-lab-secures-rights-to-vertexs-povetacicept-in-key-asian-markets/2025-01-13T20:08:11+08:00https://flcube.com/legend-biotech-gains-access-to-maxcytes-cell-engineering-tech-with-new-license-agreement/2025-01-13T19:59:00+08:00https://flcube.com/light-horse-therapeutics-partners-with-novartis-in-first-in-class-drug-development/2025-01-13T19:43:44+08:00https://flcube.com/samsung-bioepis-and-teva-partner-on-biosimilar-epylli-for-us-market/2025-01-13T19:31:24+08:00https://flcube.com/sepax-technologies-debuts-on-star-market-with-soaring-ipo-prices/2025-01-13T19:22:51+08:00https://flcube.com/bayer-files-for-finerenone-approval-in-us-and-china-for-heart-failure-fineline-info-tech/2025-01-13T19:13:51+08:00https://flcube.com/pfizers-sasanlimab-shows-positive-results-in-phase-iii-crest-study/2025-01-13T19:05:45+08:00https://flcube.com/nmpa-approves-jjs-fgfr-kinase-inhibitor-balversa-for-urothelial-carcinoma/2025-01-13T18:57:15+08:00https://flcube.com/doma-biopharma-receives-fda-clearance-for-dm002-phase-i-study-fineline-info-tech/2025-01-13T18:49:39+08:00https://flcube.com/gsks-shingrix-prefilled-syringe-accepted-for-fda-review/2025-01-13T18:40:12+08:00https://flcube.com/nhsa-launches-nationwide-self-inspection-campaign-on-medical-insurance-fund-usage/2025-01-13T18:33:16+08:00https://flcube.com/chinas-nhsa-implements-new-regulations-for-medical-insurance-payment-qualifications/2025-01-13T18:25:00+08:00https://flcube.com/shenzhen-oculgen-secures-over-rmb-100-million-in-series-a-funding/2025-01-11T22:11:01+08:00https://flcube.com/hkust-and-phirda-sign-mou-to-establish-innovation-centers/2025-01-11T21:52:49+08:00https://flcube.com/sanyou-biopharmaceuticals-expands-global-reach-with-new-cambridge-office/2025-01-11T21:49:23+08:00https://flcube.com/sanofis-dupixent-receives-priority-review-for-prurigo-nodosa-treatment/2025-01-11T21:45:53+08:00https://flcube.com/chinas-premier-li-keqiang-highlights-economic-and-social-advances-in-annual-report/2025-01-11T21:42:02+08:00https://flcube.com/eli-lillys-retevmo-launched-in-china-by-innovent-biologics/2025-01-11T21:38:03+08:00https://flcube.com/ql-biopharm-raises-series-b-funding-for-protein-drug-development/2025-01-11T21:34:34+08:00https://flcube.com/huahai-pharmas-hb0025-receives-nmpa-approval-for-clinical-trials/2025-01-11T21:31:56+08:00https://flcube.com/hengruis-adebrelimab-receives-nmpa-approval-for-lung-cancer-treatment/2025-01-11T21:26:11+08:00https://flcube.com/siyi-intelligence-raises-series-a-funding-for-neural-rehabilitation-solutions/2025-01-11T21:20:10+08:00https://flcube.com/sino-biopharmaceuticals-bevacizumab-biosimilar-approved-by-nmpa/2025-01-11T21:17:08+08:00https://flcube.com/mabwells-9mw3911-monoclonal-antibody-accepted-for-nmpa-review/2025-01-11T21:13:29+08:00https://flcube.com/venus-medtech-completes-patient-enrollment-for-liwen-rf-ablation-system-study/2025-01-11T21:10:02+08:00https://flcube.com/pulsecare-raises-pre-series-a-funding-for-minimally-invasive-treatment-devices/2025-01-11T21:07:26+08:00https://flcube.com/brightgenes-generic-halaven-approved-for-marketing-in-china/2025-01-11T20:57:55+08:00https://flcube.com/abcam-and-medx-expand-strategic-partnership-on-claudin-18-2-diagnosis/2025-01-11T20:54:09+08:00https://flcube.com/inovio-and-apollobio-announce-positive-phase-iii-data-for-vgx-3100-vaccine/2025-01-11T20:43:16+08:00https://flcube.com/sunshine-medical-procurement-platform-announces-vbp-tender-results-for-yangtze-river-delta/2025-01-11T20:33:00+08:00https://flcube.com/neo-modulus-secures-series-b-funding-for-regenerative-medical-device-development/2025-01-11T20:31:00+08:00https://flcube.com/takedas-exkivity-receives-first-prescription-in-china-with-innovative-payment-solutions/2025-01-11T20:24:20+08:00https://flcube.com/pudong-new-area-grants-duty-free-import-qualifications-to-seven-companies/2025-01-11T20:21:46+08:00https://flcube.com/harbour-biomeds-batoclimab-shows-positive-results-in-gmg-phase-iii-trial/2025-01-11T20:17:43+08:00https://flcube.com/bgi-group-subsidiaries-added-to-us-trade-blacklist-by-commerce-department/2025-01-11T20:14:34+08:00https://flcube.com/sumitomo-pharma-secures-rights-to-vibegron-for-asian-markets/2025-01-11T15:13:41+08:00https://flcube.com/suzhou-porton-biologics-partners-with-bennu-biotherapeutics-for-gene-and-cell-therapies/2025-01-11T14:57:43+08:00https://flcube.com/akeso-biopharma-and-shanghai-pharmaceuticals-collaborate-on-liposarcoma-treatment/2025-01-11T14:47:16+08:00https://flcube.com/f-star-therapeutics-acquisition-by-invox-pharma-cleared-by-cfius/2025-01-11T14:37:28+08:00https://flcube.com/sino-biopharms-subsidiary-invox-restructures-focusing-on-cd137-pd-l1-molecule-fs222/2025-01-11T14:35:37+08:00https://flcube.com/biocytogens-yh008-gets-nmpa-approval-for-phase-i-study/2025-01-11T14:32:03+08:00https://flcube.com/heranova-closes-10m-seed-round-for-womens-health-solutions/2025-01-11T14:28:43+08:00https://flcube.com/inmagenes-tavalisse-first-prescribed-in-china-for-itp-treatment/2025-01-11T14:23:32+08:00https://flcube.com/ausperbio-initiates-phase-i-trial-for-ahb-137-in-new-zealand/2025-01-11T14:19:52+08:00https://flcube.com/chinas-party-and-state-institutions-reshuffle-key-changes-for-healthcare-and-finance/2025-01-11T14:17:00+08:00https://flcube.com/haihe-pharmas-glumetinib-gains-conditional-nmpa-approval-for-nsclc/2025-01-11T14:13:13+08:00https://flcube.com/amvision-biotech-secures-nearly-14-34m-in-series-a-for-ophthalmology-innovations/2025-01-11T14:10:09+08:00https://flcube.com/jw-therapeutics-launches-carteyva-clinical-study-for-high-risk-lymphoma/2025-01-11T14:07:38+08:00https://flcube.com/chongqing-evaheart-secures-near-100m-in-series-a-for-heart-failure-platform/2025-01-11T14:04:55+08:00https://flcube.com/biocytogen-and-janssen-sign-licensing-agreement-for-renlite-platform-2/2025-01-11T14:01:42+08:00https://flcube.com/lifetechs-ibs-angel-stent-system-gains-eu-ce-mdr-certification/2025-01-11T13:57:43+08:00https://flcube.com/olipharma-secures-funding-for-manufacturing-expansion-in-pre-series-a-round/2025-01-11T13:44:03+08:00https://flcube.com/inventiva-and-chia-tai-tianqings-lanifibranor-advances-with-cde-filing/2025-01-11T13:41:35+08:00https://flcube.com/simceres-sim0237-begins-clinical-study-for-pd-l1-and-il-15-targeting-bispecific-antibody/2025-01-11T13:36:40+08:00https://flcube.com/ausperbio-and-asymchem-form-strategic-partnership-for-drug-development/2025-01-11T13:31:44+08:00https://flcube.com/nhsas-2022-healthcare-security-bulletin-reveals-break-even-performance/2025-01-11T13:28:01+08:00https://flcube.com/bio-thera-solutions-initiates-phase-i-study-for-trop2-targeting-adc-bat8008-2/2025-01-11T13:25:03+08:00https://flcube.com/astellas-and-seagen-file-for-nmpa-approval-of-enfortumab-vedotin-for-urothelial-carcinoma-2/2025-01-11T13:21:36+08:00https://flcube.com/huiliao-biomedical-raises-rmb-100-million-in-pre-series-a-round-for-mrna-development/2025-01-11T13:17:48+08:00https://flcube.com/innocare-pharma-initiates-clinical-study-for-bcl2-inhibitor-icp-248-in-china-2/2025-01-11T13:12:18+08:00https://flcube.com/thederma-pharmaceuticals-raises-rmb-100-million-for-ahr-targeted-therapies/2025-01-11T13:06:37+08:00https://flcube.com/xinrui-medtech-secures-pre-series-a-funding-for-cardiovascular-device-development-2/2025-01-11T13:03:13+08:00https://flcube.com/fosun-pharmaceuticals-fcn-437c-accepted-for-nmpa-review-for-breast-cancer-treatment/2025-01-11T01:02:59+08:00https://flcube.com/hengruis-shr4640-accepted-for-nmpa-review-for-gout-and-hyperuricemia-treatment/2025-01-11T00:53:25+08:00https://flcube.com/keymed-biosciences-licenses-cm313-to-timberlyne-therapeutics-for-global-development/2025-01-11T00:43:32+08:00https://flcube.com/biocytogen-and-sotio-biotech-partner-on-colorectal-cancer-adc-candidate-sot109/2025-01-11T00:28:06+08:00https://flcube.com/novo-nordisk-and-valo-health-expand-partnership-to-develop-treatments-for-obesity-and-diabetes/2025-01-11T00:20:31+08:00https://flcube.com/immunochina-pharmaceuticals-raises-series-e-funding-for-car-t-therapy-im19/2025-01-11T00:02:57+08:00https://flcube.com/sinogens-salmet-vec-receives-fda-orphan-drug-designation-for-pancreatic-cancer/2025-01-10T23:55:08+08:00https://flcube.com/syncardias-next-generation-artificial-heart-granted-patent-in-china/2025-01-10T23:34:09+08:00https://flcube.com/danaher-corporation-partners-with-innovaccer-to-enhance-healthcare-ai-solutions/2025-01-10T23:20:52+08:00https://flcube.com/sanofis-sarclisa-meets-co-primary-endpoints-in-phase-iii-iraklia-study-for-multiple-myeloma/2025-01-10T23:01:53+08:00https://flcube.com/fda-grants-priority-review-to-johnson-johnsons-nipocalimab-for-myasthenia-gravis/2025-01-10T22:54:02+08:00https://flcube.com/boehringer-ingelheim-licenses-adc-technology-from-synaffix-to-boost-portfolio/2025-01-10T22:40:33+08:00